SEC Info - Xenetic Biosciences, Inc. - ‘10-K’ for 12/31/23

SEC Info℠

Home

My Interests

Help

Please Sign In

Xenetic Biosciences, Inc. – ‘10-K’ for 12/31/23 – ‘XML’

On: Thursday, 3/21/24, at 5:00pm ET · For: 12/31/23 · Accession #: 1683168-24-1594 · File #: 1-37937

Previous ‘10-K’: ‘10-K/A’ on 4/28/23 for 12/31/22 · Next & Latest: ‘10-K/A’ on 4/26/24 for 12/31/23 · 32 References:

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/21/24  Xenetic Biosciences, Inc.         10-K       12/31/23   71:5.6M                                   GlobalOne Filings Inc/FA

Annual Report — Form 10-K — SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Form 10-K for Dec 2023                              HTML   1.32M 
 2: EX-4.1      Description of Registrants Securities Registered    HTML     31K 
                Pursuant to Section 12 of the Securities Exchange                
                Act of 1934                                                      
 3: EX-21.1     Subsidiaries List                                   HTML     19K 
 4: EX-23.1     Consent of Marcum LLP                               HTML     19K 
 8: EX-97.1     Policy Regarding the Mandatory Recovery of          HTML     34K 
                Compensation                                                     
 5: EX-31.1     Certification -- §302 - SOA'02                      HTML     23K 
 6: EX-31.2     Certification -- §302 - SOA'02                      HTML     23K 
 7: EX-32.1     Certification -- §906 - SOA'02                      HTML     20K 
14: R1          Cover                                               HTML     94K 
15: R2          Consolidated Balance Sheets                         HTML    102K 
16: R3          Consolidated Balance Sheets (Parenthetical)         HTML     42K 
17: R4          Consolidated Statements of Comprehensive Loss       HTML     62K 
18: R5          Consolidated Statements of Comprehensive Loss       HTML     37K 
                (Parenthetical)                                                  
19: R6          Consolidated Statements of Stockholders' Equity     HTML     60K 
20: R7          Consolidated Statements of Cash Flows               HTML     74K 
21: R8          Pay vs Performance Disclosure                       HTML     32K 
22: R9          Insider Trading Arrangements                        HTML     26K 
23: R10         The Company                                         HTML     28K 
24: R11         Risks and Uncertainties                             HTML     23K 
25: R12         Summary of Significant Accounting Policies          HTML     74K 
26: R13         Significant Strategic Collaborations                HTML     42K 
27: R14         Licensing Arrangements                              HTML     36K 
28: R15         Other Assets                                        HTML     24K 
29: R16         Accrued Expenses                                    HTML     27K 
30: R17         Fair Value Measurements                             HTML     26K 
31: R18         Income Taxes                                        HTML     74K 
32: R19         Stockholders? Equity                                HTML     60K 
33: R20         Share-Based Expense                                 HTML    122K 
34: R21         Employee Benefit Plans                              HTML     24K 
35: R22         Commitments and Contingencies                       HTML     31K 
36: R23         Related Party Transactions                          HTML     32K 
37: R24         Subsequent Events                                   HTML     23K 
38: R25         Summary of Significant Accounting Policies          HTML    125K 
                (Policies)                                                       
39: R26         Summary of Significant Accounting Policies          HTML     24K 
                (Tables)                                                         
40: R27         Accrued Expenses (Tables)                           HTML     26K 
41: R28         Income Taxes (Tables)                               HTML     60K 
42: R29         Share-Based Expense (Tables)                        HTML    115K 
43: R30         Commitments and Contingencies (Tables)              HTML     25K 
44: R31         The Company (Details Narrative)                     HTML     26K 
45: R32         Summary of Significant Accounting Policies          HTML     27K 
                (Details)                                                        
46: R33         Summary of Significant Accounting Policies          HTML     29K 
                (Details Narrative)                                              
47: R34         Significant Strategic Collaborations (Details       HTML     56K 
                Narrative)                                                       
48: R35         Licensing Arrangements (Details Narrative)          HTML     54K 
49: R36         Other Assets (Details Narrative)                    HTML     24K 
50: R37         Accrued Expenses (Details)                          HTML     30K 
51: R38         Fair Value Measurements (Details Narrative)         HTML     25K 
52: R39         Income Taxes (Details - Income by geographic        HTML     37K 
                regions)                                                         
53: R40         Income Taxes (Details - Tax reconciliation)         HTML     45K 
54: R41         Income Taxes (Details - Deferred Tax Assets)        HTML     60K 
55: R42         Income Taxes (Details Narrative)                    HTML     40K 
56: R43         Stockholders? Equity (Details Narrative)            HTML     88K 
57: R44         Share-Based Expense (Details - Share based          HTML     27K 
                expense)                                                         
58: R45         Share-Based Expense (Details - Assumptions          HTML     41K 
                Employee)                                                        
59: R46         Share-Based Expense (Details - Employee option      HTML     70K 
                activity)                                                        
60: R47         Share-Based Expense (Details - Non-Vested employee  HTML     46K 
                Option activity)                                                 
61: R48         Share-Based Expense (Details - Non-employee option  HTML     70K 
                activity)                                                        
62: R49         Share-Based Expense (Details Narrative)             HTML     67K 
63: R50         Employee Benefit Plans (Details Narrative)          HTML     25K 
64: R51         Commitments and Contingencies (Details - Cash flow  HTML     22K 
                Information)                                                     
65: R52         Commitments and Contingencies (Details Narrative)   HTML     31K 
66: R53         Related Party Transactions (Details Narrative)      HTML     35K 
68: XML         IDEA XML File -- Filing Summary                      XML    120K 
71: XML         XBRL Instance -- xenetic_i10k-123123_htm             XML    986K 
67: EXCEL       IDEA Workbook of Financial Report Info              XLSX    120K 
10: EX-101.CAL  XBRL Calculations -- xbio-20231231_cal               XML    118K 
11: EX-101.DEF  XBRL Definitions -- xbio-20231231_def                XML    587K 
12: EX-101.LAB  XBRL Labels -- xbio-20231231_lab                     XML    871K 
13: EX-101.PRE  XBRL Presentations -- xbio-20231231_pre              XML    779K 
 9: EX-101.SCH  XBRL Schema -- xbio-20231231                         XSD    116K 
69: JSON        XBRL Instance as JSON Data -- MetaLinks              409±   574K 
70: ZIP         XBRL Zipped Folder -- 0001683168-24-001594-xbrl      Zip    402K

‘XML’ — XBRL Instance — xenetic_i10k-123123_htm

This Document is an XBRL File.

<?xml version="1.0" encoding="windows-1252"?>

<link:schemaRef xlink:href="xbio-20231231.xsd" xlink:type="simple"/>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> xbio:CommonStock0.001ParValuePerShareMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> xbio:PurchaseWarrantsMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

</entity>

</period>

</context>

</entity>

</period>

</context>

</entity>

</period>

</context>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesBPreferredStockMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesBPreferredStockMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesAPreferredStockMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesAPreferredStockMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AccumulatedOtherComprehensiveIncomeMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:TreasuryStockCommonMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AccumulatedOtherComprehensiveIncomeMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:TreasuryStockCommonMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AccumulatedOtherComprehensiveIncomeMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:TreasuryStockCommonMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AccumulatedOtherComprehensiveIncomeMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:TreasuryStockCommonMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AccumulatedOtherComprehensiveIncomeMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:TreasuryStockCommonMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis"> xbio:OfficeAndComputerEquipmentMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis"> us-gaap:LeaseholdImprovementsMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis"> us-gaap:FurnitureAndFixturesMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis"> xbio:ResearchAndDevelopmentExpensesMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis"> xbio:ResearchAndDevelopmentExpensesMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis"> xbio:TakedaMember </xbrldi:explicitMember>

<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis"> xbio:RoyaltyRevenueMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis"> xbio:TakedaMember </xbrldi:explicitMember>

<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis"> xbio:RoyaltyRevenueMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis"> xbio:CatalentPharmaSolutionsMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis"> xbio:CatalentPharmaSolutionsMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis"> xbio:CatalentPharmaSolutionsMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis"> xbio:ScrippsResearchMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis"> xbio:ScrippsResearchMember </xbrldi:explicitMember>

<xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis"> xbio:ScrippsAgreementMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"> xbio:PharmsynthezMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"> xbio:PharmsynthezMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesBPreferredStockMember </xbrldi:explicitMember>

<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> xbio:PharmsynthezMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis"> xbio:CLSMember </xbrldi:explicitMember>

<xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis"> xbio:SublicenseAgreementSharesMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis"> xbio:CLSMember </xbrldi:explicitMember>

<xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis"> xbio:SublicenseAndLicenseAgreementsMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis"> xbio:SublicenseAndLicenseAgreementsMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis"> xbio:SublicenseAndLicenseAgreementsMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis"> xbio:VolitionMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis"> xbio:PatentAssignmentMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"> xbio:CLSMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis"> xbio:DNaseTechnologyMember </xbrldi:explicitMember>

<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"> xbio:CLSMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis"> xbio:SerumInstituteMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis"> xbio:SerumInstituteMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis"> us-gaap:FairValueInputsLevel3Member </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis"> us-gaap:FairValueInputsLevel3Member </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis"> country:US </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis"> country:US </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis"> country:GB </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis"> country:GB </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis"> country:DE </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis"> country:DE </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis"> country:CH </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis"> country:CH </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis"> country:GB </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis"> country:GB </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis"> country:CH </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis"> country:CH </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis"> country:DE </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis"> country:DE </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis"> country:GB </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis"> country:GB </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis"> country:US </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis"> country:US </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis"> us-gaap:StateAndLocalJurisdictionMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis"> us-gaap:StateAndLocalJurisdictionMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis"> country:DE </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis"> country:DE </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis"> country:CH </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis"> country:CH </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis"> country:US </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis"> country:CH </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis"> xbio:ATMAgreementMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis"> xbio:ATMAgreementMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis"> xbio:ATMAgreementMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis"> xbio:ATMAgreementMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesAPreferredStockMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesBPreferredStockMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesBPreferredStockMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis"> us-gaap:PrivatePlacementMember </xbrldi:explicitMember>

<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> xbio:SeriesAWarrantsMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis"> us-gaap:PrivatePlacementMember </xbrldi:explicitMember>

<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> xbio:SeriesAWarrantsMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis"> us-gaap:PrivatePlacementMember </xbrldi:explicitMember>

<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> xbio:SeriesAWarrantsMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> xbio:PubliclyTradedWarrantsMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> xbio:PubliclyTradedWarrantsMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> xbio:PubliclyTradedWarrantsMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> xbio:PubliclyTradedWarrantsMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> xbio:OtherWarrantsMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> xbio:OtherWarrantsMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> xbio:OtherWarrantsMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> xbio:OtherWarrantsMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:RestrictedStockUnitsRSUMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:RestrictedStockUnitsRSUMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> xbio:NonEmployeeStockOptionsMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> xbio:NonEmployeeStockOptionsMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> xbio:CommonStockAwardsMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> xbio:CommonStockAwardsMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> xbio:JSOPMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> xbio:JSOPMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> xbio:JSOPMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> xbio:JSOPMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis"> us-gaap:ResearchAndDevelopmentExpenseMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis"> us-gaap:ResearchAndDevelopmentExpenseMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis"> us-gaap:GeneralAndAdministrativeExpenseMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis"> us-gaap:GeneralAndAdministrativeExpenseMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> xbio:NonVestedEmployeeStockOptionMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> xbio:NonVestedEmployeeStockOptionMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> xbio:NonVestedEmployeeStockOptionMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> xbio:NonEmployeeStockOptionsMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> xbio:NonEmployeeStockOptionsMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> xbio:NonEmployeeStockOptionsMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> xbio:NonEmployeeStockOptionsMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis"> xbio:Plan401KMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis"> xbio:Plan401KMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis"> xbio:CorporateHeadquartersMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis"> xbio:CorporateHeadquartersMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis"> xbio:OfficeSpaceMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis"> xbio:OfficeSpaceMiamiFlMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis"> xbio:OfficeSpaceMiamiFlMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> xbio:PharmsynthezMember </xbrldi:explicitMember>

<xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis"> xbio:CoDevelopmentAgreementMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> xbio:PharmsynthezMember </xbrldi:explicitMember>

<xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis"> xbio:CoDevelopmentAgreementMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis"> xbio:CoDevelopmentAgreementMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> xbio:PharmsynthezMember </xbrldi:explicitMember>

<xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis"> xbio:CoDevelopmentAgreementMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> xbio:PharmsynthezMember </xbrldi:explicitMember>

<xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis"> xbio:CoDevelopmentAgreementMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> xbio:PharmsynthezMember </xbrldi:explicitMember>

<xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis"> xbio:SponsoredResearchAgreementMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

</entity>

</period>

</context>

</unit>

<measure> shares </measure>

</unit>

</unitNumerator>

<measure> shares </measure>

</unitDenominator>

</divide>

</unit>

</unit>

<dei:AmendmentFlag contextRef="From2023-01-01to2023-12-31" id="Fact000003"> false </dei:AmendmentFlag>

<dei:DocumentFiscalYearFocus contextRef="From2023-01-01to2023-12-31" id="Fact000004"> 2023 </dei:DocumentFiscalYearFocus>

<dei:DocumentFiscalPeriodFocus contextRef="From2023-01-01to2023-12-31" id="Fact000005"> FY </dei:DocumentFiscalPeriodFocus>

<dei:EntityCentralIndexKey contextRef="From2023-01-01to2023-12-31" id="Fact000006"> 0001534525 </dei:EntityCentralIndexKey>

<us-gaap:CommitmentsAndContingencies contextRef="AsOf2023-12-31" id="xdx2ixbrl0091" unitRef="USD" xsi:nil="true"/>

<us-gaap:CommitmentsAndContingencies contextRef="AsOf2022-12-31" id="xdx2ixbrl0092" unitRef="USD" xsi:nil="true"/>

<xbio:StockIssuedDuringPeriodValueReverseStockSplits contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0237" unitRef="Shares" xsi:nil="true"/>

<xbio:StockIssuedDuringPeriodValueReverseStockSplits contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0240" unitRef="Shares" xsi:nil="true"/>

<xbio:StockIssuedDuringPeriodValueReverseStockSplits contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0241" unitRef="Shares" xsi:nil="true"/>

<xbio:StockIssuedDuringPeriodValueReverseStockSplits contextRef="From2022-01-012022-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0242" unitRef="Shares" xsi:nil="true"/>

<xbio:ExerciseOfPurchaseWarrantsValue contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0247" unitRef="USD" xsi:nil="true"/>

<xbio:ExerciseOfPurchaseWarrantsValue contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0248" unitRef="USD" xsi:nil="true"/>

<xbio:ExerciseOfPurchaseWarrantsValue contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0249" unitRef="USD" xsi:nil="true"/>

<xbio:ExerciseOfPurchaseWarrantsValue contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0250" unitRef="USD" xsi:nil="true"/>

<xbio:ExerciseOfPurchaseWarrantsValue contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0251" unitRef="USD" xsi:nil="true"/>

<xbio:ExerciseOfPurchaseWarrantsValue contextRef="From2022-01-012022-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0252" unitRef="USD" xsi:nil="true"/>

<xbio:ExerciseOfPurchaseWarrantsValue contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0253" unitRef="USD" xsi:nil="true"/>

<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0261" unitRef="USD" xsi:nil="true"/>

<us-gaap:NetIncomeLoss contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0265" unitRef="USD" xsi:nil="true"/>

<us-gaap:NetIncomeLoss contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0266" unitRef="USD" xsi:nil="true"/>

<us-gaap:NetIncomeLoss contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0267" unitRef="USD" xsi:nil="true"/>

<us-gaap:NetIncomeLoss contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0269" unitRef="USD" xsi:nil="true"/>

<us-gaap:NetIncomeLoss contextRef="From2022-01-012022-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0270" unitRef="USD" xsi:nil="true"/>

<xbio:IssuanceOfCommonStockToAdjustForReverseSplitRounding contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0285" unitRef="USD" xsi:nil="true"/>

<xbio:IssuanceOfCommonStockToAdjustForReverseSplitRounding contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0288" unitRef="USD" xsi:nil="true"/>

<xbio:IssuanceOfCommonStockToAdjustForReverseSplitRounding contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0289" unitRef="USD" xsi:nil="true"/>

<xbio:IssuanceOfCommonStockToAdjustForReverseSplitRounding contextRef="From2023-01-012023-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0290" unitRef="USD" xsi:nil="true"/>

<xbio:IssuanceOfCommonStockToAdjustForReverseSplitRounding contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0291" unitRef="USD" xsi:nil="true"/>

<xbio:ConversionOfSeriesPreferredStockToSharesOfCommonStock contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0298" unitRef="USD" xsi:nil="true"/>

<xbio:ConversionOfSeriesPreferredStockToSharesOfCommonStock contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0299" unitRef="USD" xsi:nil="true"/>

<xbio:ConversionOfSeriesPreferredStockToSharesOfCommonStock contextRef="From2023-01-012023-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0300" unitRef="USD" xsi:nil="true"/>

<xbio:ConversionOfSeriesPreferredStockToSharesOfCommonStock contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0301" unitRef="USD" xsi:nil="true"/>

<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0311" unitRef="USD" xsi:nil="true"/>

<us-gaap:NetIncomeLoss contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0315" unitRef="USD" xsi:nil="true"/>

<us-gaap:NetIncomeLoss contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0316" unitRef="USD" xsi:nil="true"/>

<us-gaap:NetIncomeLoss contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0317" unitRef="USD" xsi:nil="true"/>

<us-gaap:NetIncomeLoss contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0319" unitRef="USD" xsi:nil="true"/>

<us-gaap:NetIncomeLoss contextRef="From2023-01-012023-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0320" unitRef="USD" xsi:nil="true"/>

<dei:DocumentType contextRef="From2023-01-01to2023-12-31" id="Fact000012"> 10-K </dei:DocumentType>

<dei:DocumentAnnualReport contextRef="From2023-01-01to2023-12-31" id="Fact000013"> true </dei:DocumentAnnualReport>

<dei:DocumentPeriodEndDate contextRef="From2023-01-01to2023-12-31" id="Fact000015"> 2023-12-31 </dei:DocumentPeriodEndDate>

<dei:CurrentFiscalYearEndDate contextRef="From2023-01-01to2023-12-31" id="Fact000016"> --12-31 </dei:CurrentFiscalYearEndDate>

<dei:DocumentTransitionReport contextRef="From2023-01-01to2023-12-31" id="Fact000017"> false </dei:DocumentTransitionReport>

<dei:EntityFileNumber contextRef="From2023-01-01to2023-12-31" id="Fact000018"> 001-37937 </dei:EntityFileNumber>

<dei:EntityRegistrantName contextRef="From2023-01-01to2023-12-31" id="Fact000019"> XENETIC BIOSCIENCES, INC. </dei:EntityRegistrantName>

<dei:EntityIncorporationStateCountryCode contextRef="From2023-01-01to2023-12-31" id="Fact000020"> NV </dei:EntityIncorporationStateCountryCode>

<dei:EntityTaxIdentificationNumber contextRef="From2023-01-01to2023-12-31" id="Fact000021"> 45-2952962 </dei:EntityTaxIdentificationNumber>

<dei:EntityAddressAddressLine1 contextRef="From2023-01-01to2023-12-31" id="Fact000022"> 945 Concord Street </dei:EntityAddressAddressLine1>

<dei:EntityAddressCityOrTown contextRef="From2023-01-01to2023-12-31" id="Fact000023"> Framingham </dei:EntityAddressCityOrTown>

<dei:EntityAddressStateOrProvince contextRef="From2023-01-01to2023-12-31" id="Fact000024"> MA </dei:EntityAddressStateOrProvince>

<dei:EntityAddressPostalZipCode contextRef="From2023-01-01to2023-12-31" id="Fact000025"> 01701 </dei:EntityAddressPostalZipCode>

<dei:CityAreaCode contextRef="From2023-01-01to2023-12-31" id="Fact000026"> 781 </dei:CityAreaCode>

<dei:LocalPhoneNumber contextRef="From2023-01-01to2023-12-31" id="Fact000027"> 778-7720 </dei:LocalPhoneNumber>

<dei:Security12bTitle contextRef="From2023-01-012023-12-31_custom_CommonStock0.001ParValuePerShareMember" id="Fact000028"> Common Stock, $0.001 par value per share </dei:Security12bTitle>

<dei:TradingSymbol contextRef="From2023-01-012023-12-31_custom_CommonStock0.001ParValuePerShareMember" id="Fact000029"> XBIO </dei:TradingSymbol>

<dei:SecurityExchangeName contextRef="From2023-01-012023-12-31_custom_CommonStock0.001ParValuePerShareMember" id="Fact000030"> NASDAQ </dei:SecurityExchangeName>

<dei:Security12bTitle contextRef="From2023-01-012023-12-31_custom_PurchaseWarrantsMember" id="Fact000031"> Purchase Warrants </dei:Security12bTitle>

<dei:TradingSymbol contextRef="From2023-01-012023-12-31_custom_PurchaseWarrantsMember" id="Fact000032"> XBIOW </dei:TradingSymbol>

<dei:SecurityExchangeName contextRef="From2023-01-012023-12-31_custom_PurchaseWarrantsMember" id="Fact000033"> NASDAQ </dei:SecurityExchangeName>

<dei:EntityWellKnownSeasonedIssuer contextRef="From2023-01-01to2023-12-31" id="Fact000034"> No </dei:EntityWellKnownSeasonedIssuer>

<dei:EntityVoluntaryFilers contextRef="From2023-01-01to2023-12-31" id="Fact000035"> No </dei:EntityVoluntaryFilers>

<dei:EntityCurrentReportingStatus contextRef="From2023-01-01to2023-12-31" id="Fact000036"> Yes </dei:EntityCurrentReportingStatus>

<dei:EntityInteractiveDataCurrent contextRef="From2023-01-01to2023-12-31" id="Fact000037"> Yes </dei:EntityInteractiveDataCurrent>

<dei:EntityFilerCategory contextRef="From2023-01-01to2023-12-31" id="Fact000038"> Non-accelerated Filer </dei:EntityFilerCategory>

<dei:EntitySmallBusiness contextRef="From2023-01-01to2023-12-31" id="Fact000039"> true </dei:EntitySmallBusiness>

<dei:EntityEmergingGrowthCompany contextRef="From2023-01-01to2023-12-31" id="Fact000040"> false </dei:EntityEmergingGrowthCompany>

<dei:IcfrAuditorAttestationFlag contextRef="From2023-01-01to2023-12-31" id="Fact000041"> false </dei:IcfrAuditorAttestationFlag>

<dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2023-01-01to2023-12-31" id="Fact000042"> false </dei:DocumentFinStmtErrorCorrectionFlag>

<dei:EntityShellCompany contextRef="From2023-01-01to2023-12-31" id="Fact000043"> false </dei:EntityShellCompany>

<dei:EntityPublicFloat contextRef="AsOf2023-06-30" decimals="0" id="Fact000045" unitRef="USD"> 5026928 </dei:EntityPublicFloat>

<dei:EntityCommonStockSharesOutstanding contextRef="AsOf2024-03-15" decimals="INF" id="Fact000046" unitRef="Shares"> 1540684 </dei:EntityCommonStockSharesOutstanding>

<dei:DocumentsIncorporatedByReferenceTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000047"> Information required in response to Part III of Form 10-K (Items 10, 11, 12, 13 and 14) is hereby incorporated by reference to portions of the registrant's definitive proxy statement for its 2024 Annual Meeting of Stockholders, information statement or an amendment to this Annual Report on Form 10-K. The registrant intends to file a definitive proxy statement, information statement or an amendment to this Annual Report on Form 10-K with the Securities and Exchange Commission no later than 120 days after the end of the registrant's fiscal year ended December 31, 2023. </dei:DocumentsIncorporatedByReferenceTextBlock>

<dei:AuditorFirmId contextRef="From2023-01-01to2023-12-31" id="Fact000048"> 688 </dei:AuditorFirmId>

<dei:AuditorName contextRef="From2023-01-01to2023-12-31" id="Fact000049"> Marcum LLP </dei:AuditorName>

<dei:AuditorLocation contextRef="From2023-01-01to2023-12-31" id="Fact000050"> Boston, Massachusetts </dei:AuditorLocation>

<us-gaap:Cash contextRef="AsOf2023-12-31" decimals="0" id="Fact000058" unitRef="USD"> 8983046 </us-gaap:Cash>

<us-gaap:Cash contextRef="AsOf2022-12-31" decimals="0" id="Fact000059" unitRef="USD"> 13097265 </us-gaap:Cash>

<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2023-12-31" decimals="0" id="Fact000061" unitRef="USD"> 603828 </us-gaap:PrepaidExpenseAndOtherAssetsCurrent>

<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2022-12-31" decimals="0" id="Fact000062" unitRef="USD"> 556094 </us-gaap:PrepaidExpenseAndOtherAssetsCurrent>

<us-gaap:AssetsCurrent contextRef="AsOf2023-12-31" decimals="0" id="Fact000064" unitRef="USD"> 9586874 </us-gaap:AssetsCurrent>

<us-gaap:AssetsCurrent contextRef="AsOf2022-12-31" decimals="0" id="Fact000065" unitRef="USD"> 13653359 </us-gaap:AssetsCurrent>

<us-gaap:OtherAssetsNoncurrent contextRef="AsOf2023-12-31" decimals="0" id="Fact000067" unitRef="USD"> 1018352 </us-gaap:OtherAssetsNoncurrent>

<us-gaap:OtherAssetsNoncurrent contextRef="AsOf2022-12-31" decimals="0" id="Fact000068" unitRef="USD"> 1066931 </us-gaap:OtherAssetsNoncurrent>

<us-gaap:Assets contextRef="AsOf2023-12-31" decimals="0" id="Fact000070" unitRef="USD"> 10605226 </us-gaap:Assets>

<us-gaap:Assets contextRef="AsOf2022-12-31" decimals="0" id="Fact000071" unitRef="USD"> 14720290 </us-gaap:Assets>

<us-gaap:AccountsPayableCurrent contextRef="AsOf2023-12-31" decimals="0" id="Fact000079" unitRef="USD"> 240832 </us-gaap:AccountsPayableCurrent>

<us-gaap:AccountsPayableCurrent contextRef="AsOf2022-12-31" decimals="0" id="Fact000080" unitRef="USD"> 287360 </us-gaap:AccountsPayableCurrent>

<us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="AsOf2023-12-31" decimals="0" id="Fact000082" unitRef="USD"> 568753 </us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>

<us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" id="Fact000083" unitRef="USD"> 785796 </us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>

<us-gaap:LiabilitiesCurrent contextRef="AsOf2023-12-31" decimals="0" id="Fact000085" unitRef="USD"> 809585 </us-gaap:LiabilitiesCurrent>

<us-gaap:LiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" id="Fact000086" unitRef="USD"> 1073156 </us-gaap:LiabilitiesCurrent>

<us-gaap:Liabilities contextRef="AsOf2023-12-31" decimals="0" id="Fact000088" unitRef="USD"> 809585 </us-gaap:Liabilities>

<us-gaap:Liabilities contextRef="AsOf2022-12-31" decimals="0" id="Fact000089" unitRef="USD"> 1073156 </us-gaap:Liabilities>

<us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2023-12-31" decimals="INF" id="Fact000097" unitRef="Shares"> 10000000 </us-gaap:PreferredStockSharesAuthorized>

<us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="INF" id="Fact000099" unitRef="Shares"> 10000000 </us-gaap:PreferredStockSharesAuthorized>

<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember" decimals="INF" id="Fact000101" unitRef="USDPShares"> 0.001 </us-gaap:PreferredStockParOrStatedValuePerShare>

<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember" decimals="INF" id="Fact000103" unitRef="USDPShares"> 0.001 </us-gaap:PreferredStockParOrStatedValuePerShare>

<us-gaap:PreferredStockSharesIssued contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember" decimals="INF" id="Fact000105" unitRef="Shares"> 1804394 </us-gaap:PreferredStockSharesIssued>

<us-gaap:PreferredStockSharesIssued contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember" decimals="INF" id="Fact000107" unitRef="Shares"> 1804394 </us-gaap:PreferredStockSharesIssued>

<us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember" decimals="INF" id="Fact000109" unitRef="Shares"> 1804394 </us-gaap:PreferredStockSharesOutstanding>

<us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember" decimals="INF" id="Fact000111" unitRef="Shares"> 1804394 </us-gaap:PreferredStockSharesOutstanding>

<us-gaap:PreferredStockValue contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember" decimals="0" id="Fact000113" unitRef="USD"> 1804 </us-gaap:PreferredStockValue>

<us-gaap:PreferredStockValue contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember" decimals="0" id="Fact000115" unitRef="USD"> 1804 </us-gaap:PreferredStockValue>

<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact000117" unitRef="USDPShares"> 0.001 </us-gaap:PreferredStockParOrStatedValuePerShare>

<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact000119" unitRef="USDPShares"> 0.001 </us-gaap:PreferredStockParOrStatedValuePerShare>

<us-gaap:PreferredStockSharesIssued contextRef="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact000121" unitRef="Shares"> 0 </us-gaap:PreferredStockSharesIssued>

<us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact000123" unitRef="Shares"> 0 </us-gaap:PreferredStockSharesOutstanding>

<us-gaap:PreferredStockSharesIssued contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact000125" unitRef="Shares"> 970000 </us-gaap:PreferredStockSharesIssued>

<us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact000127" unitRef="Shares"> 970000 </us-gaap:PreferredStockSharesOutstanding>

<us-gaap:PreferredStockValue contextRef="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember" decimals="0" id="Fact000129" unitRef="USD"> 0 </us-gaap:PreferredStockValue>

<us-gaap:PreferredStockValue contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember" decimals="0" id="Fact000131" unitRef="USD"> 970 </us-gaap:PreferredStockValue>

<us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2023-12-31" decimals="INF" id="Fact000136" unitRef="USDPShares"> 0.001 </us-gaap:CommonStockParOrStatedValuePerShare>

<us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2022-12-31" decimals="INF" id="Fact000138" unitRef="USDPShares"> 0.001 </us-gaap:CommonStockParOrStatedValuePerShare>

<us-gaap:CommonStockSharesAuthorized contextRef="AsOf2023-12-31" decimals="INF" id="Fact000140" unitRef="Shares"> 10000000 </us-gaap:CommonStockSharesAuthorized>

<us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="INF" id="Fact000142" unitRef="Shares"> 10000000 </us-gaap:CommonStockSharesAuthorized>

<us-gaap:CommonStockSharesIssued contextRef="AsOf2023-12-31" decimals="INF" id="Fact000144" unitRef="Shares"> 1543385 </us-gaap:CommonStockSharesIssued>

<us-gaap:CommonStockSharesIssued contextRef="AsOf2022-12-31" decimals="INF" id="Fact000146" unitRef="Shares"> 1519360 </us-gaap:CommonStockSharesIssued>

<us-gaap:CommonStockSharesOutstanding contextRef="AsOf2023-12-31" decimals="INF" id="Fact000148" unitRef="Shares"> 1540684 </us-gaap:CommonStockSharesOutstanding>

<us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-12-31" decimals="INF" id="Fact000150" unitRef="Shares"> 1516659 </us-gaap:CommonStockSharesOutstanding>

<us-gaap:CommonStockValue contextRef="AsOf2023-12-31" decimals="0" id="Fact000133" unitRef="USD"> 1544 </us-gaap:CommonStockValue>

<us-gaap:CommonStockValue contextRef="AsOf2022-12-31" decimals="0" id="Fact000134" unitRef="USD"> 1520 </us-gaap:CommonStockValue>

<us-gaap:AdditionalPaidInCapital contextRef="AsOf2023-12-31" decimals="0" id="Fact000152" unitRef="USD"> 208053935 </us-gaap:AdditionalPaidInCapital>

<us-gaap:AdditionalPaidInCapital contextRef="AsOf2022-12-31" decimals="0" id="Fact000153" unitRef="USD"> 207769904 </us-gaap:AdditionalPaidInCapital>

<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2023-12-31" decimals="0" id="Fact000155" unitRef="USD"> -193234196 </us-gaap:RetainedEarningsAccumulatedDeficit>

<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-12-31" decimals="0" id="Fact000156" unitRef="USD"> -189099618 </us-gaap:RetainedEarningsAccumulatedDeficit>

<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2023-12-31" decimals="0" id="Fact000158" unitRef="USD"> 253734 </us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>

<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2022-12-31" decimals="0" id="Fact000159" unitRef="USD"> 253734 </us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>

<us-gaap:TreasuryStockCommonValue contextRef="AsOf2023-12-31" decimals="0" id="Fact000161" unitRef="USD"> 5281180 </us-gaap:TreasuryStockCommonValue>

<us-gaap:TreasuryStockCommonValue contextRef="AsOf2022-12-31" decimals="0" id="Fact000162" unitRef="USD"> 5281180 </us-gaap:TreasuryStockCommonValue>

<us-gaap:StockholdersEquity contextRef="AsOf2023-12-31" decimals="0" id="Fact000164" unitRef="USD"> 9795641 </us-gaap:StockholdersEquity>

<us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="0" id="Fact000165" unitRef="USD"> 13647134 </us-gaap:StockholdersEquity>

<us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2023-12-31" decimals="0" id="Fact000167" unitRef="USD"> 10605226 </us-gaap:LiabilitiesAndStockholdersEquity>

<us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2022-12-31" decimals="0" id="Fact000168" unitRef="USD"> 14720290 </us-gaap:LiabilitiesAndStockholdersEquity>

<us-gaap:RoyaltyIncomeNonoperating contextRef="From2023-01-01to2023-12-31" decimals="0" id="Fact000173" unitRef="USD"> 2539986 </us-gaap:RoyaltyIncomeNonoperating>

<us-gaap:RoyaltyIncomeNonoperating contextRef="From2022-01-012022-12-31" decimals="0" id="Fact000174" unitRef="USD"> 1706925 </us-gaap:RoyaltyIncomeNonoperating>

<us-gaap:Revenues contextRef="From2023-01-01to2023-12-31" decimals="0" id="Fact000176" unitRef="USD"> 2539986 </us-gaap:Revenues>

<us-gaap:Revenues contextRef="From2022-01-012022-12-31" decimals="0" id="Fact000177" unitRef="USD"> 1706925 </us-gaap:Revenues>

<us-gaap:ResearchAndDevelopmentExpense contextRef="From2023-01-01to2023-12-31" decimals="0" id="Fact000182" unitRef="USD"> 3494765 </us-gaap:ResearchAndDevelopmentExpense>

<us-gaap:ResearchAndDevelopmentExpense contextRef="From2022-01-012022-12-31" decimals="0" id="Fact000183" unitRef="USD"> 4770834 </us-gaap:ResearchAndDevelopmentExpense>

<us-gaap:GeneralAndAdministrativeExpense contextRef="From2023-01-01to2023-12-31" decimals="0" id="Fact000185" unitRef="USD"> 3560936 </us-gaap:GeneralAndAdministrativeExpense>

<us-gaap:GeneralAndAdministrativeExpense contextRef="From2022-01-012022-12-31" decimals="0" id="Fact000186" unitRef="USD"> 3653999 </us-gaap:GeneralAndAdministrativeExpense>

<us-gaap:OperatingExpenses contextRef="From2023-01-01to2023-12-31" decimals="0" id="Fact000188" unitRef="USD"> 7055701 </us-gaap:OperatingExpenses>

<us-gaap:OperatingExpenses contextRef="From2022-01-012022-12-31" decimals="0" id="Fact000189" unitRef="USD"> 8424833 </us-gaap:OperatingExpenses>

<us-gaap:OperatingIncomeLoss contextRef="From2023-01-01to2023-12-31" decimals="0" id="Fact000191" unitRef="USD"> -4515715 </us-gaap:OperatingIncomeLoss>

<us-gaap:OperatingIncomeLoss contextRef="From2022-01-012022-12-31" decimals="0" id="Fact000192" unitRef="USD"> -6717908 </us-gaap:OperatingIncomeLoss>

<us-gaap:OtherNonoperatingIncomeExpense contextRef="From2023-01-01to2023-12-31" decimals="0" id="Fact000197" unitRef="USD"> 25380 </us-gaap:OtherNonoperatingIncomeExpense>

<us-gaap:OtherNonoperatingIncomeExpense contextRef="From2022-01-012022-12-31" decimals="0" id="Fact000198" unitRef="USD"> -1597 </us-gaap:OtherNonoperatingIncomeExpense>

<us-gaap:InterestIncomeExpenseNet contextRef="From2023-01-01to2023-12-31" decimals="0" id="Fact000200" unitRef="USD"> 355757 </us-gaap:InterestIncomeExpenseNet>

<us-gaap:InterestIncomeExpenseNet contextRef="From2022-01-012022-12-31" decimals="0" id="Fact000201" unitRef="USD"> 167152 </us-gaap:InterestIncomeExpenseNet>

<us-gaap:NonoperatingIncomeExpense contextRef="From2023-01-01to2023-12-31" decimals="0" id="Fact000203" unitRef="USD"> 381137 </us-gaap:NonoperatingIncomeExpense>

<us-gaap:NonoperatingIncomeExpense contextRef="From2022-01-012022-12-31" decimals="0" id="Fact000204" unitRef="USD"> 165555 </us-gaap:NonoperatingIncomeExpense>

<us-gaap:NetIncomeLoss contextRef="From2023-01-01to2023-12-31" decimals="0" id="Fact000206" unitRef="USD"> -4134578 </us-gaap:NetIncomeLoss>

<us-gaap:NetIncomeLoss contextRef="From2022-01-012022-12-31" decimals="0" id="Fact000207" unitRef="USD"> -6552353 </us-gaap:NetIncomeLoss>

<us-gaap:EarningsPerShareBasic contextRef="From2023-01-01to2023-12-31" decimals="INF" id="Fact000209" unitRef="USDPShares"> -2.71 </us-gaap:EarningsPerShareBasic>

<us-gaap:EarningsPerShareDiluted contextRef="From2023-01-01to2023-12-31" decimals="INF" id="Fact000211" unitRef="USDPShares"> -2.71 </us-gaap:EarningsPerShareDiluted>

<us-gaap:EarningsPerShareBasic contextRef="From2022-01-012022-12-31" decimals="INF" id="Fact000213" unitRef="USDPShares"> -4.61 </us-gaap:EarningsPerShareBasic>

<us-gaap:EarningsPerShareDiluted contextRef="From2022-01-012022-12-31" decimals="INF" id="Fact000215" unitRef="USDPShares"> -4.61 </us-gaap:EarningsPerShareDiluted>

<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2023-01-01to2023-12-31" decimals="INF" id="Fact000217" unitRef="Shares"> 1528210 </us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>

<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2023-01-01to2023-12-31" decimals="INF" id="Fact000219" unitRef="Shares"> 1528210 </us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>

<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2022-01-012022-12-31" decimals="INF" id="Fact000221" unitRef="Shares"> 1422443 </us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>

<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2022-01-012022-12-31" decimals="INF" id="Fact000223" unitRef="Shares"> 1422443 </us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>

<us-gaap:SharesOutstanding contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember" decimals="INF" id="Fact000233" unitRef="Shares"> 2774394 </us-gaap:SharesOutstanding>

<us-gaap:StockholdersEquity contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember" decimals="0" id="Fact000225" unitRef="USD"> 2774 </us-gaap:StockholdersEquity>

<us-gaap:SharesOutstanding contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" decimals="INF" id="Fact000235" unitRef="Shares"> 1346661 </us-gaap:SharesOutstanding>

<us-gaap:StockholdersEquity contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" decimals="0" id="Fact000226" unitRef="USD"> 1347 </us-gaap:StockholdersEquity>

<us-gaap:StockholdersEquity contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact000227" unitRef="USD"> 205964847 </us-gaap:StockholdersEquity>

<us-gaap:StockholdersEquity contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" decimals="0" id="Fact000228" unitRef="USD"> -182547265 </us-gaap:StockholdersEquity>

<us-gaap:StockholdersEquity contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="Fact000229" unitRef="USD"> 253734 </us-gaap:StockholdersEquity>

<us-gaap:StockholdersEquity contextRef="AsOf2021-12-31_us-gaap_TreasuryStockCommonMember" decimals="0" id="Fact000230" unitRef="USD"> -5281180 </us-gaap:StockholdersEquity>

<us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" id="Fact000231" unitRef="USD"> 18394257 </us-gaap:StockholdersEquity>

<us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" decimals="INF" id="Fact000245" unitRef="Shares"> 172500 </us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>

<xbio:StockIssuedDuringPeriodValueReverseStockSplits contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" decimals="INF" id="Fact000238" unitRef="Shares"> 173 </xbio:StockIssuedDuringPeriodValueReverseStockSplits>

<xbio:StockIssuedDuringPeriodValueReverseStockSplits contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="INF" id="Fact000239" unitRef="Shares"> 1293577 </xbio:StockIssuedDuringPeriodValueReverseStockSplits>

<xbio:StockIssuedDuringPeriodValueReverseStockSplits contextRef="From2022-01-012022-12-31" decimals="INF" id="Fact000243" unitRef="Shares"> 1293750 </xbio:StockIssuedDuringPeriodValueReverseStockSplits>

<xbio:ExerciseOfPurchaseWarrantsshares contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" decimals="INF" id="Fact000255" unitRef="Shares"> 199 </xbio:ExerciseOfPurchaseWarrantsshares>

<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact000259" unitRef="USD"> 511480 </us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2022-01-012022-12-31" decimals="0" id="Fact000263" unitRef="USD"> 511480 </us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

<us-gaap:NetIncomeLoss contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" decimals="0" id="Fact000268" unitRef="USD"> -6552353 </us-gaap:NetIncomeLoss>

<us-gaap:NetIncomeLoss contextRef="From2022-01-012022-12-31" decimals="0" id="Fact000271" unitRef="USD"> -6552353 </us-gaap:NetIncomeLoss>

<us-gaap:SharesOutstanding contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember" decimals="INF" id="Fact000281" unitRef="Shares"> 2774394 </us-gaap:SharesOutstanding>

<us-gaap:StockholdersEquity contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember" decimals="0" id="Fact000273" unitRef="USD"> 2774 </us-gaap:StockholdersEquity>

<us-gaap:SharesOutstanding contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" decimals="INF" id="Fact000283" unitRef="Shares"> 1519360 </us-gaap:SharesOutstanding>

<us-gaap:StockholdersEquity contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" decimals="0" id="Fact000274" unitRef="USD"> 1520 </us-gaap:StockholdersEquity>

<us-gaap:StockholdersEquity contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact000275" unitRef="USD"> 207769904 </us-gaap:StockholdersEquity>

<us-gaap:StockholdersEquity contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" decimals="0" id="Fact000276" unitRef="USD"> -189099618 </us-gaap:StockholdersEquity>

<us-gaap:StockholdersEquity contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="Fact000277" unitRef="USD"> 253734 </us-gaap:StockholdersEquity>

<us-gaap:StockholdersEquity contextRef="AsOf2022-12-31_us-gaap_TreasuryStockCommonMember" decimals="0" id="Fact000278" unitRef="USD"> -5281180 </us-gaap:StockholdersEquity>

<us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="0" id="Fact000279" unitRef="USD"> 13647134 </us-gaap:StockholdersEquity>

<xbio:IssuanceOfCommonStockToAdjustForReverseSplitRoundingShares contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" decimals="INF" id="Fact000293" unitRef="Shares"> 15941 </xbio:IssuanceOfCommonStockToAdjustForReverseSplitRoundingShares>

<xbio:IssuanceOfCommonStockToAdjustForReverseSplitRounding contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" decimals="0" id="Fact000286" unitRef="USD"> 16 </xbio:IssuanceOfCommonStockToAdjustForReverseSplitRounding>

<xbio:IssuanceOfCommonStockToAdjustForReverseSplitRounding contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact000287" unitRef="USD"> -16 </xbio:IssuanceOfCommonStockToAdjustForReverseSplitRounding>

<xbio:ConversionOfSeriesPreferredStockToSharesOfCommonStockShares contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember" decimals="INF" id="Fact000303" unitRef="Shares"> -970000 </xbio:ConversionOfSeriesPreferredStockToSharesOfCommonStockShares>

<xbio:ConversionOfSeriesPreferredStockToSharesOfCommonStock contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember" decimals="0" id="Fact000295" unitRef="USD"> -970 </xbio:ConversionOfSeriesPreferredStockToSharesOfCommonStock>

<xbio:ConversionOfSeriesPreferredStockToSharesOfCommonStockShares contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" decimals="INF" id="Fact000305" unitRef="Shares"> 8084 </xbio:ConversionOfSeriesPreferredStockToSharesOfCommonStockShares>

<xbio:ConversionOfSeriesPreferredStockToSharesOfCommonStock contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" decimals="0" id="Fact000296" unitRef="USD"> 8 </xbio:ConversionOfSeriesPreferredStockToSharesOfCommonStock>

<xbio:ConversionOfSeriesPreferredStockToSharesOfCommonStock contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact000297" unitRef="USD"> 962 </xbio:ConversionOfSeriesPreferredStockToSharesOfCommonStock>

<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact000309" unitRef="USD"> 283085 </us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2023-01-01to2023-12-31" decimals="0" id="Fact000313" unitRef="USD"> 283085 </us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

<us-gaap:NetIncomeLoss contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" decimals="0" id="Fact000318" unitRef="USD"> -4134578 </us-gaap:NetIncomeLoss>

<us-gaap:NetIncomeLoss contextRef="From2023-01-01to2023-12-31" decimals="0" id="Fact000321" unitRef="USD"> -4134578 </us-gaap:NetIncomeLoss>

<us-gaap:SharesOutstanding contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember" decimals="INF" id="Fact000331" unitRef="Shares"> 1804394 </us-gaap:SharesOutstanding>

<us-gaap:StockholdersEquity contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember" decimals="0" id="Fact000323" unitRef="USD"> 1804 </us-gaap:StockholdersEquity>

<us-gaap:SharesOutstanding contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" decimals="INF" id="Fact000333" unitRef="Shares"> 1543385 </us-gaap:SharesOutstanding>

<us-gaap:StockholdersEquity contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" decimals="0" id="Fact000324" unitRef="USD"> 1544 </us-gaap:StockholdersEquity>

<us-gaap:StockholdersEquity contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact000325" unitRef="USD"> 208053935 </us-gaap:StockholdersEquity>

<us-gaap:StockholdersEquity contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" decimals="0" id="Fact000326" unitRef="USD"> -193234196 </us-gaap:StockholdersEquity>

<us-gaap:StockholdersEquity contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="Fact000327" unitRef="USD"> 253734 </us-gaap:StockholdersEquity>

<us-gaap:StockholdersEquity contextRef="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember" decimals="0" id="Fact000328" unitRef="USD"> -5281180 </us-gaap:StockholdersEquity>

<us-gaap:StockholdersEquity contextRef="AsOf2023-12-31" decimals="0" id="Fact000329" unitRef="USD"> 9795641 </us-gaap:StockholdersEquity>

<us-gaap:NetIncomeLoss contextRef="From2023-01-01to2023-12-31" decimals="0" id="Fact000338" unitRef="USD"> -4134578 </us-gaap:NetIncomeLoss>

<us-gaap:NetIncomeLoss contextRef="From2022-01-012022-12-31" decimals="0" id="Fact000339" unitRef="USD"> -6552353 </us-gaap:NetIncomeLoss>

<xbio:ResearchAndDevelopmentsInProcess contextRef="From2023-01-01to2023-12-31" decimals="0" id="Fact000344" unitRef="USD"> 0 </xbio:ResearchAndDevelopmentsInProcess>

<xbio:ResearchAndDevelopmentsInProcess contextRef="From2022-01-012022-12-31" decimals="0" id="Fact000345" unitRef="USD"> 1793750 </xbio:ResearchAndDevelopmentsInProcess>

<us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="From2023-01-01to2023-12-31" decimals="0" id="Fact000347" unitRef="USD"> 0 </us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>

<us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="From2022-01-012022-12-31" decimals="0" id="Fact000348" unitRef="USD"> 27043 </us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>

<us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="From2023-01-01to2023-12-31" decimals="0" id="Fact000350" unitRef="USD"> 283085 </us-gaap:EmployeeBenefitsAndShareBasedCompensation>

<us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="From2022-01-012022-12-31" decimals="0" id="Fact000351" unitRef="USD"> 511480 </us-gaap:EmployeeBenefitsAndShareBasedCompensation>

<us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables contextRef="From2023-01-01to2023-12-31" decimals="0" id="Fact000356" unitRef="USD"> 47734 </us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>

<us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables contextRef="From2022-01-012022-12-31" decimals="0" id="Fact000357" unitRef="USD"> 103738 </us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>

<us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="From2023-01-01to2023-12-31" decimals="0" id="Fact000359" unitRef="USD"> -48579 </us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>

<us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="From2022-01-012022-12-31" decimals="0" id="Fact000360" unitRef="USD"> -25000 </us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>

<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2023-01-01to2023-12-31" decimals="0" id="Fact000362" unitRef="USD"> -263571 </us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>

<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2022-01-012022-12-31" decimals="0" id="Fact000363" unitRef="USD"> -347947 </us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>

<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2023-01-01to2023-12-31" decimals="0" id="Fact000365" unitRef="USD"> -4114219 </us-gaap:NetCashProvidedByUsedInOperatingActivities>

<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2022-01-012022-12-31" decimals="0" id="Fact000366" unitRef="USD"> -4646765 </us-gaap:NetCashProvidedByUsedInOperatingActivities>

<us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment contextRef="From2023-01-01to2023-12-31" decimals="0" id="Fact000371" unitRef="USD"> -0 </us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>

<us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment contextRef="From2022-01-012022-12-31" decimals="0" id="Fact000372" unitRef="USD"> 500000 </us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>

<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2023-01-01to2023-12-31" decimals="0" id="Fact000374" unitRef="USD"> 0 </us-gaap:NetCashProvidedByUsedInInvestingActivities>

<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2022-01-012022-12-31" decimals="0" id="Fact000375" unitRef="USD"> -500000 </us-gaap:NetCashProvidedByUsedInInvestingActivities>

<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="From2023-01-01to2023-12-31" decimals="0" id="Fact000377" unitRef="USD"> -4114219 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>

<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="From2022-01-012022-12-31" decimals="0" id="Fact000378" unitRef="USD"> -5146765 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>

<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2022-12-31" decimals="0" id="Fact000380" unitRef="USD"> 13097265 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>

<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2021-12-31" decimals="0" id="Fact000381" unitRef="USD"> 18244030 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>

<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2023-12-31" decimals="0" id="Fact000383" unitRef="USD"> 8983046 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>

<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2022-12-31" decimals="0" id="Fact000384" unitRef="USD"> 13097265 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>

<us-gaap:InterestPaidNet contextRef="From2023-01-01to2023-12-31" decimals="0" id="Fact000389" unitRef="USD"> 0 </us-gaap:InterestPaidNet>

<us-gaap:InterestPaidNet contextRef="From2022-01-012022-12-31" decimals="0" id="Fact000390" unitRef="USD"> 0 </us-gaap:InterestPaidNet>

<xbio:IssuanceOfCommonStockToAcquireInprocessResearchAndDevelopment contextRef="From2023-01-01to2023-12-31" decimals="0" id="Fact000395" unitRef="USD"> 0 </xbio:IssuanceOfCommonStockToAcquireInprocessResearchAndDevelopment>

<xbio:IssuanceOfCommonStockToAcquireInprocessResearchAndDevelopment contextRef="From2022-01-012022-12-31" decimals="0" id="Fact000396" unitRef="USD"> 1293750 </xbio:IssuanceOfCommonStockToAcquireInprocessResearchAndDevelopment>

<xbio:IssuanceOfCommonStockToAdjustForReverseStockSplit contextRef="From2023-01-01to2023-12-31" decimals="0" id="Fact000398" unitRef="USD"> 16 </xbio:IssuanceOfCommonStockToAdjustForReverseStockSplit>

<xbio:IssuanceOfCommonStockToAdjustForReverseStockSplit contextRef="From2022-01-012022-12-31" decimals="0" id="Fact000399" unitRef="USD"> 0 </xbio:IssuanceOfCommonStockToAdjustForReverseStockSplit>

<xbio:ConversionOfSeriesPreferredStockToCommonStock contextRef="From2023-01-01to2023-12-31" decimals="0" id="Fact000401" unitRef="USD"> 970 </xbio:ConversionOfSeriesPreferredStockToCommonStock>

<xbio:ConversionOfSeriesPreferredStockToCommonStock contextRef="From2022-01-012022-12-31" decimals="0" id="Fact000402" unitRef="USD"> 0 </xbio:ConversionOfSeriesPreferredStockToCommonStock>

<xbio:TheCompanyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000404">

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">1.</td> <td style="text-align: justify">The Company</td></tr> </table> Background Xenetic Biosciences, Inc. (“Xenetic” or the “Company”), incorporated in the state of Nevada and based in Framingham, Massachusetts, is a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers. The Company’s proprietary Deoxyribonuclease (“DNase”) platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (“NETs”), which have been implicated in cancer progression and resistance to cancer treatments. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors. Additionally, Xenetic has partnered with biotechnology and pharmaceutical companies to develop its proprietary drug delivery platform, PolyXen®, and receives royalty payments under an exclusive license arrangement in the field of blood coagulation disorders. The Company, directly or indirectly, through its wholly-owned subsidiaries, Hesperix S.A. (“Hesperix”) and Xenetic Biosciences (U.K.) Limited (“Xenetic UK”), and the wholly-owned subsidiaries of Xenetic UK, Lipoxen Technologies Limited (“Lipoxen”), Xenetic Bioscience, Incorporated and SymbioTec, GmbH (“SymbioTec”), own various United States (“U.S.”) federal trademark registrations and applications along with unregistered trademarks and service marks, including but not limited to XCART, OncoHist™, PolyXen, ErepoXen™, and ImuXen™, which are used throughout this Annual Report. All other company and product names may be trademarks of the respective companies with which they are associated. Going Concern and Management’s Plan Management evaluates whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. The Company has incurred substantial losses since its inception and expects to continue to incur operating losses in the near-term. These factors raise substantial doubt about its ability to continue as a going concern. The Company believes that it has access to capital resources through possible public or private equity offerings, debt financings, corporate collaborations, related party funding, or other means to continue as a going concern. The Company believes that its existing resources will be adequate to fund the Company’s operations for a period of at least twelve months from the date of the issuance of these financial statements. However, the Company anticipates it may need additional capital in the long-term to pursue its business initiatives. The terms, timing and extent of any future financing will depend upon several factors, including the achievement of progress in its product development programs, its ability to identify and enter into licensing or other strategic arrangements, its continued listing on the Nasdaq Stock Market (“Nasdaq”), and factors related to financial, economic, geo-political, industry and market conditions, many of which are beyond its control. The capital markets for the biotech industry can be highly volatile, which make the terms, timing and extent of any future financing uncertain. On June 3, 2022, the Company received a written notification (the “Notice”) from the Listing Qualifications Department of Nasdaq notifying the Company that the closing bid price for its common stock had been below $1.00 for 30 consecutive business days and that the Company therefore was not in compliance with the minimum bid price requirement for continued inclusion on Nasdaq under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). The Notice had no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market. On May 15, 2023, the Company effected a reduction, on a 1-for-10 basis, in its authorized common stock, par value $0.001, along with a corresponding and proportional decrease in the number of shares issued and outstanding (the “Reverse Stock Split”). On May 30, 2023, the Company received a letter from Nasdaq notifying the Company that it has regained compliance with the Bid Price Requirement as a result of the closing bid price of the Company’s common stock being at $1.00 per share or greater for the 10 consecutive business days from May 15, 2023 through May 26, 2023 and that this matter is closed.

</xbio:TheCompanyTextBlock>

<us-gaap:StockholdersEquityNoteStockSplit contextRef="From2023-05-142023-05-15_us-gaap_CommonStockMember" id="Fact000406"> 1-for-10 </us-gaap:StockholdersEquityNoteStockSplit>

<us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2023-05-15_us-gaap_CommonStockMember" decimals="INF" id="Fact000408" unitRef="USDPShares"> 0.001 </us-gaap:CommonStockParOrStatedValuePerShare>

<us-gaap:SharePrice contextRef="AsOf2023-05-30_us-gaap_CommonStockMember" decimals="INF" id="Fact000410" unitRef="USDPShares"> 1.00 </us-gaap:SharePrice>

<us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000416">

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 5%; text-align: justify">2.</td> <td style="width: 95%; text-align: justify">Risks and Uncertainties </td></tr> </table> Impact of Global Conflicts on Operations The short and long-term implications of Russia’s invasion of Ukraine and conflict in the Middle East are difficult to predict at this time. The imposition of current and future sanctions and counter sanctions may have an adverse effect on the economic markets generally and could impact our business, financial condition, and results of operations.

</us-gaap:ConcentrationRiskDisclosureTextBlock>

<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000418">

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 5%">3.</td> <td style="width: 95%; text-align: justify">Summary of Significant Accounting Policies </td></tr> </table> Preparation of Financial Statements On May 15, 2023, the Company effected the Reverse Stock Split. On the effective date of the Reverse Stock Split, (i) every 10 shares of common stock were reduced to one share of common stock, with any fractional amounts rounded up to one share; (ii) the number of shares of common stock into which each outstanding warrant, restricted stock unit, or option to purchase common stock was convertible into was proportionately reduced on the same basis as the common stock; (iii) the exercise price of each outstanding warrant or option to purchase common stock was proportionately increased on a 1-to-10 basis; and (iv) the number of shares of common stock into which each share of preferred stock was convertible into was proportionately reduced on the same basis as the common stock. Unless otherwise indicated, all of the share numbers, share prices, and exercise prices have been adjusted in this Annual Report, on a retroactive basis, to reflect this 1-for-10 Reverse Stock Split. Principles of Consolidation The consolidated financial statements of the Company include the accounts of Hesperix, Xenetic UK and Xenetic UK’s wholly-owned subsidiaries: Lipoxen, Xenetic Bioscience, Incorporated, and SymbioTec. All material intercompany balances and transactions have been eliminated in consolidation. Certain prior period amounts have been reclassified in this Annual Report to conform to the presentation for the current period. Use of Estimates The consolidated financial statements and accompanying notes are prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). The preparation of the financial statements in accordance with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the reported amounts of revenue, costs and expenses in the financial statements and disclosures in the accompanying notes. Actual results and outcomes may differ materially from management’s estimates, judgments and assumptions. Functional Currency Change The functional currency for the Company’s foreign subsidiaries is the U.S. dollar. The functional currency of the Company’s UK-based subsidiaries changed from the British Pound Sterling to the U.S. dollar when the Company relocated to the U.S. in 2014. The change in functional currency was applied on a prospective basis. Therefore, any gains and losses that were previously recorded in accumulated other comprehensive income remain unchanged. Foreign Currency Transactions Realized and unrealized gains and losses resulting from foreign currency transactions arising from exchange rate fluctuations on balances denominated in currencies other than the functional currencies are recognized in “Other income (expense)” in the consolidated statements of comprehensive loss. Monetary assets and liabilities that are denominated in a currency other than the functional currency are re-measured to the functional currency using the exchange rate at the balance sheet date and gains or losses are recorded in the consolidated statements of comprehensive loss. Fair Value of Financial Instruments Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurement, defines fair value as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement. Level 1 inputs are quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 2 utilizes quoted market prices in markets that are not active, broker or dealer quotations or alternative pricing sources with reasonable levels of price transparency. Level 3 inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date. As of December 31, 2023 and 2022, the carrying amount of certain of the Company’s financial instruments approximates fair value due to their short maturities. See Note 8, Fair Value Measurements, for discussion of the Company’s fair value measurements. Cash and Concentrations of Credit Risk The Company considers all highly liquid investments with an original maturity of 90 days or less from the date of purchase to be cash equivalents. Investments with original maturities of greater than 90 days from the date of purchase but less than one year from the balance sheet date are classified as short-term investments, while investments with maturities of one year or beyond from the balance sheet date are classified as long-term investments. Management determines the appropriate classification of its cash equivalents and investment securities at the time of purchase and re-evaluates such determination as of each balance sheet date. The carrying amount of cash equivalents approximate their fair value due to the short-term nature of these instruments. Financial instruments that potentially subject the Company to credit risk consist primarily of cash on deposit with financial institutions, the balances of which may exceed federally insured limits. The Company has not experienced any losses on such accounts, and does not believe it is exposed to any unusual credit risk beyond the normal credit risk currently associated with commercial banking relationships. The Company maintains its primary banking relationship with one large financial institution and all cash on deposit is covered under federally insured limits. Property and Equipment The Company records property and equipment at cost less accumulated depreciation. Expenditures for major renewals and improvements which extend the life or usefulness of the asset are capitalized. Items of an ordinary repair or maintenance nature are charged directly to operating expense as incurred. The Company calculates depreciation using the straight-line method over the estimated useful lives of the assets: <table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--AssetsEstimatedUsefulLifeTableTextBlock_zvueWWuq5bsi" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of estimated useful life of assets</td> <td> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid; width: 49%">Asset Classification</td> <td style="width: 2%"> </td> <td style="border-bottom: black 1pt solid; width: 49%; text-align: center">Estimated Useful Life</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Office and computer equipment</td> <td> </td> <td><span id="xdx_90A_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLives1_c20230101__20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeAndComputerEquipmentMember_z6jAdkTxSA44" title="Estimated useful life">3 years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Leasehold improvements</td> <td> </td> <td><span id="xdx_90C_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLives1_c20230101__20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zBNuO9upJ0ei" title="Estimated useful life">5 years or the remaining term of the lease, if shorter</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Furniture and fixtures</td> <td> </td> <td><span id="xdx_902_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLives1_c20230101__20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zqCcV8fQWZf2" title="Estimated useful life">5 years</td></tr> </table> The Company eliminates the cost of assets retired or otherwise disposed of, along with the corresponding accumulated depreciation, from the related accounts, and the resulting gain or loss is reflected in the results of operations. Indefinite-Lived Intangible Assets Assets acquired and liabilities assumed in business combinations, licensing and other transactions are generally recognized at the date of acquisition at their respective fair values. At acquisition, the Company generally determines the fair value of intangible assets, including in-process research and development (“IPR&D”), using the “income method.” Acquired IPR&D intangible assets are considered indefinite-lived intangible assets and are not amortized until completion or abandonment of the associated research and development efforts. Substantial additional research and development may be required before the Company’s IPR&D reaches technological feasibility. Upon completion of the IPR&D project, the IPR&D assets will be amortized over their estimated useful lives. IPR&D is not amortized but is reviewed for impairment at least annually or when events or changes in the business environment indicate that it is more likely than not that the carrying value may be impaired. The Company also has the option to first assess qualitative factors to determine whether the existence of events or circumstances leads the Company to determine that it is more likely than not (that is, a likelihood of more than 50%) that the acquired IPR&D is impaired. If the Company chooses to first assess the qualitative factors and it is determined that it is not more likely than not acquired IPR&D is impaired, the Company is not required to take further action to test for impairment. The Company also has the option to bypass the qualitative assessment and perform only the quantitative impairment test, which the Company may choose to perform in some periods but not in others. The impairment loss, if any, is measured as the excess of the carrying value of the intangible asset over its fair value. Intangible assets are highly vulnerable to impairment charges, particularly newly acquired assets for IPR&D. Considering the high risk nature of research and development and the industry’s success rate of bringing developmental compounds to market, IPR&D impairment charges are likely to occur in future periods. Estimating the fair value of IPR&D for potential impairment is highly sensitive to changes in projections and assumptions and changes to assumptions could potentially lead to impairment. The Company believes its estimates and assumptions are reasonable and otherwise consistent with assumptions market participants would use in their estimates of fair value. However, if future results are not consistent with the Company’s estimates and assumptions, then the Company may be exposed to an impairment charge, which could be material. Use of different estimates and judgments could yield materially different results in the Company’s analysis and could result in materially different asset values or expense. Impairment of Long-Lived Assets The Company reviews long-lived assets to be held and used, including property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be fully recoverable. Evaluation of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset or asset group and its eventual disposition. Impairment, if any, is calculated as the amount by which an asset’s carrying value exceeds its fair value, typically using discounted cash flows to determine fair value. No such impairments were recorded during the years ended December 31, 2023 and 2022. Revenue Recognition The Company enters into supply, license and collaboration arrangements with pharmaceutical and biotechnology partners, some of which include royalty agreements based on potential net sales of approved commercial pharmaceutical products. The Company recognizes revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue at a point in time, or over time, as it satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. As part of the accounting for these arrangements, the Company must use significant judgment to determine: a) the number of performance obligations based on the determination under step (ii) above; b) the transaction price under step (iii) above; and c) the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above. The Company uses judgment to determine whether milestones or other variable consideration should be included in the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. In developing the stand-alone price for a performance obligation, the Company considers applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer and estimated costs. The Company validates the stand-alone selling price for performance obligations by evaluating whether changes in the key assumptions used to determine the stand-alone selling prices will have a significant effect on the allocation of transaction price between multiple performance obligations. The Company recognizes a contract asset or liability for the difference between the Company’s performance (i.e., the goods or services transferred to the customer) and the customer’s performance (i.e., the consideration paid by, and unconditionally due from, the customer). The terms of the Company’s license agreements may include delivery of an IP license to a collaboration partner. The Company may be compensated under license arrangements through a combination of non-refundable upfront receipts, development and regulatory objective receipts and royalty receipts on future product sales by partners. The Company anticipates recognizing non-refundable upfront license payments and development and regulatory milestone payments received by the Company in license and collaboration arrangements that include future obligations, such as supply obligations, ratably over the Company’s expected performance period under each respective arrangement. The Company makes its best estimate of the period over which the Company expects to fulfill the Company’s performance obligations, which may include technology transfer assistance, research activities, clinical development activities, and manufacturing activities from development through the commercialization of the product. Given the uncertainties of these collaboration arrangements, significant judgment is required to determine the duration of the performance period. When the Company enters into an arrangement to sublicense some of its patents, it will consider the performance obligations to determine if there is a single element or multiple elements to the arrangement as it determines the proper method and timing of revenue recognition. The Company considers the terms of the license or sublicense for such elements as price adjustments or refund clauses in addition to any performance obligations for it to provide such as services, patent defense costs, technology support, marketing or sales assistance or any other elements to the arrangement that could constitute an additional deliverable to it that could change the timing of the revenue recognition. Non-refundable upfront license and sublicense fees received, whereby continued performance or future obligations are considered inconsequential or perfunctory to the relevant licensed technology, are recognized as revenue upon delivery of the technology. The Company expects to recognize royalty revenue in the period of sale, based on the underlying contract terms, provided that the reported sales are reliably measurable, the Company has no remaining performance obligations, and all other revenue recognition criteria are met. The Company anticipates reimbursements for research and development services completed by the Company related to the collaboration agreements to be recognized in operations as revenue on a gross basis. The Company’s license and collaboration agreements with certain collaboration partners could also provide for future milestone receipts to the Company based solely upon the performance of the respective collaboration partner in consideration of deadline extensions or upon the achievement of specified sales volumes of approved drugs. For such receipts, the Company expects to recognize the receipts as revenue when earned under the applicable contract terms on a performance basis or ratably over the term of the agreement. These receipts may also be recognized as revenue when continued performance or future obligations by the Company are considered inconsequential or perfunctory. See also Note 4, Significant Strategic Collaborations. Research and Development Expenses Research and development expenses consist of expenses incurred in performing research and development activities, including compensation and benefits, facilities expenses, overhead expenses, pre-clinical development, clinical trial and related clinical manufacturing expenses, fees paid to contract research organizations (“CROs”) and contract manufacturing organizations (“CMOs”) and other outside expenses. The Company expenses research and development costs as incurred. The Company expenses upfront, non-refundable payments made for research and development services as obligations are incurred. The value ascribed to intangible assets acquired but which have not met capitalization criteria is expensed as research and development at the time of acquisition. Upfront payments under license agreements are expensed upon receipt of the license. Milestone payments under license agreements are accrued, with a corresponding expense being recognized, in the period in which the milestone is determined to be probable of achievement and the related amount is reasonably estimable. The Company is required to estimate accrued research and development expenses at each reporting period. This process involves reviewing open contracts and purchase orders, communicating with Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual costs. The majority of the Company’s service providers invoice in arrears for services performed, on a pre-determined schedule or when contractual milestones are met. However, some require advanced payments. The Company makes estimates of accrued expenses as of each balance sheet date in the financial statements based on facts and circumstances known at that time. The Company periodically confirms the accuracy of the estimates with the service providers and makes adjustments, if necessary. Examples of estimated accrued research and development expenses include fees paid to: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px"> · ·</td> <td> Collaborative partners performing research and development and pre-clinical activities; Program managers in connection with overall program management of clinical trials;</td></tr> <tr style="vertical-align: top"> <td> </td> <td>·</td> <td>CMOs in connection with cGMP manufacturing; </td></tr> <tr style="vertical-align: top"> <td> </td> <td>·</td> <td>CROs in connection with clinical trials; and</td></tr> <tr style="vertical-align: top"> <td> </td> <td>·</td> <td>Investigative sites in connection with clinical trials.</td></tr> </table> The Company bases its expenses related to research and development, pre-clinical activities, manufacturing and clinical trials on its estimates of the services received and efforts expended pursuant to quotes and contracts with multiple research institutions, CMOs and CROs that conduct and manage clinical trials on the Company’s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to vendors will exceed the level of services provided and result in a prepayment of the expense. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company adjusts the accrual or prepaid accordingly. Although it does not expect its estimates to be materially different from amounts actually incurred, the Company’s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to the Company’s prior estimates of accrued research and development expenses. The Company has recorded approximately $0.5 million and $0.3 million of prepayments as a component of prepaid expenses and other current assets as of December 31, 2023 and 2022, respectively. In addition, the Company had recorded accrued program expense of approximately $<span id="xdx_904_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_dm_c20231231__us-gaap--BalanceSheetLocationAxis__custom--ResearchAndDevelopmentExpensesMember_zurhLYs1Ncv1" title="Accrued expenses"><span id="xdx_907_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_dm_c20221231__us-gaap--BalanceSheetLocationAxis__custom--ResearchAndDevelopmentExpensesMember_z8Ogqllu9htc" title="Accrued expenses">0.1 million as a component of accrued expenses as of each of December 31, 2023 and 2022. Share-based Expense The Company grants share-based payments in the form of options and restricted stock units (“RSUs”) to employees and non-employees to purchase shares of the Company’s common stock, Joint Share Ownership Plan (“JSOP”) awards to employees and agreements to issue common stock in exchange for services provided by non-employees. Share-based expense is based on the estimated fair value of the option or calculated using the Black-Scholes option pricing model. Determining the appropriate fair value model and related assumptions requires judgment, including estimating share price volatility and expected terms of the awards. The expected volatility rates are estimated based on the historical volatility of the Company. To the extent Company data is not available for the full expected term of the awards the Company uses a weighted-average of the historical volatility of the Company and of a peer group of comparable publicly traded companies over the expected term of the option. The expected term represents the time that options are expected to be outstanding. The Company accounts for forfeitures as they occur and not at the time of grant. The Company has not paid dividends and does not anticipate paying cash dividends in the foreseeable future and, accordingly, uses an expected dividend yield of zero. The risk-free interest rate is based on the rate of U.S. Treasury securities with maturities consistent with the estimated expected term of the awards. Upon exercise, stock options are redeemed for newly issued shares of common stock. RSUs are redeemed for newly issued shares of common stock as the vesting and settlement provisions of the grant are met. For employee options that vest based solely on service conditions, the fair value measurement date is generally on the date of grant and the related compensation expense is recognized on a straight-line basis over the requisite vesting period of the awards. For non-employee options issued in exchange for goods or services consumed in the Company’s operations, the fair value measurement date is the earlier of the date the performance of services is complete or the date the performance commitment has been reached. The Company generally determines that the fair value of the stock options is more reliably measurable than the fair value of the services received. Compensation expense related to stock options granted to non-employees is recognized on a straight-line basis over requisite vesting periods of the awards. Warrants In connection with certain financing, consulting and collaboration arrangements, the Company has issued warrants to purchase shares of its common stock. The outstanding warrants are standalone instruments that are not puttable or mandatorily redeemable by the holder and are classified as equity awards. The Company measures the fair value of the awards using the Black-Scholes option pricing model as of the measurement date. Warrants issued to collaboration partners in conjunction with the issuance of common stock are initially recorded at fair value as a reduction in additional paid-in capital of the common stock issued. All other warrants are recorded at fair value as expense on a straight-line basis over the requisite service period or at the date of issuance if there is not a service period or if service has already been rendered. Warrants granted in connection with ongoing arrangements are more fully described in Note 10, Stockholders’ Equity. Income Taxes The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on temporary differences resulting from the different treatment of items for tax and financial reporting purposes. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to reverse. Additionally, the Company must assess the likelihood that deferred tax assets will be recovered as deductions from future taxable income. The Company evaluates the recoverability of its deferred tax assets on a quarterly basis. Basic and Diluted Net Loss per Share The Company computes basic net loss per share by dividing net loss applicable to common stockholders by the weighted-average number of shares of the Company’s common stock outstanding during the period. The Company computes diluted net loss per share after giving consideration to the dilutive effect of stock options that are outstanding during the period, except where such non-participating securities would be anti-dilutive. The Company’s JSOP awards, prior to exercise, are considered treasury shares by the Company and thus do not impact the Company’s net loss per share calculation. For the years ended December 31, 2023 and 2022, basic and diluted net loss per share are the same for each year due to the Company’s net loss position. Potentially dilutive, non-participating securities have not been included in the calculations of diluted net loss per share, as their inclusion would be anti-dilutive. As of December 31, 2023 and 2022, approximately 5,000 potentially dilutive securities were deemed anti-dilutive for each period. Segment Information Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, who is the Company’s Chief Executive Officer, in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business in one operating segment. Leases The Company leases administrative facilities under operating leases. Lease agreements may include rent holidays, rent escalation clauses and tenant improvement allowances. The Company recognizes a lease liability and a right-of-use asset for all leases, with the exception of short-term leases, at the commencement date. See Note 13, Commitments and Contingencies for further information. Acquisitions The Company has a history of engaging in acquisition transactions that require the Company to evaluate whether the transaction meets the criteria of a business combination. If the transaction does not meet the business combination requirements, the transaction is accounted for as an asset acquisition or recapitalization and no goodwill is recognized. If the acquisition meets the definition of a business combination, the Company allocates the purchase price, including any contingent consideration, to the assets acquired and the liabilities assumed at their estimated fair values as of the date of the acquisition with any excess of the purchase price paid over the estimated fair value of net assets acquired recorded as goodwill. The fair value of the assets acquired and liabilities assumed is typically determined by using either estimates of replacement costs or discounted cash flow valuation methods. When determining the fair value of tangible assets acquired, the Company estimates the cost to replace the asset with a new asset, taking into consideration such factors as age, condition and the economic useful life of the asset. When determining the fair value of intangible assets acquired, the Company uses judgment to estimate the applicable discount rate, growth rates and the timing and amount of future cash flows. The fair value of assets acquired and liabilities assumed is typically determined using the assistance of an independent third-party specialist. Business combination related costs are expensed in the period in which the costs are incurred. Asset acquisition related costs are generally capitalized as a component of cost of the assets acquired. Recent Accounting Standards In June 2016, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The guidance modified the measurement and recognition of credit losses for most financial assets and certain other instruments. The amendment updated the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the “incurred loss” model with an “expected loss” model. This may result in earlier recognition of allowance for losses. The Company adopted ASU 2016-13 as of January 1, 2023 and the adoption did not have a material effect on our consolidated financial statements.

</us-gaap:SignificantAccountingPoliciesTextBlock>

<xbio:PreparationOfInterimFinancialStatementsPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000420">

Preparation of Financial Statements On May 15, 2023, the Company effected the Reverse Stock Split. On the effective date of the Reverse Stock Split, (i) every 10 shares of common stock were reduced to one share of common stock, with any fractional amounts rounded up to one share; (ii) the number of shares of common stock into which each outstanding warrant, restricted stock unit, or option to purchase common stock was convertible into was proportionately reduced on the same basis as the common stock; (iii) the exercise price of each outstanding warrant or option to purchase common stock was proportionately increased on a 1-to-10 basis; and (iv) the number of shares of common stock into which each share of preferred stock was convertible into was proportionately reduced on the same basis as the common stock. Unless otherwise indicated, all of the share numbers, share prices, and exercise prices have been adjusted in this Annual Report, on a retroactive basis, to reflect this 1-for-10 Reverse Stock Split.

</xbio:PreparationOfInterimFinancialStatementsPolicyTextBlock>

<us-gaap:ConsolidationPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000422">

Principles of Consolidation The consolidated financial statements of the Company include the accounts of Hesperix, Xenetic UK and Xenetic UK’s wholly-owned subsidiaries: Lipoxen, Xenetic Bioscience, Incorporated, and SymbioTec. All material intercompany balances and transactions have been eliminated in consolidation. Certain prior period amounts have been reclassified in this Annual Report to conform to the presentation for the current period.

</us-gaap:ConsolidationPolicyTextBlock>

<us-gaap:UseOfEstimates contextRef="From2023-01-01to2023-12-31" id="Fact000424">

Use of Estimates The consolidated financial statements and accompanying notes are prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). The preparation of the financial statements in accordance with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the reported amounts of revenue, costs and expenses in the financial statements and disclosures in the accompanying notes. Actual results and outcomes may differ materially from management’s estimates, judgments and assumptions.

</us-gaap:UseOfEstimates>

<us-gaap:ForeignCurrencyDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000426">

Functional Currency Change The functional currency for the Company’s foreign subsidiaries is the U.S. dollar. The functional currency of the Company’s UK-based subsidiaries changed from the British Pound Sterling to the U.S. dollar when the Company relocated to the U.S. in 2014. The change in functional currency was applied on a prospective basis. Therefore, any gains and losses that were previously recorded in accumulated other comprehensive income remain unchanged.

</us-gaap:ForeignCurrencyDisclosureTextBlock>

<us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000428">

Foreign Currency Transactions Realized and unrealized gains and losses resulting from foreign currency transactions arising from exchange rate fluctuations on balances denominated in currencies other than the functional currencies are recognized in “Other income (expense)” in the consolidated statements of comprehensive loss. Monetary assets and liabilities that are denominated in a currency other than the functional currency are re-measured to the functional currency using the exchange rate at the balance sheet date and gains or losses are recorded in the consolidated statements of comprehensive loss.

</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>

<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2023-01-01to2023-12-31" id="Fact000434">

Fair Value of Financial Instruments Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurement, defines fair value as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement. Level 1 inputs are quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 2 utilizes quoted market prices in markets that are not active, broker or dealer quotations or alternative pricing sources with reasonable levels of price transparency. Level 3 inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date. As of December 31, 2023 and 2022, the carrying amount of certain of the Company’s financial instruments approximates fair value due to their short maturities. See Note 8, Fair Value Measurements, for discussion of the Company’s fair value measurements.

</us-gaap:FairValueOfFinancialInstrumentsPolicy>

<us-gaap:ConcentrationRiskCreditRisk contextRef="From2023-01-01to2023-12-31" id="Fact000436">

Cash and Concentrations of Credit Risk The Company considers all highly liquid investments with an original maturity of 90 days or less from the date of purchase to be cash equivalents. Investments with original maturities of greater than 90 days from the date of purchase but less than one year from the balance sheet date are classified as short-term investments, while investments with maturities of one year or beyond from the balance sheet date are classified as long-term investments. Management determines the appropriate classification of its cash equivalents and investment securities at the time of purchase and re-evaluates such determination as of each balance sheet date. The carrying amount of cash equivalents approximate their fair value due to the short-term nature of these instruments. Financial instruments that potentially subject the Company to credit risk consist primarily of cash on deposit with financial institutions, the balances of which may exceed federally insured limits. The Company has not experienced any losses on such accounts, and does not believe it is exposed to any unusual credit risk beyond the normal credit risk currently associated with commercial banking relationships. The Company maintains its primary banking relationship with one large financial institution and all cash on deposit is covered under federally insured limits.

</us-gaap:ConcentrationRiskCreditRisk>

<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000438">

Property and Equipment The Company records property and equipment at cost less accumulated depreciation. Expenditures for major renewals and improvements which extend the life or usefulness of the asset are capitalized. Items of an ordinary repair or maintenance nature are charged directly to operating expense as incurred. The Company calculates depreciation using the straight-line method over the estimated useful lives of the assets: <table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--AssetsEstimatedUsefulLifeTableTextBlock_zvueWWuq5bsi" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of estimated useful life of assets</td> <td> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid; width: 49%">Asset Classification</td> <td style="width: 2%"> </td> <td style="border-bottom: black 1pt solid; width: 49%; text-align: center">Estimated Useful Life</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Office and computer equipment</td> <td> </td> <td><span id="xdx_90A_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLives1_c20230101__20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeAndComputerEquipmentMember_z6jAdkTxSA44" title="Estimated useful life">3 years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Leasehold improvements</td> <td> </td> <td><span id="xdx_90C_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLives1_c20230101__20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zBNuO9upJ0ei" title="Estimated useful life">5 years or the remaining term of the lease, if shorter</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Furniture and fixtures</td> <td> </td> <td><span id="xdx_902_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLives1_c20230101__20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zqCcV8fQWZf2" title="Estimated useful life">5 years</td></tr> </table> The Company eliminates the cost of assets retired or otherwise disposed of, along with the corresponding accumulated depreciation, from the related accounts, and the resulting gain or loss is reflected in the results of operations.

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>

<xbio:AssetsEstimatedUsefulLifeTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000440">

<table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--AssetsEstimatedUsefulLifeTableTextBlock_zvueWWuq5bsi" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of estimated useful life of assets</td> <td> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid; width: 49%">Asset Classification</td> <td style="width: 2%"> </td> <td style="border-bottom: black 1pt solid; width: 49%; text-align: center">Estimated Useful Life</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Office and computer equipment</td> <td> </td> <td><span id="xdx_90A_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLives1_c20230101__20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeAndComputerEquipmentMember_z6jAdkTxSA44" title="Estimated useful life">3 years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Leasehold improvements</td> <td> </td> <td><span id="xdx_90C_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLives1_c20230101__20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zBNuO9upJ0ei" title="Estimated useful life">5 years or the remaining term of the lease, if shorter</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Furniture and fixtures</td> <td> </td> <td><span id="xdx_902_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLives1_c20230101__20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zqCcV8fQWZf2" title="Estimated useful life">5 years</td></tr> </table>

</xbio:AssetsEstimatedUsefulLifeTableTextBlock>

<xbio:PropertyPlantAndEquipmentEstimatedUsefulLives1 contextRef="From2023-01-012023-12-31_custom_OfficeAndComputerEquipmentMember" id="Fact000442"> 3 years </xbio:PropertyPlantAndEquipmentEstimatedUsefulLives1>

<xbio:PropertyPlantAndEquipmentEstimatedUsefulLives1 contextRef="From2023-01-012023-12-31_us-gaap_LeaseholdImprovementsMember" id="Fact000444"> 5 years or the remaining term of the lease, if shorter </xbio:PropertyPlantAndEquipmentEstimatedUsefulLives1>

<xbio:PropertyPlantAndEquipmentEstimatedUsefulLives1 contextRef="From2023-01-012023-12-31_us-gaap_FurnitureAndFixturesMember" id="Fact000446"> 5 years </xbio:PropertyPlantAndEquipmentEstimatedUsefulLives1>

<us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy contextRef="From2023-01-01to2023-12-31" id="Fact000453">

Indefinite-Lived Intangible Assets Assets acquired and liabilities assumed in business combinations, licensing and other transactions are generally recognized at the date of acquisition at their respective fair values. At acquisition, the Company generally determines the fair value of intangible assets, including in-process research and development (“IPR&D”), using the “income method.” Acquired IPR&D intangible assets are considered indefinite-lived intangible assets and are not amortized until completion or abandonment of the associated research and development efforts. Substantial additional research and development may be required before the Company’s IPR&D reaches technological feasibility. Upon completion of the IPR&D project, the IPR&D assets will be amortized over their estimated useful lives. IPR&D is not amortized but is reviewed for impairment at least annually or when events or changes in the business environment indicate that it is more likely than not that the carrying value may be impaired. The Company also has the option to first assess qualitative factors to determine whether the existence of events or circumstances leads the Company to determine that it is more likely than not (that is, a likelihood of more than 50%) that the acquired IPR&D is impaired. If the Company chooses to first assess the qualitative factors and it is determined that it is not more likely than not acquired IPR&D is impaired, the Company is not required to take further action to test for impairment. The Company also has the option to bypass the qualitative assessment and perform only the quantitative impairment test, which the Company may choose to perform in some periods but not in others. The impairment loss, if any, is measured as the excess of the carrying value of the intangible asset over its fair value. Intangible assets are highly vulnerable to impairment charges, particularly newly acquired assets for IPR&D. Considering the high risk nature of research and development and the industry’s success rate of bringing developmental compounds to market, IPR&D impairment charges are likely to occur in future periods. Estimating the fair value of IPR&D for potential impairment is highly sensitive to changes in projections and assumptions and changes to assumptions could potentially lead to impairment. The Company believes its estimates and assumptions are reasonable and otherwise consistent with assumptions market participants would use in their estimates of fair value. However, if future results are not consistent with the Company’s estimates and assumptions, then the Company may be exposed to an impairment charge, which could be material. Use of different estimates and judgments could yield materially different results in the Company’s analysis and could result in materially different asset values or expense.

</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy>

<us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000455">

Impairment of Long-Lived Assets The Company reviews long-lived assets to be held and used, including property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be fully recoverable. Evaluation of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset or asset group and its eventual disposition. Impairment, if any, is calculated as the amount by which an asset’s carrying value exceeds its fair value, typically using discounted cash flows to determine fair value. No such impairments were recorded during the years ended December 31, 2023 and 2022.

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>

<us-gaap:AssetImpairmentCharges contextRef="From2023-01-01to2023-12-31" decimals="0" id="Fact000456" unitRef="USD"> 0 </us-gaap:AssetImpairmentCharges>

<us-gaap:AssetImpairmentCharges contextRef="From2022-01-012022-12-31" decimals="0" id="Fact000457" unitRef="USD"> 0 </us-gaap:AssetImpairmentCharges>

<us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000459">

Revenue Recognition The Company enters into supply, license and collaboration arrangements with pharmaceutical and biotechnology partners, some of which include royalty agreements based on potential net sales of approved commercial pharmaceutical products. The Company recognizes revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue at a point in time, or over time, as it satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. As part of the accounting for these arrangements, the Company must use significant judgment to determine: a) the number of performance obligations based on the determination under step (ii) above; b) the transaction price under step (iii) above; and c) the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above. The Company uses judgment to determine whether milestones or other variable consideration should be included in the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. In developing the stand-alone price for a performance obligation, the Company considers applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer and estimated costs. The Company validates the stand-alone selling price for performance obligations by evaluating whether changes in the key assumptions used to determine the stand-alone selling prices will have a significant effect on the allocation of transaction price between multiple performance obligations. The Company recognizes a contract asset or liability for the difference between the Company’s performance (i.e., the goods or services transferred to the customer) and the customer’s performance (i.e., the consideration paid by, and unconditionally due from, the customer). The terms of the Company’s license agreements may include delivery of an IP license to a collaboration partner. The Company may be compensated under license arrangements through a combination of non-refundable upfront receipts, development and regulatory objective receipts and royalty receipts on future product sales by partners. The Company anticipates recognizing non-refundable upfront license payments and development and regulatory milestone payments received by the Company in license and collaboration arrangements that include future obligations, such as supply obligations, ratably over the Company’s expected performance period under each respective arrangement. The Company makes its best estimate of the period over which the Company expects to fulfill the Company’s performance obligations, which may include technology transfer assistance, research activities, clinical development activities, and manufacturing activities from development through the commercialization of the product. Given the uncertainties of these collaboration arrangements, significant judgment is required to determine the duration of the performance period. When the Company enters into an arrangement to sublicense some of its patents, it will consider the performance obligations to determine if there is a single element or multiple elements to the arrangement as it determines the proper method and timing of revenue recognition. The Company considers the terms of the license or sublicense for such elements as price adjustments or refund clauses in addition to any performance obligations for it to provide such as services, patent defense costs, technology support, marketing or sales assistance or any other elements to the arrangement that could constitute an additional deliverable to it that could change the timing of the revenue recognition. Non-refundable upfront license and sublicense fees received, whereby continued performance or future obligations are considered inconsequential or perfunctory to the relevant licensed technology, are recognized as revenue upon delivery of the technology. The Company expects to recognize royalty revenue in the period of sale, based on the underlying contract terms, provided that the reported sales are reliably measurable, the Company has no remaining performance obligations, and all other revenue recognition criteria are met. The Company anticipates reimbursements for research and development services completed by the Company related to the collaboration agreements to be recognized in operations as revenue on a gross basis. The Company’s license and collaboration agreements with certain collaboration partners could also provide for future milestone receipts to the Company based solely upon the performance of the respective collaboration partner in consideration of deadline extensions or upon the achievement of specified sales volumes of approved drugs. For such receipts, the Company expects to recognize the receipts as revenue when earned under the applicable contract terms on a performance basis or ratably over the term of the agreement. These receipts may also be recognized as revenue when continued performance or future obligations by the Company are considered inconsequential or perfunctory. See also Note 4, Significant Strategic Collaborations.

</us-gaap:RevenueRecognitionPolicyTextBlock>

<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2023-01-01to2023-12-31" id="Fact000470">

Research and Development Expenses Research and development expenses consist of expenses incurred in performing research and development activities, including compensation and benefits, facilities expenses, overhead expenses, pre-clinical development, clinical trial and related clinical manufacturing expenses, fees paid to contract research organizations (“CROs”) and contract manufacturing organizations (“CMOs”) and other outside expenses. The Company expenses research and development costs as incurred. The Company expenses upfront, non-refundable payments made for research and development services as obligations are incurred. The value ascribed to intangible assets acquired but which have not met capitalization criteria is expensed as research and development at the time of acquisition. Upfront payments under license agreements are expensed upon receipt of the license. Milestone payments under license agreements are accrued, with a corresponding expense being recognized, in the period in which the milestone is determined to be probable of achievement and the related amount is reasonably estimable. The Company is required to estimate accrued research and development expenses at each reporting period. This process involves reviewing open contracts and purchase orders, communicating with Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual costs. The majority of the Company’s service providers invoice in arrears for services performed, on a pre-determined schedule or when contractual milestones are met. However, some require advanced payments. The Company makes estimates of accrued expenses as of each balance sheet date in the financial statements based on facts and circumstances known at that time. The Company periodically confirms the accuracy of the estimates with the service providers and makes adjustments, if necessary. Examples of estimated accrued research and development expenses include fees paid to: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px"> · ·</td> <td> Collaborative partners performing research and development and pre-clinical activities; Program managers in connection with overall program management of clinical trials;</td></tr> <tr style="vertical-align: top"> <td> </td> <td>·</td> <td>CMOs in connection with cGMP manufacturing; </td></tr> <tr style="vertical-align: top"> <td> </td> <td>·</td> <td>CROs in connection with clinical trials; and</td></tr> <tr style="vertical-align: top"> <td> </td> <td>·</td> <td>Investigative sites in connection with clinical trials.</td></tr> </table> The Company bases its expenses related to research and development, pre-clinical activities, manufacturing and clinical trials on its estimates of the services received and efforts expended pursuant to quotes and contracts with multiple research institutions, CMOs and CROs that conduct and manage clinical trials on the Company’s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to vendors will exceed the level of services provided and result in a prepayment of the expense. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company adjusts the accrual or prepaid accordingly. Although it does not expect its estimates to be materially different from amounts actually incurred, the Company’s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to the Company’s prior estimates of accrued research and development expenses. The Company has recorded approximately $0.5 million and $0.3 million of prepayments as a component of prepaid expenses and other current assets as of December 31, 2023 and 2022, respectively. In addition, the Company had recorded accrued program expense of approximately $<span id="xdx_904_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_dm_c20231231__us-gaap--BalanceSheetLocationAxis__custom--ResearchAndDevelopmentExpensesMember_zurhLYs1Ncv1" title="Accrued expenses"><span id="xdx_907_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_dm_c20221231__us-gaap--BalanceSheetLocationAxis__custom--ResearchAndDevelopmentExpensesMember_z8Ogqllu9htc" title="Accrued expenses">0.1 million as a component of accrued expenses as of each of December 31, 2023 and 2022.

</us-gaap:ResearchAndDevelopmentExpensePolicy>

<us-gaap:PrepaidExpenseAndOtherAssets contextRef="AsOf2023-12-31_custom_ResearchAndDevelopmentExpensesMember" decimals="0" id="Fact000472" unitRef="USD"> 500000 </us-gaap:PrepaidExpenseAndOtherAssets>

<us-gaap:PrepaidExpenseAndOtherAssets contextRef="AsOf2022-12-31_custom_ResearchAndDevelopmentExpensesMember" decimals="0" id="Fact000474" unitRef="USD"> 300000 </us-gaap:PrepaidExpenseAndOtherAssets>

<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2023-12-31_custom_ResearchAndDevelopmentExpensesMember" decimals="0" id="Fact000476" unitRef="USD"> 100000 </us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>

<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2022-12-31_custom_ResearchAndDevelopmentExpensesMember" decimals="0" id="Fact000478" unitRef="USD"> 100000 </us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>

<us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2023-01-01to2023-12-31" id="Fact000480">

Share-based Expense The Company grants share-based payments in the form of options and restricted stock units (“RSUs”) to employees and non-employees to purchase shares of the Company’s common stock, Joint Share Ownership Plan (“JSOP”) awards to employees and agreements to issue common stock in exchange for services provided by non-employees. Share-based expense is based on the estimated fair value of the option or calculated using the Black-Scholes option pricing model. Determining the appropriate fair value model and related assumptions requires judgment, including estimating share price volatility and expected terms of the awards. The expected volatility rates are estimated based on the historical volatility of the Company. To the extent Company data is not available for the full expected term of the awards the Company uses a weighted-average of the historical volatility of the Company and of a peer group of comparable publicly traded companies over the expected term of the option. The expected term represents the time that options are expected to be outstanding. The Company accounts for forfeitures as they occur and not at the time of grant. The Company has not paid dividends and does not anticipate paying cash dividends in the foreseeable future and, accordingly, uses an expected dividend yield of zero. The risk-free interest rate is based on the rate of U.S. Treasury securities with maturities consistent with the estimated expected term of the awards. Upon exercise, stock options are redeemed for newly issued shares of common stock. RSUs are redeemed for newly issued shares of common stock as the vesting and settlement provisions of the grant are met. For employee options that vest based solely on service conditions, the fair value measurement date is generally on the date of grant and the related compensation expense is recognized on a straight-line basis over the requisite vesting period of the awards. For non-employee options issued in exchange for goods or services consumed in the Company’s operations, the fair value measurement date is the earlier of the date the performance of services is complete or the date the performance commitment has been reached. The Company generally determines that the fair value of the stock options is more reliably measurable than the fair value of the services received. Compensation expense related to stock options granted to non-employees is recognized on a straight-line basis over requisite vesting periods of the awards.

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>

<xbio:WarrantsPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000486">

Warrants In connection with certain financing, consulting and collaboration arrangements, the Company has issued warrants to purchase shares of its common stock. The outstanding warrants are standalone instruments that are not puttable or mandatorily redeemable by the holder and are classified as equity awards. The Company measures the fair value of the awards using the Black-Scholes option pricing model as of the measurement date. Warrants issued to collaboration partners in conjunction with the issuance of common stock are initially recorded at fair value as a reduction in additional paid-in capital of the common stock issued. All other warrants are recorded at fair value as expense on a straight-line basis over the requisite service period or at the date of issuance if there is not a service period or if service has already been rendered. Warrants granted in connection with ongoing arrangements are more fully described in Note 10, Stockholders’ Equity.

</xbio:WarrantsPolicyTextBlock>

<us-gaap:IncomeTaxPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000488">

Income Taxes The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on temporary differences resulting from the different treatment of items for tax and financial reporting purposes. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to reverse. Additionally, the Company must assess the likelihood that deferred tax assets will be recovered as deductions from future taxable income. The Company evaluates the recoverability of its deferred tax assets on a quarterly basis.

</us-gaap:IncomeTaxPolicyTextBlock>

<us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000490">

Basic and Diluted Net Loss per Share The Company computes basic net loss per share by dividing net loss applicable to common stockholders by the weighted-average number of shares of the Company’s common stock outstanding during the period. The Company computes diluted net loss per share after giving consideration to the dilutive effect of stock options that are outstanding during the period, except where such non-participating securities would be anti-dilutive. The Company’s JSOP awards, prior to exercise, are considered treasury shares by the Company and thus do not impact the Company’s net loss per share calculation. For the years ended December 31, 2023 and 2022, basic and diluted net loss per share are the same for each year due to the Company’s net loss position. Potentially dilutive, non-participating securities have not been included in the calculations of diluted net loss per share, as their inclusion would be anti-dilutive. As of December 31, 2023 and 2022, approximately 5,000 potentially dilutive securities were deemed anti-dilutive for each period.

</us-gaap:EarningsPerSharePolicyTextBlock>

<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2023-01-01to2023-12-31" decimals="INF" id="Fact000492" unitRef="Shares"> 5000 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2022-01-012022-12-31" decimals="INF" id="Fact000494" unitRef="Shares"> 5000 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

<us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000496">

Segment Information Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, who is the Company’s Chief Executive Officer, in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business in one operating segment.

</us-gaap:SegmentReportingPolicyPolicyTextBlock>

<us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000503">

Leases The Company leases administrative facilities under operating leases. Lease agreements may include rent holidays, rent escalation clauses and tenant improvement allowances. The Company recognizes a lease liability and a right-of-use asset for all leases, with the exception of short-term leases, at the commencement date. See Note 13, Commitments and Contingencies for further information.

</us-gaap:LesseeOperatingLeasesTextBlock>

<us-gaap:BusinessCombinationsPolicy contextRef="From2023-01-01to2023-12-31" id="Fact000505">

Acquisitions The Company has a history of engaging in acquisition transactions that require the Company to evaluate whether the transaction meets the criteria of a business combination. If the transaction does not meet the business combination requirements, the transaction is accounted for as an asset acquisition or recapitalization and no goodwill is recognized. If the acquisition meets the definition of a business combination, the Company allocates the purchase price, including any contingent consideration, to the assets acquired and the liabilities assumed at their estimated fair values as of the date of the acquisition with any excess of the purchase price paid over the estimated fair value of net assets acquired recorded as goodwill. The fair value of the assets acquired and liabilities assumed is typically determined by using either estimates of replacement costs or discounted cash flow valuation methods. When determining the fair value of tangible assets acquired, the Company estimates the cost to replace the asset with a new asset, taking into consideration such factors as age, condition and the economic useful life of the asset. When determining the fair value of intangible assets acquired, the Company uses judgment to estimate the applicable discount rate, growth rates and the timing and amount of future cash flows. The fair value of assets acquired and liabilities assumed is typically determined using the assistance of an independent third-party specialist. Business combination related costs are expensed in the period in which the costs are incurred. Asset acquisition related costs are generally capitalized as a component of cost of the assets acquired.

</us-gaap:BusinessCombinationsPolicy>

<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000507">

Recent Accounting Standards In June 2016, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The guidance modified the measurement and recognition of credit losses for most financial assets and certain other instruments. The amendment updated the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the “incurred loss” model with an “expected loss” model. This may result in earlier recognition of allowance for losses. The Company adopted ASU 2016-13 as of January 1, 2023 and the adoption did not have a material effect on our consolidated financial statements.

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>

<us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000509">

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 5%">4.</td> <td style="width: 95%; text-align: justify">Significant Strategic Collaborations</td></tr> </table> Takeda Pharmaceutical Co. Ltd. ( together with its wholly-owned subsidiaries, “Takeda”) In October 2017, the Company granted to Takeda the right to grant a non-exclusive sublicense to certain patents related to the Company’s PolyXen technology that were previously exclusively licensed to Takeda in connection with products related to the treatment of blood and bleeding disorders. Royalty payments of approximately $<span id="xdx_904_eus-gaap--RoyaltyIncomeNonoperating_dm_c20230101__20231231__srt--CounterpartyNameAxis__custom--TakedaMember__srt--ProductOrServiceAxis__custom--RoyaltyRevenueMember_zh3lHl7OzW92" title="Revenue">2.5 million and $<span id="xdx_90B_eus-gaap--RoyaltyIncomeNonoperating_dm_c20220101__20221231__srt--CounterpartyNameAxis__custom--TakedaMember__srt--ProductOrServiceAxis__custom--RoyaltyRevenueMember_zBzK9aNVi5X3" title="Revenue">1.7 million were recorded as revenue by the Company during the years ended December 31, 2023 and 2022, respectively, and are based on single digit royalties on net sales of certain covered products. The Company’s policy is to recognize royalty payments as revenue when they are reliably measurable, which is upon receipt of reports from Takeda. The Company receives these reports in the quarter subsequent to the actual sublicensee sales. At the time the revenue was received, there were no remaining performance obligations and all other revenue recognition criteria were met. Catalent Pharma Solutions LLC (“Catalent”) On June 30, 2022, the Company entered into a Statement of Work (the “SOW”) with Catalent to outline the general scope of work, timeline, and pricing pursuant to which Catalent will provide certain services to the Company to perform cGMP manufacturing of the Company’s recombinant protein, Human DNase I. The parties agreed to enter into a Master Services Agreement (“MSA”) that will contain terms and conditions to govern the project contemplated by the SOW and that will supersede the addendum to the SOW containing Catalent’s standard terms and conditions. In addition, in the event of any conflict between the project-specific terms and conditions set forth in the SOW and the MSA, the MSA terms and conditions shall govern. The estimated total cost of the project contemplated by the SOW was expected to be up to approximately $5 million (exclusive of certain fees and potential alternatives) for the manufacturing services over the course of the term of the project with each phase of the project invoiced separately in connection with the commencement of such phase. The Company has paid Catalent approximately $2.5 million through December 31, 2023, of which $<span id="xdx_901_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_dm_c20231231__srt--CounterpartyNameAxis__custom--CatalentPharmaSolutionsMember_zq2A2rKr0N1d" title="Prepaid expenses and other current assets">0.1 million has been recognized as an advance payment and is included in prepaid expenses and other current assets and $0.3 million has been recognized within other assets as of December 31, 2023. As of December 31, 2022, approximately $<span id="xdx_900_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_dm_c20221231__srt--CounterpartyNameAxis__custom--CatalentPharmaSolutionsMember_zeTtUGnIqGm" title="Prepaid expenses and other current assets">0.3 million had been recorded as an advance payment and was included in prepaid expenses and other current assets. Scripps Research On March 17, 2023, the Company and Scripps Research entered into a Research Funding and Option Agreement (the “Agreement”), pursuant to which the Company has agreed to provide Scripps Research an aggregate of up to $938,000 to fund research relating to advancing the pre-clinical development of the Company’s DNase oncology platform technology. The research funding is payable by the Company to Scripps Research on a monthly basis in accordance with a negotiated budget, which provides for an initial payment of approximately $78,000 on the date of the Agreement and subsequent monthly payments of approximately $78,000 over a 12-month period. Under the Agreement, the Company has the option to acquire a worldwide exclusive license to Scripps Research’s rights in the Technology or Patent Rights (as defined in the Agreement), as well as a non-exclusive, royalty-free, non-transferrable license to make and use TSRI Technology (as defined in the Agreement) solely for the Company’s internal research purposes during the performance of the research program contemplated by the Agreement. Unless earlier terminated, the term of the Agreement continues from the date of the Agreement for fifteen (15) months. The Agreement may be terminated by the Company with 30 days advance written notice to Scripps Research beginning six (6) months after the Effective Date (as defined in the Agreement) or by Scripps Research if the Company fails to make timely payments due under the Agreement, subject to 30 days’ written notice to cure such nonpayment. The Agreement may further be terminated by either party in the event of the other party’s uncured failure to perform any obligations under the Agreement or the bankruptcy of the other party. The Company has paid Scripps Research approximately $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_dm_c20230101__20231231__srt--CounterpartyNameAxis__custom--ScrippsResearchMember__us-gaap--TransactionTypeAxis__custom--ScrippsAgreementMember_zVgRnXZFG66d" title="Research and development expenses">0.8 million under the Agreement through December 31, 2023, of which approximately $0.4 million has been recognized as an advance payment and is included in prepaid expenses and other current assets as of December 31, 2023. University of Virginia (“UVA”) On December 21, 2023, the Company entered into a Research Funding and Material Transfer Agreement with UVA (the “UVA Agreement”) to advance the development of our systemic DNase program. Under the terms of the UVA Agreement, in addition to advancing our existing intellectual property, we have an option to acquire an exclusive license to any new intellectual property arising from the DNase research program. Allan Tsung, MD, a member of the Company’s Scientific Advisory Board and Chair of the Department of Surgery at the UVA School of Medicine, will oversee the research conducted under the UVA Agreement. As a surgical oncologist and scientist, Dr. Tsung is internationally recognized for leading substantial research on the role of NETs in tumor growth, metastasis, and resistance to existing cancer therapies. PJSC Pharmsynthez In November 2009, the Company entered into a collaborative research and development license agreement with Pharmsynthez (the “Pharmsynthez Arrangement”) pursuant to which the Company granted an exclusive license to Pharmsynthez to develop, commercialize and market six product candidates based on the Company’s PolyXen and ImuXen technology in certain territories. In exchange, Pharmsynthez granted an exclusive license to the Company to use any preclinical and clinical data developed by Pharmsynthez, within the scope of the Pharmsynthez Arrangement, and to engage in further research, development and commercialization of drug candidates outside of certain territories at the Company’s own expense. Pharmsynthez directly, and indirectly through its wholly-owned subsidiary, SynBio, LLC (“SynBio”), had a share ownership in the Company of approximately <span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_c20231231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PharmsynthezMember_zmFoHFd6zsva" title="Percent ownership in Xenetic">3.4% and <span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PharmsynthezMember_z01yM7ez8Zqj" title="Percent ownership in Xenetic">2.9% of the total outstanding common stock as of December 31, 2023 and 2022, respectively. In addition to its common stock ownership, Pharmsynthez owns approximately <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_dm_c20231231__dei--LegalEntityAxis__custom--PharmsynthezMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zuivMlLHyrs4" title="Warrants outstanding">1.5 million shares of our outstanding Series B Preferred Stock (as defined in Note 10, Stockholders’ Equity.) In August 2011, SynBio and the Company entered into a stock subscription and collaborative development agreement (the “Co-Development Agreement”). The Company granted an exclusive license to SynBio to develop, market and commercialize certain drug candidates utilizing molecules based on SynBio’s technology and the Company’s proprietary technologies (PolyXen, OncoHist and ImuXen) in Russia and CIS, collectively referred to herein as the SynBio Market. In return, SynBio granted an exclusive license to the Company to use the preclinical and clinical data generated by SynBio in certain agreed products and to engage in the development of commercial candidates in any territory outside of the SynBio Market. SynBio is solely responsible for funding and conducting their own research and clinical development activities. There are no milestone or other research-related payments provided for under the Co-Development Agreement other than fees for the supply of each company’s respective research supplies based on their technology, which, when provided, are due to mutual convenience and not representative of an ongoing or recurring obligation to supply research supplies. Upon successful commercialization of any resultant products, the Company is entitled to receive a 10% royalty on sales in certain territories and pay royalties to SynBio for sales outside those certain territories, subject to the terms of the Co-Development Agreement. Effective December 20, 2021, SynBio assigned the Co-Development Agreement to Pharmsynthez. Through December 31, 2023, Pharmsynthez continued to engage in research and development activities with no resultant commercial products. In December 2020, Pharmsynthez reported positive data from its Phase 3 clinical study of Epolong, a treatment for anemia in patients with chronic kidney disease leveraging the Company’s PolyXen technology. In February 2021, Pharmsynthez reported in a press release that it had started the registration phase of Epolong by filing a registration dossier to obtain approval in Russia. Pharmsynthez had reported in its press release that it expected that the Russian stage of registration activities would be completed in 2021 and that it would be able to start production of the product as early as the first quarter of 2022. Pharmsynthez has informed the Company that it has received a response letter indicating certain deficiencies in the dossier and continues to develop a gap mitigation strategy with the intent of refiling the registration upon correction. The Company did not recognize revenue in connection with the Co-Development Agreement during the years ended December 31, 2023 and 2022. Serum Institute of India Limited In August 2011, the Company entered into a collaborative research and development agreement with Serum Institute of India Limited (“Serum Institute”) providing Serum Institute an exclusive license to use the Company’s PolyXen technology to research and develop one potential commercial product, Polysialylated Erythropoietin. Serum Institute is responsible for conducting all preclinical and clinical trials required to achieve regulatory approvals within the certain predetermined territories at Serum Institute’s own expense. Royalty payments are payable by Serum Institute to the Company for net sales to certain customers in the Serum Institute sales territory. There are no milestone or other research-related payments due under the collaborative arrangement. Through December 31, 2023, no commercial products were developed and no royalty revenue or expense was recognized by the Company related to the arrangement. Serum Institute had a share ownership of less than 1% of the total outstanding common stock of the Company as of each of December 31, 2023 and 2022.

</us-gaap:CollaborativeArrangementDisclosureTextBlock>

<us-gaap:RoyaltyIncomeNonoperating contextRef="From2023-01-012023-12-31_custom_TakedaMember_custom_RoyaltyRevenueMember" decimals="0" id="Fact000511" unitRef="USD"> 2500000 </us-gaap:RoyaltyIncomeNonoperating>

<us-gaap:RoyaltyIncomeNonoperating contextRef="From2022-01-012022-12-31_custom_TakedaMember_custom_RoyaltyRevenueMember" decimals="0" id="Fact000513" unitRef="USD"> 1700000 </us-gaap:RoyaltyIncomeNonoperating>

<us-gaap:ResearchAndDevelopmentExpense contextRef="From2023-01-012023-12-31_custom_CatalentPharmaSolutionsMember" decimals="0" id="Fact000520" unitRef="USD"> 2500000 </us-gaap:ResearchAndDevelopmentExpense>

<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2023-12-31_custom_CatalentPharmaSolutionsMember" decimals="0" id="Fact000522" unitRef="USD"> 100000 </us-gaap:PrepaidExpenseAndOtherAssetsCurrent>

<us-gaap:OtherAssets contextRef="AsOf2023-12-31_custom_CatalentPharmaSolutionsMember" decimals="0" id="Fact000524" unitRef="USD"> 300000 </us-gaap:OtherAssets>

<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2022-12-31_custom_CatalentPharmaSolutionsMember" decimals="0" id="Fact000526" unitRef="USD"> 300000 </us-gaap:PrepaidExpenseAndOtherAssetsCurrent>

<us-gaap:ResearchAndDevelopmentExpense contextRef="From2023-03-162023-03-17_custom_ScrippsResearchMember" decimals="0" id="Fact000528" unitRef="USD"> 938000 </us-gaap:ResearchAndDevelopmentExpense>

<us-gaap:OtherResearchAndDevelopmentExpense contextRef="From2023-03-162023-03-17" decimals="0" id="Fact000530" unitRef="USD"> 78000 </us-gaap:OtherResearchAndDevelopmentExpense>

<xbio:MonthlyPayment contextRef="From2023-03-162023-03-17_custom_ScrippsResearchMember" decimals="0" id="Fact000532" unitRef="USD"> 78000 </xbio:MonthlyPayment>

<us-gaap:ResearchAndDevelopmentExpense contextRef="From2023-01-012023-12-31_custom_ScrippsResearchMember_custom_ScrippsAgreementMember" decimals="0" id="Fact000534" unitRef="USD"> 800000 </us-gaap:ResearchAndDevelopmentExpense>

<us-gaap:PrepaidExpenseAndOtherAssets contextRef="AsOf2023-12-31" decimals="0" id="Fact000536" unitRef="USD"> 400000 </us-gaap:PrepaidExpenseAndOtherAssets>

<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="AsOf2023-12-31_custom_PharmsynthezMember" decimals="INF" id="Fact000543" unitRef="Pure"> 0.034 </us-gaap:EquityMethodInvestmentOwnershipPercentage>

<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="AsOf2022-12-31_custom_PharmsynthezMember" decimals="INF" id="Fact000545" unitRef="Pure"> 0.029 </us-gaap:EquityMethodInvestmentOwnershipPercentage>

<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2023-12-31_custom_PharmsynthezMember_us-gaap_SeriesBPreferredStockMember" decimals="INF" id="Fact000547" unitRef="Shares"> 1500000 </us-gaap:ClassOfWarrantOrRightOutstanding>

<xbio:LicensingArrangementsTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000552">

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 33px; text-align: justify">5.</td> <td style="text-align: justify">Licensing Arrangements</td></tr> </table> Exclusive Sublicense Agreement On April 26, 2022, the Company entered into an Exclusive Sublicense Agreement (the “Sublicense Agreement”) with CLS Therapeutics Ltd. (“CLS”) pursuant to which the Company received an exclusive license, under certain patent rights and know-how owned or controlled by CLS, to develop and commercialize pharmaceutical products and methods incorporating DNase enzyme for use in treatment of cancer (the “Sublicensed Products”). Under the terms of the Sublicense Agreement, the Company will have sole responsibility for, and shall use commercially reasonable efforts to, among other things, research, develop and obtain marketing approval for the Sublicensed Products in the U.S. and certain European markets, and to commercialize such Sublicensed Products in the relevant market once marketing approval is obtained. In consideration for the license and other rights granted to the Company under the Sublicense Agreement, the Company issued to CLS <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_c20220401__20220426__us-gaap--TransactionTypeAxis__custom--SublicenseAgreementSharesMember__srt--CounterpartyNameAxis__custom--CLSMember_zez7MG4XpDuh" title="Number of consideration shares issued">37,500 shares of the Company’s common stock (the “Sublicense Agreement Shares”), of which 25,000 Sublicense Agreement Shares were issued directly to OPKO Health, Inc. (“OPKO”) in lieu of transfer indirectly from CLS to EirGen Pharma Ltd. (“EirGen”), a wholly owned subsidiary of OPKO, in satisfaction of certain third-party contractual obligations between CLS and EirGen. Additionally, the Company is obligated to pay to CLS up to $13,000,000 in cash in potential milestone payments for the achievement of certain clinical and regulatory milestones, as well as issue an additional 95,000 shares of the Company’s common stock to CLS based on the achievement of certain regulatory milestones. In addition, the Company is obligated to pay tiered royalties ranging from the mid-single to low-double digits on net sales of licensed products falling within the scope of the license during the Royalty Term (as defined in the Sublicense Agreement), as well as pay a percentage share in the low-to-mid teens of certain consideration received by the Company from any sublicensees. Exclusive License Agreement On April 26, 2022, the Company entered into an Exclusive License Agreement (the “License Agreement”) with CLS, pursuant to which the Company received an exclusive license under certain patent rights and know-how owned or controlled by CLS to develop and commercialize pharmaceutical products and methods incorporating DNase in conjunction with CAR T therapies (the “Licensed Products”). Under the terms of the License Agreement, the Company will have sole responsibility for, and shall use commercially reasonable efforts to, among other things, research, develop and obtain marketing approval for the Licensed Products in the U.S. and certain European markets, and to commercialize such Licensed Products in the relevant market once marketing approval is obtained. In consideration for the license and other rights granted to the Company under the License Agreement, the Company paid CLS a one-time fee of $<span id="xdx_90E_eus-gaap--PaymentsForFees_pp0p0_c20220401__20220426__us-gaap--TransactionTypeAxis__custom--SublicenseAndLicenseAgreementsMember__srt--CounterpartyNameAxis__custom--CLSMember_zQE9JiOEfedj" title="One-time fee">500,000 in cash, issued to CLS <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_c20220401__20220426__us-gaap--TransactionTypeAxis__custom--SublicenseAndLicenseAgreementsMember__srt--CounterpartyNameAxis__custom--CLSMember_z5HxAvA3uY6f" title="Common stock shares issued">50,000 shares of the Company’s common stock, and is obligated to pay up to $13,000,000 in cash in potential milestone payments for the achievement of certain clinical and regulatory milestones for each Licensed Product. In addition, the Company is obligated to pay tiered royalties ranging from the mid-single to low-double digits on net sales of licensed products falling within the scope of the license during the Royalty Term (as defined in the License Agreement), as well as pay a percentage share in the mid-teens to low double digits of certain consideration received by the Company from any sublicensees. The total consideration for the Sublicense and License Agreements was approximately $<span id="xdx_90A_eus-gaap--AssetAcquisitionConsiderationTransferred_pp0p0_dm_c20220401__20220426__us-gaap--AssetAcquisitionAxis__custom--SublicenseAndLicenseAgreementsMember_zLr4tLeXkD69" title="Total consideration">1.3 million, which consisted of a $0.5 million cash payment and the fair value of the <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_c20220401__20220426__us-gaap--AssetAcquisitionAxis__custom--SublicenseAndLicenseAgreementsMember_zvEqVl4b7Y6k" title="Common shares issued">87,500 common shares issued of $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValuePurchaseOfAssets_pp0p0_dm_c20220401__20220426__us-gaap--AssetAcquisitionAxis__custom--SublicenseAndLicenseAgreementsMember_zwVlwC2oLhq8" title="Number of shares purchase of asset, value">0.8 million utilizing the closing market price of the Company’s stock price at the closing date. As there was no future alternative use for the sublicense and license, the Company recorded an expense of $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_dm_c20220101__20221231__us-gaap--AssetAcquisitionAxis__custom--SublicenseAndLicenseAgreementsMember_zKe9OJi5L1Hj" title="Research and development expense">1.3 million to research and development expense during the year ended December 31, 2022. No milestone or other contingent consideration was recognized in 2023 and 2022 as there were no development, regulatory or sales milestones that were probable of being achieved as of each of December 31, 2023 and December 31, 2022. Patent Assignment and Volition Collaboration On August 2, 2022, the Company announced a research and development collaboration with Volition to develop NETs-targeted adoptive cell therapies for the treatment of cancer. The collaboration is an early exploratory program to evaluate the potential combination of Volition’s Nu.Q® technology Test and the Company’s DNase-Armored CAR T platform to develop proprietary adoptive cell therapies potentially targeting multiple types of solid cancers. Under the terms of the collaboration agreement, Volition will fund a research program and the two parties will share proceeds from commercialization or licensing of any products arising from the collaboration. On July 10, 2023, the Company entered into the first Collaborator Statement of Work as part of this collaboration with Volition. Volition has funded approximately $0.1 million under this research program through December 31, 2023. The Company has recorded this funding as a reduction in research and development costs during the year ended December 31, 2023. On October 4, 2022, the Company completed a patent assignment related to its collaboration with Belgian Volition SARL Limited (“Volition”) and CLS. In connection with the patent assignment, the Company entered into a Subscription Agreement with CLS Therapeutics, LLC, a Delaware limited liability company (“CLS LLC ”) on October 12, 2022, pursuant to which the Company agreed to issue to CLS LLC, and CLS LLC agreed to subscribe for, 85,000 shares of the Company’s common stock (the “Shares”) as consideration for the assignment by CLS and its affiliates to the Company of certain patent rights owned by CLS and its affiliates. The total consideration for the patent assignment was approximately $0.5 million, representing the fair value of the 85,000 common shares issued utilizing the closing market price of the Company’s stock price at the closing date. As there was no future alternative use for the patent rights, the Company recorded an expense of approximately $0.5 million to research and development expense for the year ended December 31, 2022. No milestone or other contingent consideration was recognized in 2023 and 2022 as there were no development, regulatory or sales milestones that were probable of being achieved as of each of December 31, 2023 and 2022. As of December 31, 2023 and 2022, CLS owned approximately <span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_c20231231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CLSMember_zZf3Eym0DLhl" title="Ownership percentage">9.6% of the Company’s common stock. The Company incurred approximately $<span id="xdx_90C_eus-gaap--ProfessionalAndContractServicesExpense_dm_c20220101__20221231__srt--CounterpartyNameAxis__custom--DNaseTechnologyMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CLSMember_zPRye5VfeLBh" title="Consulting, transaction and development costs">0.4 million of transaction costs in connection with the licensing of the DNase technology for the year ended December 31, 2022.

</xbio:LicensingArrangementsTextBlock>

<us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets contextRef="From2022-04-012022-04-26_custom_SublicenseAgreementSharesMember_custom_CLSMember" decimals="INF" id="Fact000554" unitRef="Shares"> 37500 </us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>

<us-gaap:PaymentsForFees contextRef="From2022-04-012022-04-26_custom_SublicenseAndLicenseAgreementsMember_custom_CLSMember" decimals="0" id="Fact000556" unitRef="USD"> 500000 </us-gaap:PaymentsForFees>

<us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets contextRef="From2022-04-012022-04-26_custom_SublicenseAndLicenseAgreementsMember_custom_CLSMember" decimals="INF" id="Fact000558" unitRef="Shares"> 50000 </us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>

<us-gaap:AssetAcquisitionConsiderationTransferred contextRef="From2022-04-012022-04-26_custom_SublicenseAndLicenseAgreementsMember" decimals="0" id="Fact000560" unitRef="USD"> 1300000 </us-gaap:AssetAcquisitionConsiderationTransferred>

<us-gaap:PaymentsToAcquireProductiveAssets contextRef="From2022-01-012022-12-31_custom_SublicenseAndLicenseAgreementsMember" decimals="0" id="Fact000562" unitRef="USD"> 500000 </us-gaap:PaymentsToAcquireProductiveAssets>

<us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets contextRef="From2022-04-012022-04-26_custom_SublicenseAndLicenseAgreementsMember" decimals="INF" id="Fact000564" unitRef="Shares"> 87500 </us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>

<us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets contextRef="From2022-04-012022-04-26_custom_SublicenseAndLicenseAgreementsMember" decimals="0" id="Fact000566" unitRef="USD"> 800000 </us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>

<us-gaap:ResearchAndDevelopmentExpense contextRef="From2022-01-012022-12-31_custom_SublicenseAndLicenseAgreementsMember" decimals="0" id="Fact000568" unitRef="USD"> 1300000 </us-gaap:ResearchAndDevelopmentExpense>

<us-gaap:ResearchAndDevelopmentExpense contextRef="From2023-01-012023-12-31_custom_VolitionMember" decimals="0" id="Fact000573" unitRef="USD"> 100000 </us-gaap:ResearchAndDevelopmentExpense>

<us-gaap:ResearchAndDevelopmentExpense contextRef="From2022-01-012022-12-31_custom_PatentAssignmentMember" decimals="0" id="Fact000574" unitRef="USD"> 500000 </us-gaap:ResearchAndDevelopmentExpense>

<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="AsOf2023-12-31_custom_CLSMember" decimals="INF" id="Fact000576" unitRef="Pure"> 0.096 </us-gaap:EquityMethodInvestmentOwnershipPercentage>

<us-gaap:ProfessionalAndContractServicesExpense contextRef="From2022-01-012022-12-31_custom_DNaseTechnologyMember_custom_CLSMember" decimals="0" id="Fact000578" unitRef="USD"> 400000 </us-gaap:ProfessionalAndContractServicesExpense>

<us-gaap:OtherAssetsDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000580">

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 5%">6.</td> <td style="width: 95%; text-align: justify">Other Assets </td></tr> </table> In 2016, the Company entered into an agreement with Serum Institute for the prepayment of clinical PSA supply in exchange for the Company’s common stock. As of each of December 31, 2023 and 2022, the Company has classified $0.7 million of prepaid clinical supply as long-term as it does not anticipate utilizing the majority of the PSA supply within the next 12 months. No clinical supply was utilized during the years ended December 31, 2023 and 2022. See also Note 14, Related Party Transactions for a description of the Pharmsynthez Loan.

</us-gaap:OtherAssetsDisclosureTextBlock>

<us-gaap:PrepaidExpenseNoncurrent contextRef="AsOf2023-12-31_custom_SerumInstituteMember" decimals="0" id="Fact000582" unitRef="USD"> 700000 </us-gaap:PrepaidExpenseNoncurrent>

<us-gaap:PrepaidExpenseNoncurrent contextRef="AsOf2022-12-31_custom_SerumInstituteMember" decimals="0" id="Fact000584" unitRef="USD"> 700000 </us-gaap:PrepaidExpenseNoncurrent>

<us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000586">

<p id="xdx_80B_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zJVv3EILGbd3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 5%">7.</td> <td style="width: 95%; text-align: justify">Accrued Expenses </td></tr> </table> Accrued expenses consist of the following: <table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_z9vzPTZZs941" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued Expenses (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of accrued expenses</td><td> </td> <td colspan="2" id="xdx_494_20231231_z28Ted4Tv7gl" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_497_20221231_znix3Pu2UQ56" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pp0p0_maALCzyUW_zTEuzX74Pihi" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Accrued payroll and benefits</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">216,547</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">353,539</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maALCzyUW_z1kLtkrQl2C1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued professional fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">233,950</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">288,808</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--AccruedResearchCosts_iI_pp0p0_maALCzyUW_zBr4JFliptjk" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Accrued research costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">70,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">103,500</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maALCzyUW_zoIYMkOi1qu9" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">48,256</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">39,949</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AccruedLiabilitiesCurrent_iTI_pp0p0_mtALCzyUW_z6Qlu460Hlwd" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Total accrued expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">568,753</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">785,796</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>

<us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000588">

<table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_z9vzPTZZs941" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued Expenses (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of accrued expenses</td><td> </td> <td colspan="2" id="xdx_494_20231231_z28Ted4Tv7gl" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_497_20221231_znix3Pu2UQ56" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pp0p0_maALCzyUW_zTEuzX74Pihi" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Accrued payroll and benefits</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">216,547</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">353,539</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maALCzyUW_z1kLtkrQl2C1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued professional fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">233,950</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">288,808</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--AccruedResearchCosts_iI_pp0p0_maALCzyUW_zBr4JFliptjk" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Accrued research costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">70,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">103,500</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maALCzyUW_zoIYMkOi1qu9" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">48,256</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">39,949</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AccruedLiabilitiesCurrent_iTI_pp0p0_mtALCzyUW_z6Qlu460Hlwd" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Total accrued expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">568,753</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">785,796</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>

<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2023-12-31" decimals="0" id="Fact000590" unitRef="USD"> 216547 </us-gaap:EmployeeRelatedLiabilitiesCurrent>

<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" id="Fact000591" unitRef="USD"> 353539 </us-gaap:EmployeeRelatedLiabilitiesCurrent>

<us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2023-12-31" decimals="0" id="Fact000593" unitRef="USD"> 233950 </us-gaap:AccruedProfessionalFeesCurrent>

<us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2022-12-31" decimals="0" id="Fact000594" unitRef="USD"> 288808 </us-gaap:AccruedProfessionalFeesCurrent>

<xbio:AccruedResearchCosts contextRef="AsOf2023-12-31" decimals="0" id="Fact000596" unitRef="USD"> 70000 </xbio:AccruedResearchCosts>

<xbio:AccruedResearchCosts contextRef="AsOf2022-12-31" decimals="0" id="Fact000597" unitRef="USD"> 103500 </xbio:AccruedResearchCosts>

<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2023-12-31" decimals="0" id="Fact000599" unitRef="USD"> 48256 </us-gaap:OtherAccruedLiabilitiesCurrent>

<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" id="Fact000600" unitRef="USD"> 39949 </us-gaap:OtherAccruedLiabilitiesCurrent>

<us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2023-12-31" decimals="0" id="Fact000602" unitRef="USD"> 568753 </us-gaap:AccruedLiabilitiesCurrent>

<us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" id="Fact000603" unitRef="USD"> 785796 </us-gaap:AccruedLiabilitiesCurrent>

<us-gaap:FairValueDisclosuresTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000607">

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 5%">8.</td> <td style="width: 95%; text-align: justify">Fair Value Measurements</td></tr> </table> ASC Topic 820, Fair Value Measurement, defines fair value as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement. Level 1 inputs are quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 2 utilizes quoted market prices in markets that are not active, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. Level 3 inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date. As of December 31, 2023 and December 31, 2022, the carrying amounts of the Company’s financial instruments approximate fair value due to their short maturities. There were <span id="xdx_904_eus-gaap--FinancialInstrumentsOwnedAtFairValue_iI_pp0p0_do_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_znVct8fd6Y9c" title="Financial instruments fair value"><span id="xdx_90A_eus-gaap--FinancialInstrumentsOwnedAtFairValue_iI_pp0p0_do_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zgkN43bFvCOd" title="Financial instruments fair value">no financial instruments classified as Level 3 in the fair value hierarchy during the years ended December 31, 2023 and 2022.

</us-gaap:FairValueDisclosuresTextBlock>

<us-gaap:FinancialInstrumentsOwnedAtFairValue contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member" decimals="0" id="Fact000609" unitRef="USD"> 0 </us-gaap:FinancialInstrumentsOwnedAtFairValue>

<us-gaap:FinancialInstrumentsOwnedAtFairValue contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member" decimals="0" id="Fact000611" unitRef="USD"> 0 </us-gaap:FinancialInstrumentsOwnedAtFairValue>

<us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000613">

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 5%">9.</td> <td style="width: 95%; text-align: justify">Income Taxes </td></tr> </table> Deferred tax assets and liabilities are determined based on temporary differences resulting from the different treatment of items for tax and financial reporting purposes. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to reverse. Additionally, the Company must assess the likelihood that deferred tax assets will be recovered as deductions from future taxable income. The Company has provided a full valuation allowance on the Company’s deferred tax assets because the Company believes it is more likely than not that its deferred tax assets will not be realized. The Company evaluates the recoverability of its deferred tax assets on a quarterly basis. There was no income tax provision (benefit) for the years ended December 31, 2023 and 2022, as the Company has incurred losses to date. The components of loss before income taxes are as follows: <table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_z4FcAv0QvDW5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details - Income by geographic regions)"> <tr style="vertical-align: bottom"> <td>Schedule of components of loss before income taxes</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Domestic (U.S.)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--NetIncomeLoss_pp0p0_c20230101__20231231__srt--StatementGeographicalAxis__country--US_zTKJYo2AP8gf" style="width: 13%; text-align: right" title="Net income (loss)">(6,424,969</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--NetIncomeLoss_c20220101__20221231__srt--StatementGeographicalAxis__country--US_pp0p0" style="width: 13%; text-align: right" title="Net income (loss)">(7,905,676</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Foreign (U.K.)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--NetIncomeLoss_pp0p0_c20230101__20231231__srt--StatementGeographicalAxis__country--GB_zkNTVFCSEom5" style="text-align: right" title="Net income (loss)">2,440,857</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--NetIncomeLoss_c20220101__20221231__srt--StatementGeographicalAxis__country--GB_pp0p0" style="text-align: right" title="Net income (loss)">1,488,938</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Foreign (Germany)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--NetIncomeLoss_pp0p0_c20230101__20231231__srt--StatementGeographicalAxis__country--DE_zcaOUaGiFUth" style="text-align: right" title="Net income (loss)">(136,977</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--NetIncomeLoss_c20220101__20221231__srt--StatementGeographicalAxis__country--DE_pp0p0" style="text-align: right" title="Net income (loss)">(124,279</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Foreign (Switzerland)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--NetIncomeLoss_pp0p0_c20230101__20231231__srt--StatementGeographicalAxis__country--CH_z2LbFzOo3h2j" style="border-bottom: Black 1pt solid; text-align: right" title="Net income (loss)">(13,489</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--NetIncomeLoss_c20220101__20221231__srt--StatementGeographicalAxis__country--CH_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Net income (loss)">(11,336</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt">Loss before income taxes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--NetIncomeLoss_pp0p0_c20230101__20231231_zAHQ40dOF0zk" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income (loss)">(4,134,578</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--NetIncomeLoss_c20220101__20221231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income (loss)">(6,552,353</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> The reconciliation of income tax benefit at the U.S. corporation tax rate, being the rate applicable to the country of domicile of the Company to net income tax benefit, is as follows: <table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zkFj4aHgOGo4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details - Tax reconciliation)"> <tr style="vertical-align: bottom"> <td>Schedule of reconciliation of income tax provision</td><td> </td> <td colspan="2" id="xdx_496_20230101__20231231_zjvjEXTNhDU6" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_49F_20220101__20221231_zBozlGoVjNSd" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_maITEBzKxf_zAbhUxCIdtV5" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%">Federal</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(868,261</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(1,375,995</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_maITEBzKxf_zcqZnlbcUyB5" style="vertical-align: bottom; background-color: White"> <td>State</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(373,684</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(476,802</td><td style="text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzKxf_zfNmlPOToGUf" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Change in valuation allowance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,116,036</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,233,525</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_maITEBzKxf_zQPLvcd9A7j3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Permanent differences, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">271,546</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">197,151</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_maITEBzKxf_zpilibEmzYni" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Foreign rate differential</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">81,227</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(39,041</td><td style="text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_maITEBzKxf_zO9mKhiV4O1i" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Share-based expense, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,213</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,087</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_iN_pp0p0_di_msITEBzKxf_zpOQ7Jh2Uyo7" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Enhanced research and development tax credits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(238,631</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(109,792</td><td style="text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_d0_maITEBzKxf_zTGmtYBU4ZLf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Rate change</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,120,196</td><td style="text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBzKxf_zO2fOvoVcEl8" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Other items</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,554</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(327,937</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--IncomeTaxExpenseBenefit_iT_pp0p0_d0_mtITEBzKxf_zvbQr7daSytd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net benefit for income taxes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Deferred tax assets and liabilities reflect the net tax effect of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets are as follows: <table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zRdEY1X47B2e" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details - Deferred Tax Assets)"> <tr style="vertical-align: bottom"> <td>Schedule of deferred tax assets and liabilities</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Deferred tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 66%; text-align: left">U.K. net operating loss carryforwards</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_pp0p0_c20231231__srt--StatementGeographicalAxis__country--GB_zTYFNAHLccI9" style="width: 13%; text-align: right" title="Foreign net operating loss carryforwards">14,664,858</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_c20221231__srt--StatementGeographicalAxis__country--GB_pp0p0" style="width: 13%; text-align: right" title="Foreign net operating loss carryforwards">14,812,743</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt; text-align: left">U.K. capital loss carryforwards</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_iI_pp0p0_c20231231__srt--StatementGeographicalAxis__country--GB_zi2Wo10bwZXh" style="text-align: right" title="Foreign capital loss carryforwards">1,545,934</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_iI_pp0p0_c20221231__srt--StatementGeographicalAxis__country--GB_zvK9waBPPub4" style="text-align: right" title="Foreign capital loss carryforwards">1,545,934</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">U.S. federal net operating loss carryforwards</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pp0p0_c20231231_zdtoT2NgiPSk" style="text-align: right" title="Foreign net operating loss carryforwards">6,573,614</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pp0p0_c20221231_zleXWRAduIck" style="text-align: right" title="Foreign net operating loss carryforwards">6,085,858</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt; text-align: left">Switzerland net operating loss carryforwards</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_pp0p0_c20231231__srt--StatementGeographicalAxis__country--CH_zU4o5jmWNv3j" style="text-align: right" title="Foreign net operating loss carryforwards">23,868</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_c20221231__srt--StatementGeographicalAxis__country--CH_pp0p0" style="text-align: right" title="Foreign net operating loss carryforwards">22,722</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">IPR&D</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pp0p0_c20231231_zgzAmVFwiaB7" style="text-align: right" title="IPR&D">8,066,098</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_c20221231_pp0p0" style="text-align: right" title="IPR&D">8,546,593</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt; text-align: left">Share-based expense</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0_c20231231_z9zGRPqchnVf" style="text-align: right" title="Share-based expense">2,235,214</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_c20221231_pp0p0" style="text-align: right" title="Share-based expense">2,169,480</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Enhanced research and development tax credits</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pp0p0_c20231231_zly0cV21jx12" style="text-align: right" title="Enhanced research and development tax credits">2,038,421</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_c20221231_pp0p0" style="text-align: right" title="Enhanced research and development tax credits">1,820,269</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt; text-align: left">Germany net operating loss carryforwards</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_pp0p0_c20231231__srt--StatementGeographicalAxis__country--DE_zoFkYhiWMzQ1" style="text-align: right" title="Foreign net operating loss carryforwards">693,007</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_c20221231__srt--StatementGeographicalAxis__country--DE_pp0p0" style="text-align: right" title="Foreign net operating loss carryforwards">627,780</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Capitalized research and experimental expenditure</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseOther_iI_pp0p0_c20231231_zVouKKPxFsah" style="text-align: right" title="Capitalized research and experimental expenditure">1,473,049</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseOther_c20221231_pp0p0" style="text-align: right" title="Capitalized research and experimental expenditure">735,702</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt; text-align: left">U.S. state net operating loss carryforwards</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pp0p0_c20231231_z9TlZ98G9qHd" style="text-align: right" title="U.S. state net operating loss carryforwards">2,142,380</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_c20221231_pp0p0" style="text-align: right" title="U.S. state net operating loss carryforwards">1,913,128</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Other</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_pp0p0_c20231231_z26W8H5Tpq95" style="text-align: right" title="Depreciation">250,669</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_c20221231_pp0p0" style="text-align: right" title="Depreciation">288,887</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Lease liability</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--DeferredTaxAssetsOther_iI_pp0p0_d0_c20231231_zPW9ZJTYsqmg" style="border-bottom: Black 1pt solid; text-align: right" title="Lease liability">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--DeferredTaxAssetsOther_iI_pp0p0_d0_c20221231_zNjLOUBH8ZSk" style="border-bottom: Black 1pt solid; text-align: right" title="Lease liability">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total deferred tax assets before valuation allowance</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--DeferredTaxAssetsGross_iI_pp0p0_c20231231_zSLxWkkLxLM5" style="text-align: right" title="Total deferred tax assets before valuation allowance">39,707,112</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--DeferredTaxAssetsGross_c20221231_pp0p0" style="text-align: right" title="Total deferred tax assets before valuation allowance">38,569,096</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Valuation allowance for deferred tax assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_c20231231_zHMthwM63T8" style="border-bottom: Black 1pt solid; text-align: right" title="Valuation allowance for deferred tax assets">(39,707,112</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_c20221231_zZqQrZOAeqq2" style="border-bottom: Black 1pt solid; text-align: right" title="Valuation allowance for deferred tax assets">(38,569,096</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Net deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_d0_c20231231_zpEaDMUAt1z6" style="text-align: right" title="Net deferred tax assets">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_d0_c20221231_znitgoGeVBHl" style="text-align: right" title="Net deferred tax assets">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Deferred tax liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Right of use asset – leases</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--DeferredTaxLiabilitiesLeasingArrangements_iI_pp0p0_d0_c20231231_z4114KSOESvl" style="border-bottom: Black 1pt solid; text-align: right" title="Right of use asset - leases">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--DeferredTaxLiabilitiesLeasingArrangements_iI_pp0p0_d0_c20221231_zbBBDPoEzzD" style="border-bottom: Black 1pt solid; text-align: right" title="Right of use asset - leases">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Total deferred tax liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--DeferredIncomeTaxLiabilities_iI_pp0p0_d0_c20231231_zZpI8NjrYxY4" style="border-bottom: Black 1pt solid; text-align: right" title="Total deferred tax liabilities">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--DeferredIncomeTaxLiabilities_iI_pp0p0_d0_c20221231_zbdYiz3LRUk7" style="border-bottom: Black 1pt solid; text-align: right" title="Total deferred tax liabilities">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net deferred liability</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--DeferredTaxLiabilities_iI_pp0p0_d0_c20231231_z8oTFyfnDC61" style="border-bottom: Black 2.5pt double; text-align: right" title="Net deferred tax assets and liabilities">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--DeferredTaxLiabilities_iI_pp0p0_d0_c20221231_zLqNnRD9HlA3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net deferred tax assets and liabilities">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> For the years ended December 31, 2023 and 2022, the Company had U.K. net operating loss carryforwards of approximately $61.3 million and $61.9 million, respectively, U.S. federal net operating loss carryforwards of approximately $31.3 million and $29.0 million, respectively, U.S. state net operating loss carryforwards of approximately $33.9 million and $30.3 million, respectively, Germany net operating loss carryforwards of approximately $2.2 million and $2.0 million, respectively, and Switzerland net operating loss carryforwards of approximately $0.3 million and $0.3 million, respectively. The U.K. and Germany net operating loss carryforwards can be carried forward indefinitely. $17.9 million of the U.S. federal net operating loss carryforwards can be carried forward indefinitely, and the remaining U.S. federal and state net operating loss carryforwards begin to expire in 2031. The Switzerland net operating loss carryforwards begin to expire in 2026. The Company’s ability to use its operating loss carryforwards and tax credits generated in the U.S. to offset future taxable income is subject to restrictions under Section 382 of the U.S. Internal Revenue Code (the “Code”). These restrictions may limit the future use of the operating loss carryforwards and tax credits if certain ownership changes described in the Code occur. Future changes in stock ownership may occur that would create further limitations on the Company’s use of the operating loss carryforwards and tax credits. In such a situation, the Company may be required to pay income taxes, even though significant operating loss carryforwards and tax credits exist. The Company’s ability to use its operating loss carryforwards and tax credits generated in the U.K. are subject to restrictions under U.K. tax legislation. These regulations may limit the future use of operating loss carryforwards (i) if there is a change in ownership and a change in the nature or conduct of the business carried on by the Company, and (ii) in certain circumstances where there is a change in the nature or conduct of the business only. In such cases the carryforwards would cease to be available to set against future income. The Company’s ability to use its operating loss carryforwards and tax credits generated in Germany and Switzerland are also subject to restrictions under German and Swiss tax legislation. These regulations may limit the future use of operating loss carryforwards if there is a change in ownership. In such cases the carryforwards would cease to be available to set against future income. As of December 31, 2023 and 2022, the Company did not record any uncertain tax positions. The Company files income tax returns in the U.S. federal tax jurisdiction, Massachusetts state tax jurisdiction, and certain foreign tax jurisdictions. The Company is subject to examination by the U.S. federal, state, foreign, and local income tax authorities for calendar tax years through 2023 due to available net operating loss carryforwards and research and development tax credits arising in those years. The Company has not been notified of any examinations by the Internal Revenue Service or any other tax authorities as of December 31, 2023. The Company has not recorded any interest or penalties for unrecognized tax benefits since its inception. Potential 382 Limitation The Company’s net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service. The Company’s ability to utilize its net operating loss (“NOL”) and research and development credit (“R&D”) carryforwards may be substantially limited due to ownership changes that may have occurred or that could occur in the future, as required by Section 382 of the Code, as well as similar state provisions. These ownership changes may limit the amount of NOL and R&D credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an ownership change, as defined in Section 382 of the Code, results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50% of the outstanding stock of a company by certain stockholders or public groups. The Company has not completed a study to assess whether one or more ownership changes have occurred since it became a loss corporation as defined in Section 382 of the Code, but the Company believes that it is likely that an ownership change has occurred. If the Company has experienced an ownership change, utilization of the NOL and R&D credit carryforwards would be subject to an annual limitation, which is determined by first multiplying the value of the Company’s common stock at the time of the ownership change by the applicable long-term, tax-exempt rate, and then could be subject to additional adjustments, as required. Any such limitation may result in the expiration of a portion of the NOL or R&D credit carryforwards before utilization. Until a study is completed, and any limitation known, no amounts are being considered as an uncertain tax position or disclosed as an unrecognized tax benefit. Any carryforwards that expire prior to utilization as a result of such limitations will be removed from deferred tax assets with a corresponding adjustment to the valuation allowance. Due to the existence of the valuation allowance, it is not expected that any potential limitation will have a material impact on the Company’s operating results. From time to time the Company may be assessed interest or penalties by major tax jurisdictions, namely the Commonwealth of Massachusetts. As of December 31, 2023, the Company had no material unrecognized tax benefits and no adjustments to liabilities or operations were required. No interest and penalties have been recognized by the Company to date.

</us-gaap:IncomeTaxDisclosureTextBlock>

<us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000615">

<table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_z4FcAv0QvDW5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details - Income by geographic regions)"> <tr style="vertical-align: bottom"> <td>Schedule of components of loss before income taxes</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Domestic (U.S.)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--NetIncomeLoss_pp0p0_c20230101__20231231__srt--StatementGeographicalAxis__country--US_zTKJYo2AP8gf" style="width: 13%; text-align: right" title="Net income (loss)">(6,424,969</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--NetIncomeLoss_c20220101__20221231__srt--StatementGeographicalAxis__country--US_pp0p0" style="width: 13%; text-align: right" title="Net income (loss)">(7,905,676</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Foreign (U.K.)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--NetIncomeLoss_pp0p0_c20230101__20231231__srt--StatementGeographicalAxis__country--GB_zkNTVFCSEom5" style="text-align: right" title="Net income (loss)">2,440,857</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--NetIncomeLoss_c20220101__20221231__srt--StatementGeographicalAxis__country--GB_pp0p0" style="text-align: right" title="Net income (loss)">1,488,938</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Foreign (Germany)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--NetIncomeLoss_pp0p0_c20230101__20231231__srt--StatementGeographicalAxis__country--DE_zcaOUaGiFUth" style="text-align: right" title="Net income (loss)">(136,977</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--NetIncomeLoss_c20220101__20221231__srt--StatementGeographicalAxis__country--DE_pp0p0" style="text-align: right" title="Net income (loss)">(124,279</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Foreign (Switzerland)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--NetIncomeLoss_pp0p0_c20230101__20231231__srt--StatementGeographicalAxis__country--CH_z2LbFzOo3h2j" style="border-bottom: Black 1pt solid; text-align: right" title="Net income (loss)">(13,489</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--NetIncomeLoss_c20220101__20221231__srt--StatementGeographicalAxis__country--CH_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Net income (loss)">(11,336</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt">Loss before income taxes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--NetIncomeLoss_pp0p0_c20230101__20231231_zAHQ40dOF0zk" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income (loss)">(4,134,578</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--NetIncomeLoss_c20220101__20221231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income (loss)">(6,552,353</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>

</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>

<us-gaap:NetIncomeLoss contextRef="From2023-01-012023-12-31_country_US" decimals="0" id="Fact000617" unitRef="USD"> -6424969 </us-gaap:NetIncomeLoss>

<us-gaap:NetIncomeLoss contextRef="From2022-01-012022-12-31_country_US" decimals="0" id="Fact000619" unitRef="USD"> -7905676 </us-gaap:NetIncomeLoss>

<us-gaap:NetIncomeLoss contextRef="From2023-01-012023-12-31_country_GB" decimals="0" id="Fact000621" unitRef="USD"> 2440857 </us-gaap:NetIncomeLoss>

<us-gaap:NetIncomeLoss contextRef="From2022-01-012022-12-31_country_GB" decimals="0" id="Fact000623" unitRef="USD"> 1488938 </us-gaap:NetIncomeLoss>

<us-gaap:NetIncomeLoss contextRef="From2023-01-012023-12-31_country_DE" decimals="0" id="Fact000625" unitRef="USD"> -136977 </us-gaap:NetIncomeLoss>

<us-gaap:NetIncomeLoss contextRef="From2022-01-012022-12-31_country_DE" decimals="0" id="Fact000627" unitRef="USD"> -124279 </us-gaap:NetIncomeLoss>

<us-gaap:NetIncomeLoss contextRef="From2023-01-012023-12-31_country_CH" decimals="0" id="Fact000629" unitRef="USD"> -13489 </us-gaap:NetIncomeLoss>

<us-gaap:NetIncomeLoss contextRef="From2022-01-012022-12-31_country_CH" decimals="0" id="Fact000631" unitRef="USD"> -11336 </us-gaap:NetIncomeLoss>

<us-gaap:NetIncomeLoss contextRef="From2023-01-01to2023-12-31" decimals="0" id="Fact000633" unitRef="USD"> -4134578 </us-gaap:NetIncomeLoss>

<us-gaap:NetIncomeLoss contextRef="From2022-01-012022-12-31" decimals="0" id="Fact000635" unitRef="USD"> -6552353 </us-gaap:NetIncomeLoss>

<us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000637">

<table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zkFj4aHgOGo4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details - Tax reconciliation)"> <tr style="vertical-align: bottom"> <td>Schedule of reconciliation of income tax provision</td><td> </td> <td colspan="2" id="xdx_496_20230101__20231231_zjvjEXTNhDU6" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_49F_20220101__20221231_zBozlGoVjNSd" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_maITEBzKxf_zAbhUxCIdtV5" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%">Federal</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(868,261</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(1,375,995</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_maITEBzKxf_zcqZnlbcUyB5" style="vertical-align: bottom; background-color: White"> <td>State</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(373,684</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(476,802</td><td style="text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzKxf_zfNmlPOToGUf" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Change in valuation allowance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,116,036</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,233,525</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_maITEBzKxf_zQPLvcd9A7j3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Permanent differences, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">271,546</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">197,151</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_maITEBzKxf_zpilibEmzYni" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Foreign rate differential</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">81,227</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(39,041</td><td style="text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_maITEBzKxf_zO9mKhiV4O1i" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Share-based expense, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,213</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,087</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_iN_pp0p0_di_msITEBzKxf_zpOQ7Jh2Uyo7" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Enhanced research and development tax credits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(238,631</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(109,792</td><td style="text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_d0_maITEBzKxf_zTGmtYBU4ZLf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Rate change</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,120,196</td><td style="text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBzKxf_zO2fOvoVcEl8" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Other items</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,554</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(327,937</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--IncomeTaxExpenseBenefit_iT_pp0p0_d0_mtITEBzKxf_zvbQr7daSytd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net benefit for income taxes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>

<us-gaap:CurrentFederalTaxExpenseBenefit contextRef="From2023-01-01to2023-12-31" decimals="0" id="Fact000639" unitRef="USD"> -868261 </us-gaap:CurrentFederalTaxExpenseBenefit>

<us-gaap:CurrentFederalTaxExpenseBenefit contextRef="From2022-01-012022-12-31" decimals="0" id="Fact000640" unitRef="USD"> -1375995 </us-gaap:CurrentFederalTaxExpenseBenefit>

<us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="From2023-01-01to2023-12-31" decimals="0" id="Fact000642" unitRef="USD"> -373684 </us-gaap:CurrentStateAndLocalTaxExpenseBenefit>

<us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="From2022-01-012022-12-31" decimals="0" id="Fact000643" unitRef="USD"> -476802 </us-gaap:CurrentStateAndLocalTaxExpenseBenefit>

<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2023-01-01to2023-12-31" decimals="0" id="Fact000645" unitRef="USD"> 1116036 </us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>

<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2022-01-012022-12-31" decimals="0" id="Fact000646" unitRef="USD"> 7233525 </us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>

<us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="From2023-01-01to2023-12-31" decimals="0" id="Fact000648" unitRef="USD"> 271546 </us-gaap:IncomeTaxReconciliationNondeductibleExpense>

<us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="From2022-01-012022-12-31" decimals="0" id="Fact000649" unitRef="USD"> 197151 </us-gaap:IncomeTaxReconciliationNondeductibleExpense>

<us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="From2023-01-01to2023-12-31" decimals="0" id="Fact000651" unitRef="USD"> 81227 </us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>

<us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="From2022-01-012022-12-31" decimals="0" id="Fact000652" unitRef="USD"> -39041 </us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>

<us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="From2023-01-01to2023-12-31" decimals="0" id="Fact000654" unitRef="USD"> 7213 </us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>

<us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="From2022-01-012022-12-31" decimals="0" id="Fact000655" unitRef="USD"> 19087 </us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>

<us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="From2023-01-01to2023-12-31" decimals="0" id="Fact000657" unitRef="USD"> 238631 </us-gaap:IncomeTaxReconciliationTaxCreditsResearch>

<us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="From2022-01-012022-12-31" decimals="0" id="Fact000658" unitRef="USD"> 109792 </us-gaap:IncomeTaxReconciliationTaxCreditsResearch>

<us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="From2023-01-01to2023-12-31" decimals="0" id="Fact000660" unitRef="USD"> 0 </us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>

<us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="From2022-01-012022-12-31" decimals="0" id="Fact000661" unitRef="USD"> -5120196 </us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>

<us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="From2023-01-01to2023-12-31" decimals="0" id="Fact000663" unitRef="USD"> 4554 </us-gaap:IncomeTaxReconciliationOtherAdjustments>

<us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="From2022-01-012022-12-31" decimals="0" id="Fact000664" unitRef="USD"> -327937 </us-gaap:IncomeTaxReconciliationOtherAdjustments>

<us-gaap:IncomeTaxExpenseBenefit contextRef="From2023-01-01to2023-12-31" decimals="0" id="Fact000666" unitRef="USD"> 0 </us-gaap:IncomeTaxExpenseBenefit>

<us-gaap:IncomeTaxExpenseBenefit contextRef="From2022-01-012022-12-31" decimals="0" id="Fact000667" unitRef="USD"> 0 </us-gaap:IncomeTaxExpenseBenefit>

<us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000673">

<table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zRdEY1X47B2e" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details - Deferred Tax Assets)"> <tr style="vertical-align: bottom"> <td>Schedule of deferred tax assets and liabilities</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Deferred tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 66%; text-align: left">U.K. net operating loss carryforwards</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_pp0p0_c20231231__srt--StatementGeographicalAxis__country--GB_zTYFNAHLccI9" style="width: 13%; text-align: right" title="Foreign net operating loss carryforwards">14,664,858</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_c20221231__srt--StatementGeographicalAxis__country--GB_pp0p0" style="width: 13%; text-align: right" title="Foreign net operating loss carryforwards">14,812,743</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt; text-align: left">U.K. capital loss carryforwards</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_iI_pp0p0_c20231231__srt--StatementGeographicalAxis__country--GB_zi2Wo10bwZXh" style="text-align: right" title="Foreign capital loss carryforwards">1,545,934</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_iI_pp0p0_c20221231__srt--StatementGeographicalAxis__country--GB_zvK9waBPPub4" style="text-align: right" title="Foreign capital loss carryforwards">1,545,934</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">U.S. federal net operating loss carryforwards</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pp0p0_c20231231_zdtoT2NgiPSk" style="text-align: right" title="Foreign net operating loss carryforwards">6,573,614</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pp0p0_c20221231_zleXWRAduIck" style="text-align: right" title="Foreign net operating loss carryforwards">6,085,858</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt; text-align: left">Switzerland net operating loss carryforwards</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_pp0p0_c20231231__srt--StatementGeographicalAxis__country--CH_zU4o5jmWNv3j" style="text-align: right" title="Foreign net operating loss carryforwards">23,868</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_c20221231__srt--StatementGeographicalAxis__country--CH_pp0p0" style="text-align: right" title="Foreign net operating loss carryforwards">22,722</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">IPR&D</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pp0p0_c20231231_zgzAmVFwiaB7" style="text-align: right" title="IPR&D">8,066,098</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_c20221231_pp0p0" style="text-align: right" title="IPR&D">8,546,593</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt; text-align: left">Share-based expense</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0_c20231231_z9zGRPqchnVf" style="text-align: right" title="Share-based expense">2,235,214</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_c20221231_pp0p0" style="text-align: right" title="Share-based expense">2,169,480</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Enhanced research and development tax credits</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pp0p0_c20231231_zly0cV21jx12" style="text-align: right" title="Enhanced research and development tax credits">2,038,421</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_c20221231_pp0p0" style="text-align: right" title="Enhanced research and development tax credits">1,820,269</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt; text-align: left">Germany net operating loss carryforwards</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_pp0p0_c20231231__srt--StatementGeographicalAxis__country--DE_zoFkYhiWMzQ1" style="text-align: right" title="Foreign net operating loss carryforwards">693,007</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_c20221231__srt--StatementGeographicalAxis__country--DE_pp0p0" style="text-align: right" title="Foreign net operating loss carryforwards">627,780</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Capitalized research and experimental expenditure</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseOther_iI_pp0p0_c20231231_zVouKKPxFsah" style="text-align: right" title="Capitalized research and experimental expenditure">1,473,049</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseOther_c20221231_pp0p0" style="text-align: right" title="Capitalized research and experimental expenditure">735,702</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt; text-align: left">U.S. state net operating loss carryforwards</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pp0p0_c20231231_z9TlZ98G9qHd" style="text-align: right" title="U.S. state net operating loss carryforwards">2,142,380</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_c20221231_pp0p0" style="text-align: right" title="U.S. state net operating loss carryforwards">1,913,128</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Other</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_pp0p0_c20231231_z26W8H5Tpq95" style="text-align: right" title="Depreciation">250,669</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_c20221231_pp0p0" style="text-align: right" title="Depreciation">288,887</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Lease liability</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--DeferredTaxAssetsOther_iI_pp0p0_d0_c20231231_zPW9ZJTYsqmg" style="border-bottom: Black 1pt solid; text-align: right" title="Lease liability">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--DeferredTaxAssetsOther_iI_pp0p0_d0_c20221231_zNjLOUBH8ZSk" style="border-bottom: Black 1pt solid; text-align: right" title="Lease liability">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total deferred tax assets before valuation allowance</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--DeferredTaxAssetsGross_iI_pp0p0_c20231231_zSLxWkkLxLM5" style="text-align: right" title="Total deferred tax assets before valuation allowance">39,707,112</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--DeferredTaxAssetsGross_c20221231_pp0p0" style="text-align: right" title="Total deferred tax assets before valuation allowance">38,569,096</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Valuation allowance for deferred tax assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_c20231231_zHMthwM63T8" style="border-bottom: Black 1pt solid; text-align: right" title="Valuation allowance for deferred tax assets">(39,707,112</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_c20221231_zZqQrZOAeqq2" style="border-bottom: Black 1pt solid; text-align: right" title="Valuation allowance for deferred tax assets">(38,569,096</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Net deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_d0_c20231231_zpEaDMUAt1z6" style="text-align: right" title="Net deferred tax assets">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_d0_c20221231_znitgoGeVBHl" style="text-align: right" title="Net deferred tax assets">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Deferred tax liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Right of use asset – leases</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--DeferredTaxLiabilitiesLeasingArrangements_iI_pp0p0_d0_c20231231_z4114KSOESvl" style="border-bottom: Black 1pt solid; text-align: right" title="Right of use asset - leases">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--DeferredTaxLiabilitiesLeasingArrangements_iI_pp0p0_d0_c20221231_zbBBDPoEzzD" style="border-bottom: Black 1pt solid; text-align: right" title="Right of use asset - leases">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Total deferred tax liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--DeferredIncomeTaxLiabilities_iI_pp0p0_d0_c20231231_zZpI8NjrYxY4" style="border-bottom: Black 1pt solid; text-align: right" title="Total deferred tax liabilities">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--DeferredIncomeTaxLiabilities_iI_pp0p0_d0_c20221231_zbdYiz3LRUk7" style="border-bottom: Black 1pt solid; text-align: right" title="Total deferred tax liabilities">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net deferred liability</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--DeferredTaxLiabilities_iI_pp0p0_d0_c20231231_z8oTFyfnDC61" style="border-bottom: Black 2.5pt double; text-align: right" title="Net deferred tax assets and liabilities">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--DeferredTaxLiabilities_iI_pp0p0_d0_c20221231_zLqNnRD9HlA3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net deferred tax assets and liabilities">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>

<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign contextRef="AsOf2023-12-31_country_GB" decimals="0" id="Fact000675" unitRef="USD"> 14664858 </us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>

<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign contextRef="AsOf2022-12-31_country_GB" decimals="0" id="Fact000677" unitRef="USD"> 14812743 </us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>

<us-gaap:DeferredTaxAssetsCapitalLossCarryforwards contextRef="AsOf2023-12-31_country_GB" decimals="0" id="Fact000679" unitRef="USD"> 1545934 </us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>

<us-gaap:DeferredTaxAssetsCapitalLossCarryforwards contextRef="AsOf2022-12-31_country_GB" decimals="0" id="Fact000681" unitRef="USD"> 1545934 </us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>

<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="AsOf2023-12-31" decimals="0" id="Fact000683" unitRef="USD"> 6573614 </us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>

<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="AsOf2022-12-31" decimals="0" id="Fact000685" unitRef="USD"> 6085858 </us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>

<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign contextRef="AsOf2023-12-31_country_CH" decimals="0" id="Fact000687" unitRef="USD"> 23868 </us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>

<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign contextRef="AsOf2022-12-31_country_CH" decimals="0" id="Fact000689" unitRef="USD"> 22722 </us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>

<us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2023-12-31" decimals="0" id="Fact000691" unitRef="USD"> 8066098 </us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>

<us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2022-12-31" decimals="0" id="Fact000693" unitRef="USD"> 8546593 </us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>

<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2023-12-31" decimals="0" id="Fact000695" unitRef="USD"> 2235214 </us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>

<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2022-12-31" decimals="0" id="Fact000697" unitRef="USD"> 2169480 </us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>

<us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="AsOf2023-12-31" decimals="0" id="Fact000699" unitRef="USD"> 2038421 </us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>

<us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="AsOf2022-12-31" decimals="0" id="Fact000701" unitRef="USD"> 1820269 </us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>

<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign contextRef="AsOf2023-12-31_country_DE" decimals="0" id="Fact000703" unitRef="USD"> 693007 </us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>

<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign contextRef="AsOf2022-12-31_country_DE" decimals="0" id="Fact000705" unitRef="USD"> 627780 </us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>

<us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther contextRef="AsOf2023-12-31" decimals="0" id="Fact000707" unitRef="USD"> 1473049 </us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>

<us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther contextRef="AsOf2022-12-31" decimals="0" id="Fact000709" unitRef="USD"> 735702 </us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>

<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="AsOf2023-12-31" decimals="0" id="Fact000711" unitRef="USD"> 2142380 </us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>

<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="AsOf2022-12-31" decimals="0" id="Fact000713" unitRef="USD"> 1913128 </us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>

<us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="AsOf2023-12-31" decimals="0" id="Fact000715" unitRef="USD"> 250669 </us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>

<us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="AsOf2022-12-31" decimals="0" id="Fact000717" unitRef="USD"> 288887 </us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>

<us-gaap:DeferredTaxAssetsOther contextRef="AsOf2023-12-31" decimals="0" id="Fact000719" unitRef="USD"> 0 </us-gaap:DeferredTaxAssetsOther>

<us-gaap:DeferredTaxAssetsOther contextRef="AsOf2022-12-31" decimals="0" id="Fact000721" unitRef="USD"> 0 </us-gaap:DeferredTaxAssetsOther>

<us-gaap:DeferredTaxAssetsGross contextRef="AsOf2023-12-31" decimals="0" id="Fact000723" unitRef="USD"> 39707112 </us-gaap:DeferredTaxAssetsGross>

<us-gaap:DeferredTaxAssetsGross contextRef="AsOf2022-12-31" decimals="0" id="Fact000725" unitRef="USD"> 38569096 </us-gaap:DeferredTaxAssetsGross>

<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2023-12-31" decimals="0" id="Fact000727" unitRef="USD"> 39707112 </us-gaap:DeferredTaxAssetsValuationAllowance>

<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2022-12-31" decimals="0" id="Fact000729" unitRef="USD"> 38569096 </us-gaap:DeferredTaxAssetsValuationAllowance>

<us-gaap:DeferredTaxAssetsNet contextRef="AsOf2023-12-31" decimals="0" id="Fact000731" unitRef="USD"> 0 </us-gaap:DeferredTaxAssetsNet>

<us-gaap:DeferredTaxAssetsNet contextRef="AsOf2022-12-31" decimals="0" id="Fact000733" unitRef="USD"> 0 </us-gaap:DeferredTaxAssetsNet>

<us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="AsOf2023-12-31" decimals="0" id="Fact000735" unitRef="USD"> 0 </us-gaap:DeferredTaxLiabilitiesLeasingArrangements>

<us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="AsOf2022-12-31" decimals="0" id="Fact000737" unitRef="USD"> 0 </us-gaap:DeferredTaxLiabilitiesLeasingArrangements>

<us-gaap:DeferredIncomeTaxLiabilities contextRef="AsOf2023-12-31" decimals="0" id="Fact000739" unitRef="USD"> 0 </us-gaap:DeferredIncomeTaxLiabilities>

<us-gaap:DeferredIncomeTaxLiabilities contextRef="AsOf2022-12-31" decimals="0" id="Fact000741" unitRef="USD"> 0 </us-gaap:DeferredIncomeTaxLiabilities>

<us-gaap:DeferredTaxLiabilities contextRef="AsOf2023-12-31" decimals="0" id="Fact000743" unitRef="USD"> 0 </us-gaap:DeferredTaxLiabilities>

<us-gaap:DeferredTaxLiabilities contextRef="AsOf2022-12-31" decimals="0" id="Fact000745" unitRef="USD"> 0 </us-gaap:DeferredTaxLiabilities>

<us-gaap:OperatingLossCarryforwards contextRef="AsOf2023-12-31_country_GB646441421" decimals="0" id="Fact000747" unitRef="USD"> 61300000 </us-gaap:OperatingLossCarryforwards>

<us-gaap:OperatingLossCarryforwards contextRef="AsOf2022-12-31_country_GB646441437" decimals="0" id="Fact000749" unitRef="USD"> 61900000 </us-gaap:OperatingLossCarryforwards>

<us-gaap:OperatingLossCarryforwards contextRef="AsOf2023-12-31_country_US" decimals="0" id="Fact000751" unitRef="USD"> 31300000 </us-gaap:OperatingLossCarryforwards>

<us-gaap:OperatingLossCarryforwards contextRef="AsOf2022-12-31_country_US" decimals="-6" id="Fact000753" unitRef="USD"> 29000000 </us-gaap:OperatingLossCarryforwards>

<us-gaap:OperatingLossCarryforwards contextRef="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember" decimals="0" id="Fact000755" unitRef="USD"> 33900000 </us-gaap:OperatingLossCarryforwards>

<us-gaap:OperatingLossCarryforwards contextRef="AsOf2022-12-31_us-gaap_StateAndLocalJurisdictionMember" decimals="0" id="Fact000757" unitRef="USD"> 30300000 </us-gaap:OperatingLossCarryforwards>

<us-gaap:OperatingLossCarryforwards contextRef="AsOf2023-12-31_country_DE646441453" decimals="0" id="Fact000759" unitRef="USD"> 2200000 </us-gaap:OperatingLossCarryforwards>

<us-gaap:OperatingLossCarryforwards contextRef="AsOf2022-12-31_country_DE646441453" decimals="-6" id="Fact000761" unitRef="USD"> 2000000 </us-gaap:OperatingLossCarryforwards>

<us-gaap:OperatingLossCarryforwards contextRef="AsOf2023-12-31_country_CH646441468" decimals="0" id="Fact000763" unitRef="USD"> 300000 </us-gaap:OperatingLossCarryforwards>

<us-gaap:OperatingLossCarryforwards contextRef="AsOf2022-12-31_country_CH646441468" decimals="0" id="Fact000765" unitRef="USD"> 300000 </us-gaap:OperatingLossCarryforwards>

<xbio:OperatingLossCarryforwardsExpirationDate1 contextRef="From2023-01-012023-12-31_country_US646441468" id="Fact000767"> begin to expire in 2031 </xbio:OperatingLossCarryforwardsExpirationDate1>

<xbio:OperatingLossCarryforwardsExpirationDate1 contextRef="From2023-01-012023-12-31_country_CH646441468" id="Fact000769"> 2026 </xbio:OperatingLossCarryforwardsExpirationDate1>

<us-gaap:LiabilityForUncertainTaxPositionsCurrent contextRef="AsOf2023-12-31" decimals="0" id="Fact000775" unitRef="USD"> 0 </us-gaap:LiabilityForUncertainTaxPositionsCurrent>

<us-gaap:LiabilityForUncertainTaxPositionsCurrent contextRef="AsOf2022-12-31" decimals="0" id="Fact000777" unitRef="USD"> 0 </us-gaap:LiabilityForUncertainTaxPositionsCurrent>

<us-gaap:UnrecognizedTaxBenefits contextRef="AsOf2023-12-31" decimals="0" id="Fact000779" unitRef="USD"> 0 </us-gaap:UnrecognizedTaxBenefits>

<us-gaap:UnrecognizedTaxBenefits contextRef="AsOf2022-12-31" decimals="0" id="Fact000781" unitRef="USD"> 0 </us-gaap:UnrecognizedTaxBenefits>

<us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued contextRef="AsOf2023-12-31" decimals="0" id="Fact000783" unitRef="USD"> 0 </us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>

<us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued contextRef="AsOf2022-12-31" decimals="0" id="Fact000785" unitRef="USD"> 0 </us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>

<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000787">

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 5%">10.</td> <td style="width: 95%; text-align: justify">Stockholders’ Equity</td></tr> </table> Common Stock Each share of the Company’s common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. Common stockholders are entitled to dividends when and if declared by the Board of Directors. In the event of any voluntary or involuntary liquidation, dissolution or winding-up of the Company, the holders of common stock are entitled to share ratably in the assets of the Company available for distribution. On May 11, 2023, the Company filed a Certificate of Change to the Company’s Articles of Incorporation with the Secretary of State of Nevada to effect the Reverse Stock Split. The Reverse Stock Split was effective at 12:01 a.m., Eastern Time, on May 15, 2023. No fractional shares were issued as a result of the Reverse Stock Split and any remaining share fractions were rounded up to the nearest whole share, resulting in <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzYXbiDadynk" title="Issuance of common stock to adjust for reverse split rounding, shares">15,941 new shares of common stock being issued to existing holders of the Company’s common stock. Authorized Share Increase On December 21, 2022, shareholders of the Company voted to approve an amendment to the Company’s Articles of Incorporation to increase the authorized shares of common stock to 10,000,000 shares (the “Authorized Share Increase”). The Company filed a Certificate of Amendment to the Company’s Articles of Incorporation with the Secretary of the State of Nevada to effect the Authorized Share Increase as of December 21, 2022. At the Market (“ATM”) Offering On November 19, 2021, the Company entered into an ATM Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC, as the exclusive sales agent (“Wainwright”), pursuant to which the Company may offer and sell, from time to time through Wainwright, shares of its common stock, par value $0.001 per share. The offer and sale of the shares will be made pursuant to a shelf registration statement on Form S-3 (File No. 333-260201) and the related prospectus, filed with the SEC on October 12, 2021 and declared effective on October 22, 2021, and is currently limited to a number of securities it can sell under the ATM Agreement of up to $4 million, provided that the Company may be limited in the amount of securities that it can sell pursuant to General Instruction I.B.6 of Form S-3. Pursuant to the ATM Agreement, Wainwright may sell the shares in sales deemed to be “at-the-market” equity offerings as defined in Rule 415 promulgated under the Securities Act, including sales made directly on or through the Nasdaq Capital Market. If agreed to in a separate terms agreement, the Company may sell shares to Wainwright as principal, at a purchase price agreed upon by Wainwright and the Company. Wainwright may also sell shares in privately negotiated transactions with the Company’s prior approval. Sales of the shares through Wainwright, if any, will be made in amounts and at times to be determined by the Company from time to time, but the Company has no obligation to sell any of the shares and either the Company or Wainwright may at any time suspend offers under the agreement or terminate the agreement. Actual sales will depend on a variety of factors to be determined by the Company from time to time, including (among others) market conditions, the trading price of the Company’s common stock and determinations by the Company of the appropriate sources of funding for the Company. The offer and sale of the shares pursuant to the ATM Agreement will terminate upon the earlier of (a) the issuance and sale of all of the shares subject to the ATM Agreement or (b) the termination of the ATM Agreement by Wainwright or the Company pursuant to the terms thereof. No shares were sold under the ATM Agreement during the years ended December 31, 2023 and 2022. The Company incurred approximately $0.2 million of costs associated with the ATM which were expensed during the year ended December 31, 2023. These costs were recorded within prepaid expenses and other current assets as of December 31, 2022. Series A Preferred Stock The Company has designated 1,000,000 shares as Series A preferred stock with each share having a par value of $0.001 and stated value of $<span id="xdx_902_ecustom--PreferredStockStatedValuePerShare_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zYXTSuDegH0a" title="Preferred stock stated value per share">4.80 (the “Series A Preferred Stock”). The following is a summary of the material terms of the Series A Preferred Stock. Liquidation. Upon any dissolution, liquidation or winding up, whether voluntary or involuntary, holders of Series A Preferred Stock will be entitled to receive distributions out of the Company’s assets, of an amount equal to the stated value per share of Series A Preferred Stock (as adjusted for stock splits, combinations, reorganizations and the like) plus any accrued and unpaid dividends thereon before any distributions shall be made on the common stock or any series of preferred stock ranked junior to the Series A Preferred Stock. Dividends. Holders of the Series A Preferred Stock are entitled to receive a non-cumulative cash dividend at an annual rate of 5% of the stated value per share of Series A Preferred Stock, when and if declared by the Company’s Board, out of the Company’s assets legally available therefor. No dividends or other distribution will be made on the common stock or any series of preferred stock ranked junior to the Series A Preferred Stock unless the dividend on the Series A Preferred Stock has been paid current and a reserve has been made for the next calendar year. The Company’s ability to pay dividends on Series A Preferred Stock is subject to restrictions in the Company’s Series B Preferred Stock, which ranks senior to the Series A Preferred Stock in right of payment. Conversion. Series A Preferred Stock is convertible, at any time and from time to time at the option of the holder thereof, with a minimum of 61 days’ advance notice to the Company, at a rate of one hundred twenty shares of Series A Preferred Stock to one share of common stock basis. Redemption. Upon 30 days’ prior written notice, the Company may require the holder of any Series A Preferred Stock to convert any or all of such holder’s Series A Preferred Stock to common stock at a rate of one hundred twenty shares of Series A Preferred Stock to one share of common stock basis. The Series A Preferred Stock has additional terms covering stock dividends and splits, voting rights, fractional shares and fundamental transactions. As of December 31, 2022, there were approximately 1.0 million shares of Series A Preferred Stock issued and outstanding. During 2023, the holder of the Series A Preferred Stock converted all of their shares into <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zApd1RpMuHC8" title="Converted shares">8,084 shares of Company common stock. As a result, there was no Series A Preferred Stock outstanding as of December 31, 2023. Series B Preferred Stock The Company has designated 2,500,000 shares as Series B preferred stock with each share having a stated value of $<span id="xdx_90B_ecustom--PreferredStockStatedValuePerShare_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zhXAGPxiu3Bi" title="Preferred stock stated value per share">4.00 per share (the “Series B Preferred Stock”). The following is a summary of the material terms of the Company’s Series B Preferred Stock. Liquidation. Upon any dissolution, liquidation or winding up, whether voluntary or involuntary, holders of Series B Preferred Stock will be entitled to receive distributions out of the Company’s assets of an amount equal to the stated value per share of Series B Preferred Stock (as adjusted for stock splits, combinations, reorganizations and the like) plus any accrued and unpaid dividends thereon and any other fees or liquidated damages then due and owing thereon under the amended and restated certificate of designation before any distributions shall be made on the common stock or any series of preferred stock ranked junior to the Series B Preferred Stock, which includes Series A Preferred Stock. A fundamental transaction or change of control under the amended and restated certificate of designation shall constitute a liquidation for purposes of this right. Xenetic will give each holder of Series B Preferred Stock written notice of any liquidation at least 30 days before any meeting of stockholders to approve such liquidation or at least 45 days before the date of such liquidation if no meeting is to be held. Dividends. Subject to any preferential rights of any outstanding series of preferred stock created by the Company’s Board from time to time, the holders of shares of the Company’s Series B Preferred Stock will be entitled to such cash dividends, non-cumulative, as may be declared from time to time by the Company’s Board on shares of the Company’s common stock (on an as-converted basis) from funds available therefore. The Company shall not directly or indirectly pay or declare any dividend or make any distribution upon, nor shall any distribution be made in respect of, any junior securities, including Series A Preferred Stock, as long as any dividends due on the Series B Preferred Stock remain unpaid, nor shall any monies be set aside for or applied to the purchase or redemption of any junior securities or shares pari passu with the Series B Preferred Stock. Conversion. Series B Preferred Stock is convertible, at any time and from time to time at the option of the holder thereof, at a rate of one preferred share to approximately 0.033 common share basis, subject to an issuable maximum and the adjustments described below. There were <span id="xdx_907_eus-gaap--ConversionOfStockSharesConverted1_do_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zUIqSKMTXJKb" title="Stock converted, shares converted"><span id="xdx_901_eus-gaap--ConversionOfStockSharesConverted1_do_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zCQkEt1JnOb1" title="Stock converted, shares converted">no Series B Preferred Stock conversions during the years ended December 31, 2023 and 2022. Subsequent Equity Sales. The Series B Preferred Stock has ratchet price based anti-dilution protection, subject to customary carve outs, in the event of a down-round financing at a price per share below the stated value of the Series B Preferred Stock. There is no bifurcation of the embedded conversion option being clearly and closely related to the host instrument. The Series B Preferred Stock has additional terms covering stock dividends and splits, voting rights, fractional shares and fundamental transactions. As of December 31, 2023 and 2022, there were approximately 1.8 million shares of Series B Preferred Stock issued and outstanding which are convertible into approximately 60,000 shares of common stock in each year, which represents the issuable maximum that can be issued upon the conversion of the currently outstanding Series B Preferred Stock. Warrants Related to Financing Arrangements In connection with its July 2021 private placement, the Company issued warrants to purchase an aggregate of <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20210731__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsMember_zCnh0L6ggyY9" title="Warrants issued">462,963 shares of the Company’s common stock (the “Series A Warrants”). The Series A Warrants are immediately exercisable at a price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210731__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsMember_zr6DlNjRgRHg" title="Exercise price">33.00 per share of common stock and expire on <span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20210731__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsMember_zCFNzAnvySl2" title="Maturity date">February 23, 2025. <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_do_c20230101__20231231__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsMember_zsoAAFNIA5fg" title="Warrants exercised"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_do_c20220101__20221231__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsMember_zSeFjKapl7sh" title="Warrants exercised">No Series A Warrants were exercised or forfeited during the years ended December 31, 2023 and 2022. In addition, the Company has publicly traded warrants to purchase approximately 2,100 shares of common stock outstanding as of both December 31, 2023 and 2022. These warrants have an exercise price of $130.00 per share and expire on July 17, 2024. The warrants trade on Nasdaq under the symbol “XBIOW.” The warrants also provide that if the weighted-average price of common stock on any trading day on or after 30 days after issuance is lower than the then-applicable exercise price per share, each warrant may be exercised, at the option of the holder, on a cashless basis for one share of common stock. None of these warrants were exercised during the year ended December 31, 2023. Warrants to purchase approximately 200 shares of common stock were exercised on a cashless, one-for-one basis during the year ended December 31, 2022. None of these warrants were forfeited during the years ended December 31, 2023 and 2022. The Company also has outstanding warrants to purchase approximately 800 shares of the Company’s common stock as of December 31, 2023 and 2022. These warrants have an exercise price of $29.09 per share and expire on July 3, 2026. None of these warrants were exercised or forfeited during the years ended December 31, 2023 and 2022.

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>

<us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" decimals="INF" id="Fact000789" unitRef="Shares"> 15941 </us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>

<us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-12-21" decimals="INF" id="Fact000796" unitRef="Shares"> 10000000 </us-gaap:CommonStockSharesAuthorized>

<us-gaap:SaleOfStockPricePerShare contextRef="AsOf2021-11-19_custom_ATMAgreementMember" decimals="INF" id="Fact000798" unitRef="USDPShares"> 0.001 </us-gaap:SaleOfStockPricePerShare>

<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2023-01-012023-12-31_custom_ATMAgreementMember" decimals="INF" id="Fact000800" unitRef="Shares"> 0 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>

<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2022-01-012022-12-31_custom_ATMAgreementMember" decimals="INF" id="Fact000802" unitRef="Shares"> 0 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>

<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2023-12-31_custom_ATMAgreementMember" decimals="0" id="Fact000804" unitRef="USD"> 200000 </us-gaap:PrepaidExpenseAndOtherAssetsCurrent>

<us-gaap:PreferredUnitsAuthorized contextRef="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact000806" unitRef="Shares"> 1000000 </us-gaap:PreferredUnitsAuthorized>

<xbio:PreferredStockStatedValuePerShare contextRef="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact000808" unitRef="USDPShares"> 4.80 </xbio:PreferredStockStatedValuePerShare>

<us-gaap:PreferredStockDividendRatePercentage contextRef="From2023-01-012023-12-31_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact000810" unitRef="Pure"> 0.05 </us-gaap:PreferredStockDividendRatePercentage>

<us-gaap:PreferredUnitsIssued contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact000816" unitRef="Shares"> 1000000.0 </us-gaap:PreferredUnitsIssued>

<us-gaap:PreferredUnitsOutstanding contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact000818" unitRef="Shares"> 1000000.0 </us-gaap:PreferredUnitsOutstanding>

<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2023-01-012023-12-31_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact000820" unitRef="Shares"> 8084 </us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>

<us-gaap:PreferredUnitsOutstanding contextRef="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact000822" unitRef="Shares"> 0 </us-gaap:PreferredUnitsOutstanding>

<us-gaap:PreferredUnitsAuthorized contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember" decimals="INF" id="Fact000824" unitRef="Shares"> 2500000 </us-gaap:PreferredUnitsAuthorized>

<xbio:PreferredStockStatedValuePerShare contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember" decimals="INF" id="Fact000826" unitRef="USDPShares"> 4.00 </xbio:PreferredStockStatedValuePerShare>

<us-gaap:ConversionOfStockSharesConverted1 contextRef="From2023-01-012023-12-31_us-gaap_SeriesBPreferredStockMember" decimals="INF" id="Fact000828" unitRef="Shares"> 0 </us-gaap:ConversionOfStockSharesConverted1>

<us-gaap:ConversionOfStockSharesConverted1 contextRef="From2022-01-012022-12-31_us-gaap_SeriesBPreferredStockMember" decimals="INF" id="Fact000830" unitRef="Shares"> 0 </us-gaap:ConversionOfStockSharesConverted1>

<us-gaap:PreferredUnitsIssued contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember" decimals="INF" id="Fact000832" unitRef="Shares"> 1800000 </us-gaap:PreferredUnitsIssued>

<us-gaap:PreferredUnitsIssued contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember" decimals="INF" id="Fact000834" unitRef="Shares"> 1800000 </us-gaap:PreferredUnitsIssued>

<us-gaap:PreferredUnitsOutstanding contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember" decimals="INF" id="Fact000836" unitRef="Shares"> 1800000 </us-gaap:PreferredUnitsOutstanding>

<us-gaap:PreferredUnitsOutstanding contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember" decimals="INF" id="Fact000838" unitRef="Shares"> 1800000 </us-gaap:PreferredUnitsOutstanding>

<xbio:ConvertibleCommonStockInEachYear contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember" decimals="INF" id="Fact000840" unitRef="Shares"> 60000 </xbio:ConvertibleCommonStockInEachYear>

<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2021-07-31_us-gaap_PrivatePlacementMember_custom_SeriesAWarrantsMember" decimals="INF" id="Fact000846" unitRef="Shares"> 462963 </us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>

<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2021-07-31_us-gaap_PrivatePlacementMember_custom_SeriesAWarrantsMember" decimals="INF" id="Fact000848" unitRef="USDPShares"> 33.00 </us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>

<us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2021-07-31_us-gaap_PrivatePlacementMember_custom_SeriesAWarrantsMember" id="Fact000850"> 2025-02-23 </us-gaap:WarrantsAndRightsOutstandingMaturityDate>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="From2023-01-012023-12-31_us-gaap_PrivatePlacementMember_custom_SeriesAWarrantsMember" decimals="INF" id="Fact000852" unitRef="Shares"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="From2022-01-012022-12-31_us-gaap_PrivatePlacementMember_custom_SeriesAWarrantsMember" decimals="INF" id="Fact000854" unitRef="Shares"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>

<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2023-12-31_custom_PubliclyTradedWarrantsMember" decimals="INF" id="Fact000856" unitRef="Shares"> 2100 </us-gaap:ClassOfWarrantOrRightOutstanding>

<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2022-12-31_custom_PubliclyTradedWarrantsMember" decimals="INF" id="Fact000858" unitRef="Shares"> 2100 </us-gaap:ClassOfWarrantOrRightOutstanding>

<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2023-12-31_custom_PubliclyTradedWarrantsMember" decimals="INF" id="Fact000860" unitRef="USDPShares"> 130.00 </us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>

<us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2023-12-31_custom_PubliclyTradedWarrantsMember" id="Fact000862"> 2024-07-17 </us-gaap:WarrantsAndRightsOutstandingMaturityDate>

<xbio:WarrantsExercisedShares contextRef="From2023-01-012023-12-31_custom_PubliclyTradedWarrantsMember" decimals="INF" id="Fact000864" unitRef="Shares"> 0 </xbio:WarrantsExercisedShares>

<xbio:WarrantsExercisedShares contextRef="From2022-01-012022-12-31_custom_PubliclyTradedWarrantsMember" decimals="INF" id="Fact000866" unitRef="Shares"> 200 </xbio:WarrantsExercisedShares>

<xbio:WarrantsForfeitedShares contextRef="From2023-01-012023-12-31_custom_OtherWarrantsMember" decimals="INF" id="Fact000868" unitRef="Shares"> 0 </xbio:WarrantsForfeitedShares>

<xbio:WarrantsForfeitedShares contextRef="From2022-01-012022-12-31_custom_OtherWarrantsMember" decimals="INF" id="Fact000870" unitRef="Shares"> 0 </xbio:WarrantsForfeitedShares>

<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2023-12-31_custom_OtherWarrantsMember" decimals="INF" id="Fact000872" unitRef="Shares"> 800 </us-gaap:ClassOfWarrantOrRightOutstanding>

<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2022-12-31_custom_OtherWarrantsMember" decimals="INF" id="Fact000874" unitRef="Shares"> 800 </us-gaap:ClassOfWarrantOrRightOutstanding>

<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2023-12-31_custom_OtherWarrantsMember" decimals="INF" id="Fact000876" unitRef="USDPShares"> 29.09 </us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>

<us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2023-12-31_custom_OtherWarrantsMember" id="Fact000878"> 2026-07-03 </us-gaap:WarrantsAndRightsOutstandingMaturityDate>

<xbio:WarrantsExercisedShares contextRef="From2023-01-012023-12-31_custom_OtherWarrantsMember" decimals="INF" id="Fact000880" unitRef="Shares"> 0 </xbio:WarrantsExercisedShares>

<xbio:WarrantsExercisedShares contextRef="From2022-01-012022-12-31_custom_OtherWarrantsMember" decimals="INF" id="Fact000882" unitRef="Shares"> 0 </xbio:WarrantsExercisedShares>

<xbio:WarrantsForfeitedShares contextRef="From2023-01-012023-12-31_custom_OtherWarrantsMember" decimals="INF" id="Fact000884" unitRef="Shares"> 0 </xbio:WarrantsForfeitedShares>

<xbio:WarrantsForfeitedShares contextRef="From2022-01-012022-12-31_custom_OtherWarrantsMember" decimals="INF" id="Fact000886" unitRef="Shares"> 0 </xbio:WarrantsForfeitedShares>

<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000888">

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 5%">11.</td> <td style="width: 95%; text-align: justify">Share-Based Expense </td></tr> </table> Total share-based expense related to stock options, RSUs and common stock awards was approximately $0.3 million and $0.5 million for the years ended December 31, 2023 and 2022, respectively. Share-based expense is classified in the consolidated statements of comprehensive loss as follows: <table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zl6Fu0MHWVb8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Share-Based Expense (Details - Share based expense)"> <tr style="vertical-align: bottom"> <td id="xdx_8BC_zcptWSVJntFd" style="display: none">Schedule of Share-Based Compensation Expense</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Research and development expenses</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zQyFxHPG45Md" style="width: 13%; text-align: right" title="Share-based compensation">56,112</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zGAple485Csg" style="width: 13%; text-align: right" title="Share-based compensation">86,305</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">General and administrative expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zYJORzmMMBs8" style="border-bottom: Black 1pt solid; text-align: right" title="Share-based compensation">226,973</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z1Inqlrfar43" style="border-bottom: Black 1pt solid; text-align: right" title="Share-based compensation">425,175</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231_zQBYjYl9c1sd" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based compensation">283,085</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20221231_za9ZzCDyjQv3" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based compensation">511,480</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Stock Options The Company grants stock option awards and RSUs to employees and non-employees with varying vesting terms under the Xenetic Biosciences, Inc. Amended and Restated Equity Incentive Plan. The Company measures the fair value of stock option awards using the Black-Scholes option pricing model, which uses the assumptions noted in the tables below, including the risk-free interest rate, expected term, share price volatility, dividend yield and forfeiture rate. The risk-free interest rate is based upon the U.S. Treasury yield curve in effect at the time of grant, with a term that approximates the expected life of the option. For stock options issued in 2023 and 2022 that qualify as “plain vanilla” stock options, the expected term is based on the simplified method. The Company has a limited history of stock option exercises, which does not provide a reasonable basis for the Company to estimate the expected term of employee and non-employee stock options. For all other stock options, the Company estimates the expected life using judgment based on the anticipated research and development milestones of the Company’s clinical projects and behavior of the Company’s employees and non-employees. The expected life of non-employee options is the contractual life of the option. The expected volatility rates are estimated based on the actual volatility of the Company. To the extent Company data is not available for the full expected term of the awards the Company uses a price volatility based on a blended rate of the Company’s historical volatility with that of comparable publicly traded companies with drug candidates in similar therapeutic areas and stages of nonclinical and clinical development to the Company’s drug candidates. The Company has applied an expected dividend yield of 0% as the Company has not historically declared a dividend and does not anticipate declaring a dividend during the expected life of the options. The Company accounts for forfeitures as they occur. Employee Stock Options During the years ended December 31, 2023 and 2022, <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zpPfKKINQyvg" title="Options granted">57,500 and <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zdxdixeukw5i" title="Options granted">35,000 total stock options to purchase shares of common stock were granted by the Company, respectively. The weighted average grant date fair value per option was $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTlEjqa1UEC4" title="Weighted average grant date fair value">3.49 and $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zBBhRkRr4bp7" title="Weighted average grant date fair value">7.29, respectively. No employee stock options were exercised and none expired during the years ended December 31, 2023 and 2022. During the years ended December 31, 2023 and 2022, <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zuZtnt4NgNl9" title="Options vested">33,333 and <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEsvNLQmAl5j" title="Options vested">37,503 total stock options vested, respectively, with total fair values of approximately $<span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_dm_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zBEqaEsBVB64" title="Fair value of options vested">0.3 million and $<span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_dm_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zWOUwtSpekX" title="Fair value of options vested">0.6 million, respectively. As of December 31, 2023, there was approximately $<span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_dm_c20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAy9AoTApDEd" title="Unrecognized compensation expense">0.3 million of unrecognized share-based payments related to employee stock options that are expected to vest. The Company expects to recognize this expense over a weighted-average period of approximately <span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlN01Eh1nLH2" title="Unrecognized compensation expense recognition period">2.1 years. Key assumptions used in the Black-Scholes option pricing model for options granted to employees during the years ending December 31, 2023 and 2022 are as follows: <table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z1ma3mLFFKif" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Share-Based Expense (Details - Assumptions Employee)"> <tr style="vertical-align: bottom"> <td>Schedule of assumptions used</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Weighted-average expected dividend yield (%)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zxFgX8lpS69a" title="Weighted-average expected dividend yield">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4gCMWm2Q1R5" title="Weighted-average expected dividend yield">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 66%; text-align: left">Weighted-average expected volatility (%)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1bekoKwa6U2" title="Weighted-average expected volatility">121.50</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlXuFLm3yjSf" title="Weighted-average expected volatility">126.51</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Weighted-average risk-free interest rate (%)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ze16qTsCjB43" title="Weighted-average risk-free interest rate">4.21</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6c7rwKO4YH1" title="Weighted-average risk-free interest rate">2.90</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-average expected life of option (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjubn7yX8c7j" title="Weighted-average expected life of option">5.76</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKPvXDYtERz3" title="Weighted-average expected life of option">5.72</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Weighted-average exercise price ($)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zQhvifalnwCd" title="Weighted-average exercise price">4.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zyDwkwqmWCCk" title="Weighted-average exercise price">8.27</td><td style="text-align: left"> </td></tr> </table> The following is a summary of employee stock option activity for the years ended December 31, 2023 and 2022: <table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zxNSPq473Wvf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Share-Based Expense (Details - Employee option activity)"> <tr style="vertical-align: bottom"> <td id="xdx_8B5_zxUpB6khHmn5" style="display: none"> Schedule of option activity</td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid; text-align: center">Number of shares</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted- average exercise price</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted- average remaining life (years)</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Aggregate intrinsic value</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 41%">Outstanding as of January 1, 2022</td> <td style="width: 2%"> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zH7LLUmR1cp6" style="width: 11%; text-align: right" title="Options outstanding, beginning balance">108,888</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7sdbjmbNDfg" style="width: 11%; text-align: right" title="Weighted-average exercise price outstanding, beginning balance">62.66</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgTGk2jOFQti" title="Weighted-average remaining life outstanding beginning">8.22</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgie5wa5XBZf" style="width: 11%; text-align: right" title="Aggregate intrinsic value, outstanding beginning balance">23,750</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td> <td> </td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zyDmK8hXrCYe" style="text-align: right" title="Options granted">35,000</td> <td> </td> <td> </td> <td> </td> <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zc5Sc7QkqXQj" style="text-align: right" title="Weighted-average exercise price, granted">8.27</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Expired</td> <td> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_d0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZzeGOoN5FJ4" style="border-bottom: black 1pt solid; text-align: right" title="Options expired">–</td> <td> </td> <td> </td> <td> </td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_d0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1qJZWmKfEU4" style="text-align: right" title="Weighted-average exercise price, expired">–</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Outstanding as of December 31, 2022</td> <td> </td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ziQ1ov4AJZeb" style="text-align: right" title="Options outstanding, beginning balance">143,888</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zWOXp2KXNjib" style="text-align: right" title="Weighted-average exercise price outstanding, beginning balance">49.43</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zxuqq3zLCq85" title="Weighted-average remaining life outstanding beginning">7.78</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_d0_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zdla8j61BuC2" style="text-align: right" title="Aggregate intrinsic value, outstanding beginning balance">–</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Granted</td> <td> </td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zWCPwRkxnuvj" style="text-align: right" title="Options granted">57,500</td> <td> </td> <td> </td> <td> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNQnKyDZdBO3" style="text-align: right" title="Weighted-average exercise price, granted">4.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expired</td> <td> </td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_d0_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zCovjNQD8QD7" style="border-bottom: black 1pt solid; text-align: right" title="Options expired">–</td> <td> </td> <td> </td> <td> </td> <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_d0_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHukRHq4JcO2" style="text-align: right" title="Weighted-average exercise price, expired">–</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Outstanding as of December 31, 2023</td> <td> </td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNUlinejAEfj" style="border-bottom: black 2.25pt double; text-align: right" title="Options outstanding, ending balance">201,388</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zuAwmJ1wJAt8" style="text-align: right" title="Weighted-average exercise price, ending balance">36.46</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zk9bXuNcklM9" title="Weighted-average remaining life outstanding ending">7.69</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_d0_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNrpnDQN9xta" style="text-align: right" title="Aggregate intrinsic value, outstanding ending balance">–</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Vested or expected to vest as of December 31, 2023</td> <td> </td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zh53I0BBlVE9" style="border-bottom: black 2.25pt double; text-align: right" title="Options vested or expected to vest">201,388</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zekSMdrhv1l2" style="text-align: right" title="Weighted-average exercise price, vested or expected to vest">36.46</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zJogcZpMjeS1" title="Weighted-average remaining life, vested or expected to vest">7.69</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_pp0p0_d0_c20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zVlHTUdVzYUd" style="text-align: right" title="Aggregate intrinsic value, vested or expected to vest">–</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Exercisable as of December 31, 2022</td> <td> </td> <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4AcvXH4Vw99" style="text-align: right" title="Options exercisable">100,555</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z89hYt6Mom0h" style="text-align: right" title="Weighted-average exercise price, exercisable">65.70</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqj0HCZUL2u5" title="Weighted-average remaining life, exercisable">7.14</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_d0_c20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKJLVFMCyd03" style="text-align: right" title="Aggregate intrinsic value, exercisable">–</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercisable as of December 31, 2023</td> <td> </td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z93tfKgtXW6" style="text-align: right" title="Options exercisable">133,888</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zJQ8Ujsa2Plf" style="text-align: right" title="Weighted-average exercise price, exercisable">52.10</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6hdsouAqNNd" title="Weighted-average remaining life, exercisable">6.69</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_d0_c20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zVniChariVsa" style="text-align: right" title="Aggregate intrinsic value, exercisable">–</td> <td> </td></tr> </table> A summary of the status of the Company’s non-vested employee stock option shares as of December 31, 2023, and the changes during the year ended December 31, 2023, is as follows: <table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_z3DrgAETIPEg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Share-Based Expense (Details - Non-Vested employee Option activity)"> <tr style="vertical-align: bottom"> <td id="xdx_8BE_zFgwwWwsTRAk" style="display: none"> Schedule of non-vested options</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted- average grant date fair value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%">Balance as of January 1, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonVestedEmployeeStockOptionMember_zgLsdx2e86P8" style="width: 13%; text-align: right" title="Non-vested options outstanding, beginning balance">43,334</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonVestedEmployeeStockOptionMember_zzjb4rVzGjWf" style="width: 13%; text-align: right" title="Non-vested weighted-average grant date fair value per share, beginning balance">10.39</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonVestedEmployeeStockOptionMember_zjq5Ocf5v659" style="text-align: right" title="Options granted">57,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonVestedEmployeeStockOptionMember_z8P4cTwhzg6l" style="text-align: right" title="Weighted-average grant date fair value per share, options granted">3.49</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d0_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonVestedEmployeeStockOptionMember_zpE6rrcl2MI4" style="text-align: right" title="Options forfeited">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_d0_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonVestedEmployeeStockOptionMember_z3Y9UGqH2R1j" style="text-align: right" title="Weighted-average grant date fair value per share, options forfeited">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Vested</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonVestedEmployeeStockOptionMember_z8zjWlCnEwxc" style="border-bottom: Black 1pt solid; text-align: right" title="Options vested">(33,333</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonVestedEmployeeStockOptionMember_zlo9TrlkCU15" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-average grant date fair value per share, options vested">9.86</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Balance as of December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonVestedEmployeeStockOptionMember_zcxYgtCwxO7" style="border-bottom: Black 2.5pt double; text-align: right" title="Non-vested options outstanding, ending balance">67,501</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonVestedEmployeeStockOptionMember_zMffHO7pUEia" style="border-bottom: Black 2.5pt double; text-align: right" title="Non-vested weighted-average grant date fair value per share, ending balance">4.77</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Restricted Stock Units There are <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEVrsLxnQ7Rj" title="Other than options granted, shares"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zieMBDKwpMqa" title="Other than options granted, shares">417 RSUs outstanding as of December 31, 2023 and 2022, respectively. The RSUs are fully vested and had a grant date fair value of $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zsGQd17gCUDi" title="Other than options, grant date fair value per share">253.70 per share. <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_do_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zsauTf9ccK05" title="Other than options, shares expired"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_do_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLLpJ1NqZ3l2" title="Other than options, shares expired">No RSUs were granted or expired during the years ended December 31, 2023 and 2022. Non-Employee Stock Options Share-based expense related to stock options granted to non-employees is recognized as the services are rendered on a straight-line basis. The Company determined that the fair value of the stock options is more reliably measurable than the fair value of the services received. No stock options to purchase shares of common stock were granted by the Company to non-employees during the years ended December 31, 2023 and 2022. No non-employee stock options were exercised during the years ended December 31, 2023 and 2022. <span id="xdx_90F_eus-gaap--AllocatedShareBasedCompensationExpense_do_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zJzjnNAWOAji" title="Share-based compensation expense"><span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_do_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zn6Y3KdG2Yni" title="Share-based compensation expense">No compensation expense related to non-employee options during the years ended December 31, 2023 and December 31, 2022 as all non-employee stock options were fully vested as of December 31, 2020. The following is a summary of non-employee stock option activity for the years ended December 31, 2023 and 2022: <table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zv0QyUbwyg9a" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Share-Based Expense (Details - Non-employee option activity)"> <tr style="vertical-align: bottom"> <td id="xdx_8B8_zjZXu7AW9Rj6" style="display: none"> Schedule of option activity</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted- average exercise price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted- average remaining life (years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate intrinsic value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 40%">Outstanding as of January 1, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_z2LpWHoWdNaa" style="width: 11%; text-align: right" title="Options outstanding, beginning balance">2,009</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zN63yf1FYsx8" style="width: 11%; text-align: right" title="Weighted-average exercise price outstanding, beginning balance">120.83</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zM8KZ3qCNeVl" title="Weighted-average remaining life outstanding beginning">2.83</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zlOWUnmaF3Wj" style="width: 11%; text-align: right" title="Aggregate intrinsic value, outstanding beginning balance">3,255</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_d0_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_z2bYUMcljJGe" style="text-align: right" title="Options granted">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d0_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zQZrGmXjbKsd" style="text-align: right" title="Weighted-average exercise price, granted">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di0_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zPONKlt6IQHi" style="border-bottom: Black 1pt solid; text-align: right" title="Options expired">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d0_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zL1rufBO0zD6" style="padding-bottom: 1pt; text-align: right" title="Weighted-average exercise price, forfeited/expired">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Outstanding as of December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zhAmvLDUZov7" style="text-align: right" title="Options outstanding, beginning balance">2,009</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_z5CUTObFG8jj" style="text-align: right" title="Weighted-average exercise price outstanding, beginning balance">120.83</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zv4bTDMbw4se" title="Weighted-average remaining life outstanding beginning">1.83</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_d0_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zVRdlHUFNYX7" style="text-align: right" title="Aggregate intrinsic value, outstanding beginning balance">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_d0_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_z5PHJpgusZYk" style="text-align: right" title="Options granted">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d0_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_ztoL8MOBG9Vk" style="text-align: right" title="Weighted-average exercise price, granted">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zTn3yK7fXi4e" style="border-bottom: Black 1pt solid; text-align: right" title="Options expired">(84</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zpBPxvWYBWlc" style="padding-bottom: 1pt; text-align: right" title="Weighted-average exercise price, forfeited/expired">231.60</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Outstanding as of December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zknFNB4x3QWl" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, ending balance">1,925</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_z7Nlx3Y7PmD5" style="padding-bottom: 2.5pt; text-align: right" title="Weighted-average exercise price, ending balance">115.99</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zA5YV7Iump6k" title="Weighted-average remaining life outstanding ending">0.91</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_d0_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zhlkf6Pclwif" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, outstanding ending balance">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Vested or expected to vest as of December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20231231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zizuQ4DjEM18" style="border-bottom: Black 2.5pt double; text-align: right" title="Options vested or expected to vest">1,925</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20231231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zfWHEWnMfAhf" style="padding-bottom: 2.5pt; text-align: right" title="Weighted-average exercise price, vested or expected to vest">115.99</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zGjqQIyaPfT6" title="Weighted-average remaining life, vested or expected to vest">0.91</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_pp0p0_d0_c20231231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zaGY4EGTsIf8" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, vested or expected to vest">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Exercisable as of December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20221231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_z8M4jor1Mocc" style="text-align: right" title="Options exercisable">2,009</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20221231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zkN5KKmNkq3e" style="text-align: right" title="Weighted-average exercise price, exercisable">120.83</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zqYweAgDSXNa" title="Weighted-average remaining life, exercisable">1.83</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_d0_c20221231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_z0uLqW8jDy78" style="text-align: right" title="Aggregate intrinsic value, exercisable">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercisable as of December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20231231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zEH0bjRQz0x" style="text-align: right" title="Options exercisable">1,925</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20231231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zNYIvOMHmz0k" style="text-align: right" title="Weighted-average exercise price, exercisable">115.99</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zPucFoPH30z4" title="Weighted-average remaining life, exercisable">0.91</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_d0_c20231231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_ztbBtcJSze6e" style="text-align: right" title="Aggregate intrinsic value, exercisable">–</td><td style="text-align: left"> </td></tr> </table> Common Stock Awards The Company has granted common stock awards to non-employees in exchange for services provided. The Company measures the fair value of these awards using the fair value of the services provided or the fair value of the awards granted, whichever is more reliably measurable. The fair value measurement date of these awards is generally the date the performance of services is complete. The fair value of the awards is recognized as services are rendered on a straight-line basis. <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_do_c20230101__20231231__us-gaap--AwardTypeAxis__custom--CommonStockAwardsMember_zeVtzA8ZRt3b" title="Common stock awards granted"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_do_c20220101__20221231__us-gaap--AwardTypeAxis__custom--CommonStockAwardsMember_zkektke9RaY4" title="Common stock awards granted">No common stock awards were granted or issued during the years ended December 31, 2023 and 2022. Joint Share Ownership Plan As of December 31, 2023 and 2022, there were approximately <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20231231__us-gaap--AwardTypeAxis__custom--JSOPMember_zeMFYPXesszc" title="Other than options, shares outstanding"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20221231__us-gaap--AwardTypeAxis__custom--JSOPMember_zKMvKteKLJqj" title="Other than options, shares outstanding">2,701 JSOP awards issued and outstanding to two former senior executives. Under the JSOP, shares in the Company are jointly purchased at fair market value by the participating executives and the trustees of the JSOP trust, with such shares held in the JSOP trust. For U.S. GAAP purposes the awards were valued as employee options and recorded as a reduction in equity as treasury shares until they are exercised by the employee. The JSOP awards are fully vested and have no expiration date. There were no compensation charges during the years ended December 31, 2023 and 2022.

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>

<us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2023-01-01to2023-12-31" decimals="0" id="Fact000890" unitRef="USD"> 300000 </us-gaap:AllocatedShareBasedCompensationExpense>

<us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2022-01-012022-12-31" decimals="0" id="Fact000892" unitRef="USD"> 500000 </us-gaap:AllocatedShareBasedCompensationExpense>

<us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000894">

<table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zl6Fu0MHWVb8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Share-Based Expense (Details - Share based expense)"> <tr style="vertical-align: bottom"> <td id="xdx_8BC_zcptWSVJntFd" style="display: none">Schedule of Share-Based Compensation Expense</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Research and development expenses</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zQyFxHPG45Md" style="width: 13%; text-align: right" title="Share-based compensation">56,112</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zGAple485Csg" style="width: 13%; text-align: right" title="Share-based compensation">86,305</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">General and administrative expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zYJORzmMMBs8" style="border-bottom: Black 1pt solid; text-align: right" title="Share-based compensation">226,973</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z1Inqlrfar43" style="border-bottom: Black 1pt solid; text-align: right" title="Share-based compensation">425,175</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231_zQBYjYl9c1sd" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based compensation">283,085</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20221231_za9ZzCDyjQv3" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based compensation">511,480</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>

<us-gaap:ShareBasedCompensation contextRef="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="0" id="Fact000896" unitRef="USD"> 56112 </us-gaap:ShareBasedCompensation>

<us-gaap:ShareBasedCompensation contextRef="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="0" id="Fact000898" unitRef="USD"> 86305 </us-gaap:ShareBasedCompensation>

<us-gaap:ShareBasedCompensation contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="0" id="Fact000900" unitRef="USD"> 226973 </us-gaap:ShareBasedCompensation>

<us-gaap:ShareBasedCompensation contextRef="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="0" id="Fact000902" unitRef="USD"> 425175 </us-gaap:ShareBasedCompensation>

<us-gaap:ShareBasedCompensation contextRef="From2023-01-01to2023-12-31" decimals="0" id="Fact000904" unitRef="USD"> 283085 </us-gaap:ShareBasedCompensation>

<us-gaap:ShareBasedCompensation contextRef="From2022-01-012022-12-31" decimals="0" id="Fact000906" unitRef="USD"> 511480 </us-gaap:ShareBasedCompensation>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact000913" unitRef="Shares"> 57500 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact000915" unitRef="Shares"> 35000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact000917" unitRef="USDPShares"> 3.49 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact000919" unitRef="USDPShares"> 7.29 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>

<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact000921" unitRef="Shares"> 0 </us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>

<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact000923" unitRef="Shares"> 0 </us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>

<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact000925" unitRef="Shares"> 33333 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>

<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact000927" unitRef="Shares"> 37503 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>

<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact000929" unitRef="USD"> 300000 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>

<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact000931" unitRef="USD"> 600000 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>

<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact000933" unitRef="USD"> 300000 </us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>

<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000935"> P2Y1M6D </us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>

<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000937">

<table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z1ma3mLFFKif" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Share-Based Expense (Details - Assumptions Employee)"> <tr style="vertical-align: bottom"> <td>Schedule of assumptions used</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Weighted-average expected dividend yield (%)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zxFgX8lpS69a" title="Weighted-average expected dividend yield">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4gCMWm2Q1R5" title="Weighted-average expected dividend yield">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 66%; text-align: left">Weighted-average expected volatility (%)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1bekoKwa6U2" title="Weighted-average expected volatility">121.50</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlXuFLm3yjSf" title="Weighted-average expected volatility">126.51</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Weighted-average risk-free interest rate (%)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ze16qTsCjB43" title="Weighted-average risk-free interest rate">4.21</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6c7rwKO4YH1" title="Weighted-average risk-free interest rate">2.90</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-average expected life of option (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjubn7yX8c7j" title="Weighted-average expected life of option">5.76</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKPvXDYtERz3" title="Weighted-average expected life of option">5.72</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Weighted-average exercise price ($)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zQhvifalnwCd" title="Weighted-average exercise price">4.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zyDwkwqmWCCk" title="Weighted-average exercise price">8.27</td><td style="text-align: left"> </td></tr> </table>

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact000939" unitRef="Pure"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact000941" unitRef="Pure"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact000943" unitRef="Pure"> 1.2150 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact000945" unitRef="Pure"> 1.2651 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact000947" unitRef="Pure"> 0.0421 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact000949" unitRef="Pure"> 0.0290 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>

<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000951"> P5Y9M3D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>

<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000953"> P5Y8M19D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact000955" unitRef="USDPShares"> 4.00 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact000957" unitRef="USDPShares"> 8.27 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>

<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000959">

<table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zxNSPq473Wvf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Share-Based Expense (Details - Employee option activity)"> <tr style="vertical-align: bottom"> <td id="xdx_8B5_zxUpB6khHmn5" style="display: none"> Schedule of option activity</td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid; text-align: center">Number of shares</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted- average exercise price</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted- average remaining life (years)</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Aggregate intrinsic value</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 41%">Outstanding as of January 1, 2022</td> <td style="width: 2%"> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zH7LLUmR1cp6" style="width: 11%; text-align: right" title="Options outstanding, beginning balance">108,888</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7sdbjmbNDfg" style="width: 11%; text-align: right" title="Weighted-average exercise price outstanding, beginning balance">62.66</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgTGk2jOFQti" title="Weighted-average remaining life outstanding beginning">8.22</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgie5wa5XBZf" style="width: 11%; text-align: right" title="Aggregate intrinsic value, outstanding beginning balance">23,750</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td> <td> </td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zyDmK8hXrCYe" style="text-align: right" title="Options granted">35,000</td> <td> </td> <td> </td> <td> </td> <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zc5Sc7QkqXQj" style="text-align: right" title="Weighted-average exercise price, granted">8.27</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Expired</td> <td> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_d0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZzeGOoN5FJ4" style="border-bottom: black 1pt solid; text-align: right" title="Options expired">–</td> <td> </td> <td> </td> <td> </td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_d0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1qJZWmKfEU4" style="text-align: right" title="Weighted-average exercise price, expired">–</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Outstanding as of December 31, 2022</td> <td> </td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ziQ1ov4AJZeb" style="text-align: right" title="Options outstanding, beginning balance">143,888</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zWOXp2KXNjib" style="text-align: right" title="Weighted-average exercise price outstanding, beginning balance">49.43</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zxuqq3zLCq85" title="Weighted-average remaining life outstanding beginning">7.78</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_d0_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zdla8j61BuC2" style="text-align: right" title="Aggregate intrinsic value, outstanding beginning balance">–</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Granted</td> <td> </td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zWCPwRkxnuvj" style="text-align: right" title="Options granted">57,500</td> <td> </td> <td> </td> <td> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNQnKyDZdBO3" style="text-align: right" title="Weighted-average exercise price, granted">4.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expired</td> <td> </td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_d0_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zCovjNQD8QD7" style="border-bottom: black 1pt solid; text-align: right" title="Options expired">–</td> <td> </td> <td> </td> <td> </td> <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_d0_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHukRHq4JcO2" style="text-align: right" title="Weighted-average exercise price, expired">–</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Outstanding as of December 31, 2023</td> <td> </td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNUlinejAEfj" style="border-bottom: black 2.25pt double; text-align: right" title="Options outstanding, ending balance">201,388</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zuAwmJ1wJAt8" style="text-align: right" title="Weighted-average exercise price, ending balance">36.46</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zk9bXuNcklM9" title="Weighted-average remaining life outstanding ending">7.69</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_d0_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNrpnDQN9xta" style="text-align: right" title="Aggregate intrinsic value, outstanding ending balance">–</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Vested or expected to vest as of December 31, 2023</td> <td> </td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zh53I0BBlVE9" style="border-bottom: black 2.25pt double; text-align: right" title="Options vested or expected to vest">201,388</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zekSMdrhv1l2" style="text-align: right" title="Weighted-average exercise price, vested or expected to vest">36.46</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zJogcZpMjeS1" title="Weighted-average remaining life, vested or expected to vest">7.69</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_pp0p0_d0_c20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zVlHTUdVzYUd" style="text-align: right" title="Aggregate intrinsic value, vested or expected to vest">–</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Exercisable as of December 31, 2022</td> <td> </td> <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4AcvXH4Vw99" style="text-align: right" title="Options exercisable">100,555</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z89hYt6Mom0h" style="text-align: right" title="Weighted-average exercise price, exercisable">65.70</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqj0HCZUL2u5" title="Weighted-average remaining life, exercisable">7.14</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_d0_c20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKJLVFMCyd03" style="text-align: right" title="Aggregate intrinsic value, exercisable">–</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercisable as of December 31, 2023</td> <td> </td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z93tfKgtXW6" style="text-align: right" title="Options exercisable">133,888</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zJQ8Ujsa2Plf" style="text-align: right" title="Weighted-average exercise price, exercisable">52.10</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6hdsouAqNNd" title="Weighted-average remaining life, exercisable">6.69</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_d0_c20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zVniChariVsa" style="text-align: right" title="Aggregate intrinsic value, exercisable">–</td> <td> </td></tr> </table>

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact000961" unitRef="Shares"> 108888 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact000963" unitRef="USDPShares"> 62.66 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>

<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000965"> P8Y2M19D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact000967" unitRef="USD"> 23750 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact000969" unitRef="Shares"> 35000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>

<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact000971" unitRef="USDPShares"> 8.27 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact000973" unitRef="Shares"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>

<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact000975" unitRef="USDPShares"> 0 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact000977" unitRef="Shares"> 143888 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact000979" unitRef="USDPShares"> 49.43 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>

<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000981"> P7Y9M10D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact000983" unitRef="USD"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact000985" unitRef="Shares"> 57500 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>

<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact000987" unitRef="USDPShares"> 4.00 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact000989" unitRef="Shares"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>

<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact000991" unitRef="USDPShares"> 0 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact000993" unitRef="Shares"> 201388 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact000995" unitRef="USDPShares"> 36.46 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>

<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000997"> P7Y8M8D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact000999" unitRef="USD"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact001001" unitRef="Shares"> 201388 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact001003" unitRef="USDPShares"> 36.46 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>

<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001005"> P7Y8M8D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact001007" unitRef="USD"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact001009" unitRef="Shares"> 100555 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact001011" unitRef="USDPShares"> 65.70 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>

<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001013"> P7Y1M20D </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>

<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact001015" unitRef="USD"> 0 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact001017" unitRef="Shares"> 133888 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact001019" unitRef="USDPShares"> 52.10 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>

<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001021"> P6Y8M8D </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>

<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact001023" unitRef="USD"> 0 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>

<us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001030">

<table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_z3DrgAETIPEg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Share-Based Expense (Details - Non-Vested employee Option activity)"> <tr style="vertical-align: bottom"> <td id="xdx_8BE_zFgwwWwsTRAk" style="display: none"> Schedule of non-vested options</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted- average grant date fair value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%">Balance as of January 1, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonVestedEmployeeStockOptionMember_zgLsdx2e86P8" style="width: 13%; text-align: right" title="Non-vested options outstanding, beginning balance">43,334</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonVestedEmployeeStockOptionMember_zzjb4rVzGjWf" style="width: 13%; text-align: right" title="Non-vested weighted-average grant date fair value per share, beginning balance">10.39</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonVestedEmployeeStockOptionMember_zjq5Ocf5v659" style="text-align: right" title="Options granted">57,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonVestedEmployeeStockOptionMember_z8P4cTwhzg6l" style="text-align: right" title="Weighted-average grant date fair value per share, options granted">3.49</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d0_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonVestedEmployeeStockOptionMember_zpE6rrcl2MI4" style="text-align: right" title="Options forfeited">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_d0_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonVestedEmployeeStockOptionMember_z3Y9UGqH2R1j" style="text-align: right" title="Weighted-average grant date fair value per share, options forfeited">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Vested</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonVestedEmployeeStockOptionMember_z8zjWlCnEwxc" style="border-bottom: Black 1pt solid; text-align: right" title="Options vested">(33,333</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonVestedEmployeeStockOptionMember_zlo9TrlkCU15" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-average grant date fair value per share, options vested">9.86</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Balance as of December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonVestedEmployeeStockOptionMember_zcxYgtCwxO7" style="border-bottom: Black 2.5pt double; text-align: right" title="Non-vested options outstanding, ending balance">67,501</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonVestedEmployeeStockOptionMember_zMffHO7pUEia" style="border-bottom: Black 2.5pt double; text-align: right" title="Non-vested weighted-average grant date fair value per share, ending balance">4.77</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>

<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="AsOf2022-12-31_custom_NonVestedEmployeeStockOptionMember" decimals="INF" id="Fact001032" unitRef="Shares"> 43334 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>

<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2022-12-31_custom_NonVestedEmployeeStockOptionMember" decimals="INF" id="Fact001034" unitRef="USDPShares"> 10.39 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="From2023-01-012023-12-31_custom_NonVestedEmployeeStockOptionMember" decimals="INF" id="Fact001036" unitRef="Shares"> 57500 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2023-01-012023-12-31_custom_NonVestedEmployeeStockOptionMember" decimals="INF" id="Fact001038" unitRef="USDPShares"> 3.49 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2023-01-012023-12-31_custom_NonVestedEmployeeStockOptionMember" decimals="INF" id="Fact001040" unitRef="Shares"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>

<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue contextRef="From2023-01-012023-12-31_custom_NonVestedEmployeeStockOptionMember" decimals="INF" id="Fact001042" unitRef="USDPShares"> 0 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>

<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="From2023-01-012023-12-31_custom_NonVestedEmployeeStockOptionMember" decimals="INF" id="Fact001044" unitRef="Shares"> 33333 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>

<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="From2023-01-012023-12-31_custom_NonVestedEmployeeStockOptionMember" decimals="INF" id="Fact001046" unitRef="USDPShares"> 9.86 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>

<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="AsOf2023-12-31_custom_NonVestedEmployeeStockOptionMember" decimals="INF" id="Fact001048" unitRef="Shares"> 67501 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>

<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2023-12-31_custom_NonVestedEmployeeStockOptionMember" decimals="INF" id="Fact001050" unitRef="USDPShares"> 4.77 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact001052" unitRef="Shares"> 417 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact001054" unitRef="Shares"> 417 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact001056" unitRef="USDPShares"> 253.70 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact001058" unitRef="Shares"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact001060" unitRef="Shares"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>

<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2023-01-012023-12-31_custom_NonEmployeeStockOptionsMember" decimals="INF" id="Fact001062" unitRef="Shares"> 0 </us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>

<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2022-01-012022-12-31_custom_NonEmployeeStockOptionsMember" decimals="INF" id="Fact001064" unitRef="Shares"> 0 </us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>

<us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2023-01-012023-12-31_custom_NonEmployeeStockOptionsMember" decimals="0" id="Fact001066" unitRef="USD"> 0 </us-gaap:AllocatedShareBasedCompensationExpense>

<us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2022-01-012022-12-31_custom_NonEmployeeStockOptionsMember" decimals="0" id="Fact001068" unitRef="USD"> 0 </us-gaap:AllocatedShareBasedCompensationExpense>

<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2023-01-012023-12-31_custom_NonEmployeeStockOptionsMember" id="Fact001070">

<table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zv0QyUbwyg9a" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Share-Based Expense (Details - Non-employee option activity)"> <tr style="vertical-align: bottom"> <td id="xdx_8B8_zjZXu7AW9Rj6" style="display: none"> Schedule of option activity</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted- average exercise price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted- average remaining life (years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate intrinsic value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 40%">Outstanding as of January 1, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_z2LpWHoWdNaa" style="width: 11%; text-align: right" title="Options outstanding, beginning balance">2,009</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zN63yf1FYsx8" style="width: 11%; text-align: right" title="Weighted-average exercise price outstanding, beginning balance">120.83</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zM8KZ3qCNeVl" title="Weighted-average remaining life outstanding beginning">2.83</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zlOWUnmaF3Wj" style="width: 11%; text-align: right" title="Aggregate intrinsic value, outstanding beginning balance">3,255</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_d0_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_z2bYUMcljJGe" style="text-align: right" title="Options granted">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d0_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zQZrGmXjbKsd" style="text-align: right" title="Weighted-average exercise price, granted">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di0_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zPONKlt6IQHi" style="border-bottom: Black 1pt solid; text-align: right" title="Options expired">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d0_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zL1rufBO0zD6" style="padding-bottom: 1pt; text-align: right" title="Weighted-average exercise price, forfeited/expired">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Outstanding as of December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zhAmvLDUZov7" style="text-align: right" title="Options outstanding, beginning balance">2,009</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_z5CUTObFG8jj" style="text-align: right" title="Weighted-average exercise price outstanding, beginning balance">120.83</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zv4bTDMbw4se" title="Weighted-average remaining life outstanding beginning">1.83</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_d0_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zVRdlHUFNYX7" style="text-align: right" title="Aggregate intrinsic value, outstanding beginning balance">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_d0_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_z5PHJpgusZYk" style="text-align: right" title="Options granted">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d0_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_ztoL8MOBG9Vk" style="text-align: right" title="Weighted-average exercise price, granted">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zTn3yK7fXi4e" style="border-bottom: Black 1pt solid; text-align: right" title="Options expired">(84</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zpBPxvWYBWlc" style="padding-bottom: 1pt; text-align: right" title="Weighted-average exercise price, forfeited/expired">231.60</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Outstanding as of December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zknFNB4x3QWl" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, ending balance">1,925</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_z7Nlx3Y7PmD5" style="padding-bottom: 2.5pt; text-align: right" title="Weighted-average exercise price, ending balance">115.99</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zA5YV7Iump6k" title="Weighted-average remaining life outstanding ending">0.91</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_d0_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zhlkf6Pclwif" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, outstanding ending balance">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Vested or expected to vest as of December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20231231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zizuQ4DjEM18" style="border-bottom: Black 2.5pt double; text-align: right" title="Options vested or expected to vest">1,925</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20231231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zfWHEWnMfAhf" style="padding-bottom: 2.5pt; text-align: right" title="Weighted-average exercise price, vested or expected to vest">115.99</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zGjqQIyaPfT6" title="Weighted-average remaining life, vested or expected to vest">0.91</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_pp0p0_d0_c20231231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zaGY4EGTsIf8" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, vested or expected to vest">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Exercisable as of December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20221231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_z8M4jor1Mocc" style="text-align: right" title="Options exercisable">2,009</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20221231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zkN5KKmNkq3e" style="text-align: right" title="Weighted-average exercise price, exercisable">120.83</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zqYweAgDSXNa" title="Weighted-average remaining life, exercisable">1.83</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_d0_c20221231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_z0uLqW8jDy78" style="text-align: right" title="Aggregate intrinsic value, exercisable">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercisable as of December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20231231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zEH0bjRQz0x" style="text-align: right" title="Options exercisable">1,925</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20231231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zNYIvOMHmz0k" style="text-align: right" title="Weighted-average exercise price, exercisable">115.99</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_zPucFoPH30z4" title="Weighted-average remaining life, exercisable">0.91</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_d0_c20231231__us-gaap--AwardTypeAxis__custom--NonEmployeeStockOptionsMember_ztbBtcJSze6e" style="text-align: right" title="Aggregate intrinsic value, exercisable">–</td><td style="text-align: left"> </td></tr> </table>

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2021-12-31_custom_NonEmployeeStockOptionsMember" decimals="INF" id="Fact001072" unitRef="Shares"> 2009 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2021-12-31_custom_NonEmployeeStockOptionsMember" decimals="INF" id="Fact001074" unitRef="USDPShares"> 120.83 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>

<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31_custom_NonEmployeeStockOptionsMember" id="Fact001076"> P2Y9M29D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2021-12-31_custom_NonEmployeeStockOptionsMember" decimals="0" id="Fact001078" unitRef="USD"> 3255 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="From2022-01-012022-12-31_custom_NonEmployeeStockOptionsMember" decimals="INF" id="Fact001080" unitRef="Shares"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>

<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2022-01-012022-12-31_custom_NonEmployeeStockOptionsMember" decimals="INF" id="Fact001082" unitRef="USDPShares"> 0 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="From2022-01-012022-12-31_custom_NonEmployeeStockOptionsMember" decimals="INF" id="Fact001084" unitRef="Shares"> -0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>

<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2022-01-012022-12-31_custom_NonEmployeeStockOptionsMember" decimals="INF" id="Fact001086" unitRef="USDPShares"> 0 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2022-12-31_custom_NonEmployeeStockOptionsMember" decimals="INF" id="Fact001088" unitRef="Shares"> 2009 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2022-12-31_custom_NonEmployeeStockOptionsMember" decimals="INF" id="Fact001090" unitRef="USDPShares"> 120.83 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>

<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-12-31_custom_NonEmployeeStockOptionsMember" id="Fact001092"> P1Y9M29D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2022-12-31_custom_NonEmployeeStockOptionsMember" decimals="0" id="Fact001094" unitRef="USD"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="From2023-01-012023-12-31_custom_NonEmployeeStockOptionsMember" decimals="INF" id="Fact001096" unitRef="Shares"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>

<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2023-01-012023-12-31_custom_NonEmployeeStockOptionsMember" decimals="INF" id="Fact001098" unitRef="USDPShares"> 0 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="From2023-01-012023-12-31_custom_NonEmployeeStockOptionsMember" decimals="INF" id="Fact001100" unitRef="Shares"> 84 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>

<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2023-01-012023-12-31_custom_NonEmployeeStockOptionsMember" decimals="INF" id="Fact001102" unitRef="USDPShares"> 231.60 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2023-12-31_custom_NonEmployeeStockOptionsMember" decimals="INF" id="Fact001104" unitRef="Shares"> 1925 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2023-12-31_custom_NonEmployeeStockOptionsMember" decimals="INF" id="Fact001106" unitRef="USDPShares"> 115.99 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>

<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2023-01-012023-12-31_custom_NonEmployeeStockOptionsMember" id="Fact001108"> P0Y10M28D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2023-12-31_custom_NonEmployeeStockOptionsMember" decimals="0" id="Fact001110" unitRef="USD"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2023-12-31_custom_NonEmployeeStockOptionsMember" decimals="INF" id="Fact001112" unitRef="Shares"> 1925 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice contextRef="AsOf2023-12-31_custom_NonEmployeeStockOptionsMember" decimals="INF" id="Fact001114" unitRef="USDPShares"> 115.99 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>

<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2023-01-012023-12-31_custom_NonEmployeeStockOptionsMember" id="Fact001116"> P0Y10M28D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="AsOf2023-12-31_custom_NonEmployeeStockOptionsMember" decimals="0" id="Fact001118" unitRef="USD"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2022-12-31_custom_NonEmployeeStockOptionsMember" decimals="INF" id="Fact001120" unitRef="Shares"> 2009 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2022-12-31_custom_NonEmployeeStockOptionsMember" decimals="INF" id="Fact001122" unitRef="USDPShares"> 120.83 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>

<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-12-31_custom_NonEmployeeStockOptionsMember" id="Fact001124"> P1Y9M29D </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>

<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2022-12-31_custom_NonEmployeeStockOptionsMember" decimals="0" id="Fact001126" unitRef="USD"> 0 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2023-12-31_custom_NonEmployeeStockOptionsMember" decimals="INF" id="Fact001128" unitRef="Shares"> 1925 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2023-12-31_custom_NonEmployeeStockOptionsMember" decimals="INF" id="Fact001130" unitRef="USDPShares"> 115.99 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>

<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2023-01-012023-12-31_custom_NonEmployeeStockOptionsMember" id="Fact001132"> P0Y10M28D </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>

<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2023-12-31_custom_NonEmployeeStockOptionsMember" decimals="0" id="Fact001134" unitRef="USD"> 0 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="From2023-01-012023-12-31_custom_CommonStockAwardsMember" decimals="INF" id="Fact001140" unitRef="Shares"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="From2022-01-012022-12-31_custom_CommonStockAwardsMember" decimals="INF" id="Fact001142" unitRef="Shares"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="AsOf2023-12-31_custom_JSOPMember" decimals="INF" id="Fact001144" unitRef="Shares"> 2701 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="AsOf2022-12-31_custom_JSOPMember" decimals="INF" id="Fact001146" unitRef="Shares"> 2701 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>

<us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2023-01-012023-12-31_custom_JSOPMember" decimals="0" id="Fact001148" unitRef="USD"> 0 </us-gaap:AllocatedShareBasedCompensationExpense>

<us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2022-01-012022-12-31_custom_JSOPMember" decimals="0" id="Fact001150" unitRef="USD"> 0 </us-gaap:AllocatedShareBasedCompensationExpense>

<us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001152">

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 5%">12.</td> <td style="width: 95%; text-align: justify">Employee Benefit Plans</td></tr> </table> The Company has a defined contribution 401(k) savings plan (the “401(k) Plan”). The 401(k) Plan covers substantially all U.S. employees, and allows participants to defer a portion of their annual compensation on a pre-tax basis or make post-tax contributions. Company contributions to the 401(k) Plan may be made at the discretion of the Board of Directors. During the years ended December 31, 2023 and 2022, the Company made contributions of approximately $<span id="xdx_90E_eus-gaap--DefinedBenefitPlanContributionsByEmployer_pp0p0_c20230101__20231231__us-gaap--RetirementPlanNameAxis__custom--Plan401KMember_zO2uvMkPZzr2" title="Contribution to defined contribution plan">41,000 and $<span id="xdx_907_eus-gaap--DefinedBenefitPlanContributionsByEmployer_pp0p0_c20220101__20221231__us-gaap--RetirementPlanNameAxis__custom--Plan401KMember_zPiI2blnpuWi" title="Contribution to defined contribution plan">38,000 to the 401(k) Plan, respectively.

</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>

<us-gaap:DefinedBenefitPlanContributionsByEmployer contextRef="From2023-01-012023-12-31_custom_Plan401KMember" decimals="0" id="Fact001154" unitRef="USD"> 41000 </us-gaap:DefinedBenefitPlanContributionsByEmployer>

<us-gaap:DefinedBenefitPlanContributionsByEmployer contextRef="From2022-01-012022-12-31_custom_Plan401KMember" decimals="0" id="Fact001156" unitRef="USD"> 38000 </us-gaap:DefinedBenefitPlanContributionsByEmployer>

<us-gaap:CommitmentsDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001158">

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 5%">13.</td> <td style="width: 95%; text-align: justify">Commitments and Contingencies</td></tr> </table> Leases The Company determines whether an arrangement is a lease at inception. On October 1, 2020, the Company entered into a two-year lease for its corporate headquarters in Framingham, Massachusetts. This lease called for total future minimum rent payments of approximately $<span id="xdx_90D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_c20231231__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__custom--CorporateHeadquartersMember_zTXHst9EaNWe" title="Future minimum rental payments">78,000 at inception and had a termination date of <span id="xdx_904_eus-gaap--LeaseExpirationDate1_dd_c20230101__20231231__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__custom--CorporateHeadquartersMember_zgIi6es1KCO3" title="Lease termination date">September 30, 2022. The Company recorded a right-of-use (“ROU”) asset and corresponding lease liability on the consolidated balance sheet. The Company did not have options to extend, termination options or material residual value guarantees. The lease was not renewed and the Company entered into a 12-month lease for office space in a shared office location effective October 1, 2022. As this lease has a term of 12 months at inception, the Company did not apply the provisions of ASU 2016-02 and will account for it as an operating lease. As of December 31, 2023, total minimum lease payments on this lease were approximately $<span id="xdx_901_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0_c20231231__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__custom--OfficeSpaceMember_zYwxeVkFdnhd" title="Future minimum rental payments">15,000. Supplemental cash flow information and non-cash activity related to our operating leases are as follows: <table cellpadding="0" cellspacing="0" id="xdx_885_eus-gaap--CashFlowOperatingCapitalTableTextBlock_zL7BZ5hbLBd9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details - Cash flow Information)"> <tr style="vertical-align: bottom"> <td id="xdx_8B5_z1oW5mmHB8zk" style="display: none">Cash flow information regarding leases</td><td> </td> <td colspan="2" id="xdx_49F_20230101__20231231_zglKWVA55vb" style="text-align: center"> </td><td style="text-align: center"> </td><td> </td> <td colspan="2" id="xdx_49C_20220101__20221231_zCKSUPNvTZel" style="text-align: center"> </td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: center">Year Ended December 31,</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Year Ended December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--SupplementalCashFlowInformationAbstract_iB" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; font-weight: bold; text-align: left">Operating cash flow information:</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--OperatingLeasePayments_i01_pp0p0_d0_z8BoVxkkr5Hd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Cash paid for amounts included in the measurement of lease liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">27,043</td><td style="text-align: left"> </td></tr> </table> The Company did not apply the provisions of ASU 2016-02 to the lease of its office space in Miami, Florida. Effective November 1, 2023, the Company renewed its Miami office lease for twelve-months to November 2024. As this lease has a term of 12 months at inception, the Company accounts for it as an operating lease. As of December 31, 2023, total minimum lease payments on this lease were approximately $<span id="xdx_905_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_pp0p0_c20231231__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__custom--OfficeSpaceMiamiFlMember_zQ3n8z59CJMi" title="Future minimum rental payments">15,000.

</us-gaap:CommitmentsDisclosureTextBlock>

<us-gaap:LesseeOperatingLeaseDescription contextRef="From2023-01-012023-12-31_custom_CorporateHeadquartersMember" id="Fact001159"> On October 1, 2020, the Company entered into a two-year lease for its corporate headquarters in Framingham, Massachusetts. </us-gaap:LesseeOperatingLeaseDescription>

<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2023-12-31_custom_CorporateHeadquartersMember" decimals="0" id="Fact001161" unitRef="USD"> 78000 </us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>

<us-gaap:LeaseExpirationDate1 contextRef="From2023-01-012023-12-31_custom_CorporateHeadquartersMember" id="Fact001163"> 2022-09-30 </us-gaap:LeaseExpirationDate1>

<us-gaap:LesseeOperatingLeaseTermOfContract contextRef="AsOf2023-12-31_custom_OfficeSpaceMember" id="Fact001165"> P12M </us-gaap:LesseeOperatingLeaseTermOfContract>

<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2023-12-31_custom_OfficeSpaceMember" decimals="0" id="Fact001167" unitRef="USD"> 15000 </us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>

<us-gaap:CashFlowOperatingCapitalTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001169">

<table cellpadding="0" cellspacing="0" id="xdx_885_eus-gaap--CashFlowOperatingCapitalTableTextBlock_zL7BZ5hbLBd9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details - Cash flow Information)"> <tr style="vertical-align: bottom"> <td id="xdx_8B5_z1oW5mmHB8zk" style="display: none">Cash flow information regarding leases</td><td> </td> <td colspan="2" id="xdx_49F_20230101__20231231_zglKWVA55vb" style="text-align: center"> </td><td style="text-align: center"> </td><td> </td> <td colspan="2" id="xdx_49C_20220101__20221231_zCKSUPNvTZel" style="text-align: center"> </td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: center">Year Ended December 31,</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Year Ended December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--SupplementalCashFlowInformationAbstract_iB" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; font-weight: bold; text-align: left">Operating cash flow information:</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--OperatingLeasePayments_i01_pp0p0_d0_z8BoVxkkr5Hd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Cash paid for amounts included in the measurement of lease liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">27,043</td><td style="text-align: left"> </td></tr> </table>

</us-gaap:CashFlowOperatingCapitalTableTextBlock>

<us-gaap:OperatingLeasePayments contextRef="From2023-01-01to2023-12-31" decimals="0" id="Fact001174" unitRef="USD"> 0 </us-gaap:OperatingLeasePayments>

<us-gaap:OperatingLeasePayments contextRef="From2022-01-012022-12-31" decimals="0" id="Fact001175" unitRef="USD"> 27043 </us-gaap:OperatingLeasePayments>

<us-gaap:LesseeOperatingLeaseDescription contextRef="From2023-01-012023-12-31_custom_OfficeSpaceMiamiFlMember" id="Fact001176"> Effective November 1, 2023, the Company renewed its Miami office lease for twelve-months to November 2024. </us-gaap:LesseeOperatingLeaseDescription>

<us-gaap:LesseeOperatingLeaseTermOfContract contextRef="AsOf2023-12-31_custom_OfficeSpaceMiamiFlMember" id="Fact001178"> P12M </us-gaap:LesseeOperatingLeaseTermOfContract>

<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2023-12-31_custom_OfficeSpaceMiamiFlMember" decimals="0" id="Fact001180" unitRef="USD"> 15000 </us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>

<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001187">

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 5%">14.</td> <td style="width: 95%; text-align: justify">Related Party Transactions </td></tr> </table> The Company has entered into various research, development, license and supply agreements with Serum Institute and Pharmsynthez, each a related party whose relationship, ownership, and nature of transactions is disclosed within other sections of these footnotes. Please refer to Note 4, Significant Strategic Collaborations, and Note 6, Other Assets, for details on arrangements with collaboration partners that are also related parties. During the fourth quarter of 2019, the Company entered into a loan agreement with Pharmsynthez (the “Pharmsynthez Loan”), pursuant to which the Company advanced Pharmsynthez an aggregate principal amount of up to $<span id="xdx_903_eus-gaap--PaymentsToAcquireNotesReceivable_pp0p0_c20191001__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PharmsynthezMember__us-gaap--TransactionTypeAxis__custom--CoDevelopmentAgreementMember_zx8EuOpDdARh" title="Payments to acquire notes receivable">500,000 to be used for the development of a specific product under the Company’s Co-Development Agreement with Pharmsynthez. The Pharmsynthez Loan had an initial term of 15-months and accrued interest at a rate of <span id="xdx_902_ecustom--NoteReceivableInterestRate_iI_dp_c20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PharmsynthezMember__us-gaap--TransactionTypeAxis__custom--CoDevelopmentAgreementMember_zgGzH9S1pBle" title="Accrued interest rate">10% per annum. The Pharmsynthez Loan was guaranteed by all of the operating subsidiaries of Pharmsynthez, including SynBio and AS Kevelt, and was secured by all of the common and preferred stock of the Company owned by Pharmsynthez and SynBio. Pharmsynthez paid all obligations due under the Pharmsynthez Loan in May 2023, and no further amounts are due under the Pharmsynthez Loan. As a result, the Company recognized approximately $<span id="xdx_900_eus-gaap--InterestAndFeeIncomeOtherLoans_pp0p0_c20230101__20231231__us-gaap--TransactionTypeAxis__custom--CoDevelopmentAgreementMember_zlcQYPjYFZg1" title="Interest and fee income, other loans">65,000 of income related to interest and fees associated with the Pharmsynthez Loan including approximately $<span id="xdx_909_eus-gaap--InterestAndFeeIncomeOtherLoans_pp0p0_do_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PharmsynthezMember__us-gaap--TransactionTypeAxis__custom--CoDevelopmentAgreementMember_zHSUMsp5F9Qa" title="Interest and fee income, other loans">40,000 related to interest income during the twelve months ended December 31, 2023. The Company recognized approximately $<span id="xdx_90B_eus-gaap--InterestAndFeeIncomeOtherLoans_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PharmsynthezMember__us-gaap--TransactionTypeAxis__custom--CoDevelopmentAgreementMember_zwpSgNCWFDL8" title="Interest and fee income, other loans">9,000 of interest income related to the Pharmsynthez Loan during the year ended December 31, 2022. As of December 31, 2022, approximately $<span id="xdx_900_eus-gaap--OtherPrepaidExpenseCurrent_iI_dm_c20221231__us-gaap--TransactionTypeAxis__custom--SponsoredResearchAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PharmsynthezMember_zrf9mcn19vjh" title="Prepaid expenses and other current asset">0.4 million was included in other assets on the consolidated balance sheet. No amounts were outstanding as of December 31, 2023. In April 2022, the Company entered into certain agreements with CLS as described in Note 5. One of the Company’s directors, Roger Kornberg, is a member of the scientific advisory board of CLS. However, Mr. Kornberg does not own any equity of CLS and is not receiving any economic benefit as a result of the transactions contemplated by such agreements. Mr. Adam Logal, one of our directors, is Senior Vice President, Chief Financial Officer, Chief Accounting Officer and Treasurer of OPKO. Dr. Dmitry Genkin is a significant shareholder of CLS. Dr. Genkin was elected to our board of directors on December 6, 2023.

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>

<us-gaap:PaymentsToAcquireNotesReceivable contextRef="From2019-10-012019-12-31_custom_PharmsynthezMember_custom_CoDevelopmentAgreementMember" decimals="0" id="Fact001189" unitRef="USD"> 500000 </us-gaap:PaymentsToAcquireNotesReceivable>

<xbio:NoteReceivableInterestRate contextRef="AsOf2019-12-31_custom_PharmsynthezMember_custom_CoDevelopmentAgreementMember" decimals="INF" id="Fact001191" unitRef="Pure"> 0.10 </xbio:NoteReceivableInterestRate>

<us-gaap:InterestAndFeeIncomeOtherLoans contextRef="From2023-01-012023-12-31_custom_CoDevelopmentAgreementMember" decimals="0" id="Fact001193" unitRef="USD"> 65000 </us-gaap:InterestAndFeeIncomeOtherLoans>

<us-gaap:InterestAndFeeIncomeOtherLoans contextRef="From2023-01-012023-12-31_custom_PharmsynthezMember_custom_CoDevelopmentAgreementMember" decimals="0" id="Fact001195" unitRef="USD"> 40000 </us-gaap:InterestAndFeeIncomeOtherLoans>

<us-gaap:InterestAndFeeIncomeOtherLoans contextRef="From2022-01-012022-12-31_custom_PharmsynthezMember_custom_CoDevelopmentAgreementMember" decimals="0" id="Fact001197" unitRef="USD"> 9000 </us-gaap:InterestAndFeeIncomeOtherLoans>

<us-gaap:OtherPrepaidExpenseCurrent contextRef="AsOf2022-12-31_custom_SponsoredResearchAgreementMember_custom_PharmsynthezMember" decimals="0" id="Fact001199" unitRef="USD"> 400000 </us-gaap:OtherPrepaidExpenseCurrent>

<us-gaap:SubsequentEventsTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001201">

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 5%">15.</td> <td style="width: 95%; text-align: justify">Subsequent Events </td></tr> </table> The Company performed a review of events subsequent to the balance sheet date through the date the financial statements were issued and determined that there were no such events requiring recognition or disclosure in the financial statements.

</us-gaap:SubsequentEventsTextBlock>

<ecd:Rule10b51ArrAdoptedFlag contextRef="From2023-10-012023-12-31" id="Fact001202"> false </ecd:Rule10b51ArrAdoptedFlag>

<ecd:NonRule10b51ArrAdoptedFlag contextRef="From2023-10-012023-12-31" id="Fact001203"> false </ecd:NonRule10b51ArrAdoptedFlag>

<ecd:Rule10b51ArrTrmntdFlag contextRef="From2023-10-012023-12-31" id="Fact001204"> false </ecd:Rule10b51ArrTrmntdFlag>

<ecd:NonRule10b51ArrTrmntdFlag contextRef="From2023-10-012023-12-31" id="Fact001205"> false </ecd:NonRule10b51ArrTrmntdFlag>

</xbrl>

32 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/12/23  Xenetic Biosciences, Inc.         8-K:3,5,7,9 5/11/23   13:415K                                   GlobalOne Filings Inc/FA
 5/11/23  Xenetic Biosciences, Inc.         10-Q        3/31/23   45:2.3M                                   GlobalOne Filings Inc/FA
 3/22/23  Xenetic Biosciences, Inc.         10-K       12/31/22   74:6.6M                                   GlobalOne Filings Inc/FA
 8/11/22  Xenetic Biosciences, Inc.         10-Q        6/30/22   50:3.2M                                   GlobalOne Filings Inc/FA
 3/22/22  Xenetic Biosciences, Inc.         10-K       12/31/21   75:6M                                     GlobalOne Filings Inc/FA
11/19/21  Xenetic Biosciences, Inc.         8-K:1,9    11/19/21   13:520K                                   GlobalOne Filings Inc/FA
10/15/21  Xenetic Biosciences, Inc.         DEF 14A    12/07/21    1:601K                                   GlobalOne Filings Inc/FA
 7/28/21  Xenetic Biosciences, Inc.         8-K:1,3,7   7/26/21    7:701K                                   GlobalOne Filings Inc/FA
 3/16/21  Xenetic Biosciences, Inc.         10-K       12/31/20   78:5.1M                                   GlobalOne Filings Inc/FA
 3/26/20  Xenetic Biosciences, Inc.         10-K       12/31/19   79:4.9M                                   GlobalOne Filings Inc/FA
 7/22/19  Xenetic Biosciences, Inc.         8-K:1,3,5,8 7/17/19    6:932K                                   GlobalOne Filings Inc/FA
 7/16/19  Xenetic Biosciences, Inc.         8-K:9       7/16/19    2:91K                                    GlobalOne Filings Inc/FA
 7/16/19  Xenetic Biosciences, Inc.         8-K:1,9     7/15/19    3:45K                                    GlobalOne Filings Inc/FA
 6/25/19  Xenetic Biosciences, Inc.         8-K:1,3,9   6/24/19    3:202K                                   GlobalOne Filings Inc/FA
 6/24/19  Xenetic Biosciences, Inc.         8-K:1,3,5   6/19/19    6:96K                                    GlobalOne Filings Inc/FA
 6/13/19  Xenetic Biosciences, Inc.         8-K:1,8,9   6/07/19    3:56K                                    GlobalOne Filings Inc/FA
 5/20/19  Xenetic Biosciences, Inc.         8-K/A:8,9   3/01/19    2:428K                                   GlobalOne Filings Inc/FA
 3/30/18  Xenetic Biosciences, Inc.         10-K       12/31/17   85:5.1M                                   GlobalOne Filings Inc/FA
 8/14/17  Xenetic Biosciences, Inc.         10-Q        6/30/17   46:1.5M                                   GlobalOne Filings Inc/FA
 4/04/17  Xenetic Biosciences, Inc.         8-K:3,5,7,9 4/04/17    4:280K                                   GlobalOne Filings Inc/FA
 2/27/17  Xenetic Biosciences, Inc.         8-K:5,9     2/27/17    2:171K                                   Feather Filings LLC/FA
 1/04/17  Xenetic Biosciences, Inc.         8-K:5,7,8,9 1/01/17    3:777K                                   Feather Filings LLC/FA
10/27/16  Xenetic Biosciences, Inc.         S-1/A      10/26/16   98:6.7M                                   GlobalOne Filings Inc/FA
10/11/16  Xenetic Biosciences, Inc.         S-1/A                 99:7.1M                                   GlobalOne Filings Inc/FA
 7/14/16  Xenetic Biosciences, Inc.         S-1/A                  5:661K                                   Publicease Inc./FA
 9/30/15  Xenetic Biosciences, Inc.         8-K:5,9     9/24/15    2:23K                                    Westward Law LLC/FA
 4/15/15  Xenetic Biosciences, Inc.         10-K       12/31/14   74:5.9M                                   Publicease Inc./FA
 2/18/15  Xenetic Biosciences, Inc.         10-K/A     12/31/13   22:4.8M                                   Publicease Inc./FA
 1/10/14  Xenetic Biosciences, Inc.         10-Q       11/30/13   40:1.2M                                   Timber Pharmas, Inc.
 2/27/13  Xenetic Biosciences, Inc.         8-K:5,8,9   2/25/13    2:19K                                    Clark Corp Law Group LLP
 2/12/13  Xenetic Biosciences, Inc.         8-K:2,5     2/11/13    2:24K                                    Clark Corp Law Group LLP
11/21/11  Xenetic Biosciences, Inc.         S-1                    7:607K

↑Top

Filing Submission 0001683168-24-001594 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Xenetic Biosciences, Inc. – ‘10-K’ for 12/31/23 – ‘XML’

On: Thursday, 3/21/24, at 5:00pm ET · For: 12/31/23 · Accession #: 1683168-24-1594 · File #: 1-37937

Annual Report — Form 10-K — SEA’34Filing Table of Contents

‘XML’ — XBRL Instance — xenetic_i10k-123123_htm

This Document is an XBRL File.

32 Previous Filings that this Filing References

Annual Report — Form 10-K — SEA’34

Filing Table of Contents